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Despite the discovery of cis-platin in the treatment of cancer there has 
been a considerable exploration on the antitumoral activity of other 
transition metal complexes. One of the main problems about the 
application of transition metal complexes for chemotherapy is their 
potential toxicity.  For instance, recently the attention has been focused 
on titanium based complexes, which could have significant potential 
effect against solid tumor. The advantage of Ti(IV) complexes is their 
relative biological compatibility, which mostly leads to mild and revisable 
side effects. However, the hydrolytic instability of known Ti(IV) 
complexes and formation of various different species upon water addition 
makes their therapeutic application problematic, and raises a strong 
interest in the development of relatively stable Ti(IV) complexes with well 
defined hydrolytic behavior that demonstrate appreciable cytotoxic 
activity. Strong ligand binding is also of interest to avoid complete ligand 
stripping by transferrin, so that the ligand may be used as a target for 
structure–activity relationship investigations. 
Titanocene dichloride (Cp2TiCl2) shows an average antiproliferative 
activity in vitro but promising results in vivo. Considerable work has been 
performed in developing therapeutic analogues of Cp2TiCl2 by varying 
the central metal, the labile ligands (Cl) and the bis-cyclopentadienyl 
moiety. In particular, small changes to the Cp ligand can strongly affect 
 
the hydrolytic stability and water solubility properties of the metallocenes 
and have an impact on the cytotoxic activity. 
For a better exploration of the parameters affecting activity and its 
mechanistic aspects, the synthesis and investigation of particularly 
designed complexes based on different strongly coordinating ligands has 
been our main purpose 
We synthesized novel titanocene and half-titanocene derivatives, having 
substituted cyclopentadienyl ligands; all the complexes have been  fully 
characterized by NMR, elemental analysis and MS. Additionally we 
studied  the rate of hydrolysis of these complexes. Starting from the 
reflection that the different activities of the complexes could be related to 
their different stabilities, the hydrolysis stability represents a first 
possible indication on the achievable cytotoxic effects of synthesized 
compounds.  
The synthesized compounds have been evaluated for their cytotoxic 
potential against cancer cell lines. Most of these compounds showed 





This chapter contains an overview on all the medical fields in which  
organo-metallic compounds are involved, with a special  
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1 Introduction 
Biomedical inorganic chemistry, known as elemental medicine, is an 
important new area of chemistry. It really offers the potential for the 
design of novel therapeutic and diagnostic agents and hence for the 
treatment and understanding of diseases which are now intractable[1-2] 
(Figure 1). Inorganic elements has a central roles in biological and 
biomedical processes, and it is evident that many organic compounds 
used in medicine do not have a merely organic mode of action; some of 
them are activated or biotransformed by metal ions including metallo-
enzymes[4], others have a direct or indirect effect on metal ion metabolism.  
Elemental medicine offers real possibilities to pharmaceutical industries, 
which have traditionally been dominated by organic chemistry alone, for 
the discovery of novel drugs with new mechanisms of action. This field 
has been encouraged by the success of cisplatin, the worlds best selling 
anticancer drug, and platinum complexes with oral activity, reduced 
toxicity, and activity against resistant tumors are now on clinical trial. [3] 
 The organo-metallic complex titanocene dichloride has also been tested 
on patients, and RuIII complexes have a promising metastatic activity.  
The toxicity of GdIII complexes can be controlled so that they can be 
injected in gram quantities as magnetic resonance imaging (MRI) contrast 
agents with no risk and ligand design allows paramagnetic ions to be 
targeted to specific organs. 
Designed ligands also allow the targeting of radiodiagnostic (e.g. 99mTc) 
and radio- therapeutic isotopes (e.g. 186Re).  
There has been recent impreovment in understanding the coordination 
chemistry and biochemistry of older metallo-drugs such as gold 
antiarthritic and bismuth antiulcer drugs, and further work might lead to 
their  effective use.  
Current areas with exciting clinical potential include vanadium insulin 
mimics, manganese superoxide dismutase mimics, lanthanide-based 
photo-ensitizers, ruthenium nitric oxide scavengers, and metal-targeted 
organic agents.  
The increasing knowledge of organo-metallic chemistry will provide an 
opportunity for the design of new drugs (both inorganic and organic) in 
many other areas too, for example neuropharmaceutical and antiinfective 
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agents. Progress in medicinal coordination chemistry is closely dependent 
on understanding not only the thermodynamics (equilibria and structures) 
but also the kinetics (and mechanisms) of reactions of metal complexes, 
especially under biologically relevant conditions. 
 
   
 
Figure 1 Some of the key areas of medicinal inorganic chemistry 
1.1 MRI Contrast Agents 
Magnetic resonance imaging is now a strong instrument in clinical 
diagnosis.[5] Diseases can be detected from differences in 1H NMR 
resonances (mainly of H2O) between normal and abnormal tissues by 
injections of external paramagnetic agents, known as contrast agents. 
Most contrast agents contain FeIII GdIII, or MnII ions which have a large 
number of unpaired electrons (7, 5, and 5, respectively, high spin) and 
long electron spin relaxation times.[6, 7] 
Four GdIII complexes have been approved for clinical use, and are 
nowadays widely used, for example, for the detection of abnormalities of 
the blood-brain barrier.[14] Complexes containing DTPA (1, Magnevist) 
and DOTA ligands (2, Dotarem) are ionic, whereas those of BMA-DTPA 
(3, Omniscan) and HP-DOTA (4, Prohance) are neutral; their low 
osmolarity decreases the pain of the injections. All these agents are 
extracellular, and they diffuse rapidly into the interstitial space. The GdIII 
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ligand.Water exchange on GdIII is dissociative and steric hyndrance at 
the H2O site increases the exchange rate. 
Complex 1 does not enter cells and is excreted almost exclusively by the 
kidney.  
The insertion of a benzyloxymethyl substituent on the a-C atom of a 
terminal acetate of DTPA as in BOPTA gives a GdIII complex (5, 
Gadobenate), which enters hepatocytes and is excreted in bile.[8] The 
coordination sphere of GdIII in complex 5 is almost identical to that in 
complex1 (distorted tricapped trigonal prism, nine-coordinate), and both 
complexes show similar stabilities and relaxivities (see Figure 3).[8] 
  
  
Figure 2 Complexes used as MRI agents 
The distorted octahedral complex 6 (Teslascan is the mangafodipir 
trisodium salt),[9] is currently in clinical use for increasing contrast in the 
liver (detection of hepatocellular carcinomas).[10] The relaxivity of 6 is 
about 35 % greater than that of Mn complexes of DTPA and DOTA, 
which also do not contain directly coordinated water.[11] 
  






Figure 3 Crystal structure of 5 (on the left) and Teslacan (on the right). 
1.2 Radiopharmaceuticals 
Clinical interest in radionuclides centers not only on highintensity γ-ray 
emitters, especially 111In, 67Ga, 51Co 99mTc and 201Tl, , 51Cr, and 169Yb for 
diagnostic imaging, but also on β- emitters, for example 186Re, 89Sr, and 
153Sm for therapy.[1] Some 99mTc-based radiopharmaceuticals and several 
other radionuclides are currently utilized in clinical diagnosis. Complex 7 
([99mTcV(dl-hm-pao)], Ceretec) is an approved perfusion imaging agent 
for diagnosis and evaluation of cerebral stroke. It is absorbed by the brain 
and is transformed into a more hydrophilic drug which is retained in the 
brain. Complex 8 ([99mTcI(sestamibi)], Cardiolite), instead, is used for 
myocardial perfusion imaging. It was projected on the idea that cationic 
lipophilic complexes behave as potassium mimics and are taken up by the 
heart.[13] The sequential metabolism of the six equivalent methoxy groups 
of 8 to hydroxyl groups in the liver leads to formation of 99mTc complexes 
with stronger hydrophilicity which are not retained in myocardial 
tissues.[14] Monoclonal antibodies (mAbs) combined with radionuclides 
such as 111Insatumomab pendetide (which contains the murine mAb 
B72.3, which is directed to TAG-72, an antigen expressed by many 
adenocarcinomas) are currently used for diagnosis of ovarian and 
colorectal cancer.[15] Several other murine mAbs linked to 111In  and 99mTc  
are now  in clinical trials.[16] Substantial progress has been performed 
recently in the development of 99mTc-based receptor-specific 
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radiopharmaceuticals.[17] Encapsulation in fullerenes may also give a 
novel method for the delivery of radionuclides to target sites.[18, 19] 
 
Figure 4 Structure of Cardiolite. 
1.3 Antiinfective Agents 
Historically silver compounds have widely been used as antimicrobial 
agents in medicine. Silver  has a low toxicity and is active at low 
concentrations. The practice of instilling the eyes of babies with 1% 
AgNO3 solution immediately after delivery is still common in some 
countries for prevention of ophthalmia neonatorum.[20] Silver sulfadiazine 
9, made from AgI and sulfadiazine A, is currently used as an antifungal 
and antimicrobial agent. It is a polymeric insoluble drug which releases 
AgI ions slowly, and is applied topically as a cream to prevent bacterial 
infections in cases of acute burns. The slow release of antimicrobial AgI 
ions from inorganic or organic polymer matrices[21] is important for 
pharmaceutical industries.. 
The mode of action of AgI is unknown. Cell-wall damage may be 
irelevant, and it has been shown that Cys150 in phosphomannose 
isomerase, an essential enzyme for the biosynthesis of cell walls of 
Candida albicans, is a AgI target in this organism.[22] Silver-resistant 
bacteria are well known,[20] and improvement in understanding the 
mechanism of resistance is now being made. 
Antimony has been used for medical purposes for many centuries. 
Complexes of SbIII are conventionally more toxic than those of SbV. Two 
SbV drugs, sodium stibogluconate (Pentostam) and N-methylglucamine 
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antimonate (Glucantime), are currently used for the treatment of 
leishmaniasis, an infection caused by intracellular parasites.[23] The 
carbohydrates contained in the drugs may sbe useful for delivering SbV to 
macrophages. The SbV complexes may be considered prodrugs because 
the more toxic SbIII forms at or near the site of action. There is current 
interest in improving the solubility, stability, and efficacy of Sb drugs, 
and SbIII and SbV complexes with yeast mannan are reported to be 
promising.[24, 25] 
The iron chelating complex, named desferrioxamine 10 is clinically 
approved for the treatment of malaria disease. Its activity may results 
from the interfernce of FeIII metabolism inside the digestive vacuole of 
malaria parasites.[26]  
Several antisense oligonucleotides are strong inhibitors of HIV-1 
integrase,[27] and are currently on clinical trial. These have key sequences 
such as 5'-d(GTGGTGGGTGGGTGGGT) (11, T30175), and are only 
formed of thymidine  and deoxyguanosine. They fold up in the presence 
of K+ ions to give four-stranded structures dominated by two stacked 
guanine-quartet motifs.[28] 
This structure is very stable under physiological conditions (e.g., K-11 is 
resistant to serum nucleases with a half-life of 5 h) and is probably critical 
for biological properties. Macrocyclic bicyclam ligands such as 12 
(JM3100) are certainly amongst the strongest inhibitors of HIV ever 
described, being active at nanomolar concentration.[29] Since they are safe 
at these levels, they have a high selectivity index (ca. 105).  
The zinc complex of ligand 12 is also active.[30] The bicyclams appear to 
obstacle the virus entry and membrane fusion through interaction with the 
CXCR4 coreceptor during the early stages of the retrovirus replicative 
cycle.[31] 







Figure 5 Structure of complexes used as antinfective agents 
1.4 Superoxide Dismutase Mimics 
The free radical superoxide, O2-, is a product of endothelial cells  and 
activated leukocytes, and has been postulated to mediate the ischemia-
reperfusion injury as well as inflammatory and vascular diseases. It can 
react with NO  forming damaging peroxynitrite, ONO2-. The 
metalloenzyme superoxide dismutase, known as SOD can destroy O2-: 
Cu,Zn-SOD in the cytoplasm of eukaryotic cells, Mn-SOD in 
mitochondria [see Eqs. (1) and (2) below]. 
 
Mn+1   +  O2-                                 Mn+ + O2 (1) 
Mn+  +  O2-  +  2H+                          Mn+1 + H2O2 (2) 
 
However, the use of SOD in therapy is restricted by itsbrief plasma half-
life (clearance by the kidney) and inability to penetrate cell membranes 
giving only an extracellular activity. Low molecular mass mimics of SOD 
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are, for this reason,of much potential medical interest.[32] For example, a 
variety of Fe-based  and Mn-  porphyrins and macrocyclic complexes 
show SOD mimic activity.[33-36] Notably, MnII and MnIII macrocycles 
appear to be promising.[37, 38] For example, complex 13 (SC-52608) is 
able to scavenge superoxide and therefore effectively protect the ischemic 
and reperfused myocardium from injury.[39] Another example is 
manganese(III) 5,10,15,20-tetrakis(4-benzoic acid)- porphyrin 
(MnTBAP), which can protect against neurodegeneration and is for this 
reason of potential interest for the treatment of brain diseases such as 
Alzheimer’s  and Parkinson’s diseases.[40] 
 
 
Figure 6 Structure of SC-52608 
1.5 Cardiovascular System 
The FeII complex sodium nitroprusside 14 is the only clinically used 
among the metal-nitrosyl complex.[41] It is often used to rapidly decrease 
the blood pressure in humans. Its hypotensive effect is evident within 
seconds after infjection, and the required blood pressure is usually 
obtained within one to two minutes. It is also useful in cases of heart 
attacks, emergency hypertension, or surgery.[42] The therapeutic effects of 
14 is based on the quick release of nitric oxide, which relaxes vascular 
smooth muscle. Activation in vivo may involve reduction to 
[Fe(CN)5(NO)]3-, which then releases cyanide to give [Fe(CN)4(NO)]2- 
and then nitric oxide.[43, 44] 
Ruthenium complexes such as K[Ru(Hedta)Cl] K-15 (JM1226) have been 
proposed as nitric oxide scavengers for the control of NO levels under 
conditions of clinical interest.  
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In water complex 15 is in equilibrium with the aqua species 16 (JM6245; 
the pKa of the dangling arm carboxyl group is 2.4).[45] Both complexes 
bind to NO very quickly (rate constant>108m-1 s-1 at body temperature 310 
K) and tightly (K>108m-1), giving the linear nitrosonium RuII -NO+ adduct 
17.[45] Complex 16 has been demonstrated to reverse the poor response of 
the artery to vasoconstrictor drugs,[46] which is one of the major clinical 
problem in the treatment of patients with septic shock (caused by very 
high levels of circulating bacteria in the body). The excessive production 
of NO not only appears to be a main contributory factor in septic shock, 
but also in arthritis, inflammation, diabetes and epilepsy.  
 
 
Figure 7 Structures of complexes used in the cardiovascular system 
1.6 Insulin Mimetics 
Nearly 20 years ago It was founded that VV as vanadate and VIV as 
vanadyl can mimic some of the effects of insulin (stimulate glucose 
uptake and oxidation as well as glycoge synthesis).[47, 48] Vanadium 
complexes having organic ligands are often less toxic and can show 
improved aqueous solubility and lipophilicity. The orally active complex 
bis-(maltolato) oxovanadium(IV) (18,BMOV)[49] is about three times 
more effective in vivo as an insulin-mimetic agent than VOSO4[50] 
Complex 18 has, in the solid-state, a five-coordinate square pyramidal 
geometry with the oxo ligand in the axial position and trans maltolato 
ligands.[51] In aerobic aqueous solutions, the complex is quickly oxidized 
to the dioxovanadium(V) species.[52] 
Low molecular weight chromium-binding substance (LMWCr), a 
naturally occuring oligopeptide (ca. 1500 Da, consisting of CrIII, Asp, 
Glu, Gly, and Cys in a 4:2:4:2:2 ratio), has been demostrated to activate 
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the insulin-dependent tyrosine kinase activity of the insulin receptor 
protein, with the activity being proportional to the Cr content of the 
oligopeptide (maximium activity with four CrIII per oligopeptide) .[53] The 
trinuclear cation 19 can stimulate the tyrosine kinase activity of the 
insulin receptor in a manner quite identical to that of LMWCr.[54] 
Interestingly when acetate groups replaces propionate in 19, the complex 
does not activate but rather inhibits both the kinase and membrane 





Figure 8 Structures of complexes used as insulin mimics. 
1.7 Gold Antiarthritic Drugs 
Some injectable 1:1 AuI thiolato complexes are used clinically for the 
treatment of severe cases of rheumatoid arthritis, including sodium 
aurothiomalate (20, Myocrisin), aurothioglucose (21, Solganol), and 
sodium aurothiopropanol sulfonate (22, Allochrysine).[55] Most of the 
gold thiolates are polymeric complexes (e.g. chain or ring forms) with 
thiolate S-bridging and linear AuI ions and  have a gold-to-ligand ratio 
close to 1:1, as shown by EXAFS[56] and WAXS data.[57] Crystal 
structures of the gold thiolate drugs themselves have been ambiguous, the 
only example is given by  the crystallization of 20 by Bau[58] using 
techniques for macromolecules crystallization. The linear S-Au-S units 
are disposed into polymeric double-helical chains. Hexameric Au6S6 
rings of the type previously  predicted [59] have also been demostrated to 
exist in crystals with 2,4,6-tri(isopropyl)thiophenol as the thiolato 
ligand.[60] The formulated gold thiolate drugs often contain thiols in small 
Pag.12  Studies of novel organo-metallic compounds  E. Sirignano 
 
molar excess (e.g. 10%) over AuI, and readily undergo thiolate exchange 
and thiolate addition reactions.[61] 
 
 
Figure 9 Structures of gold antiarthritic drugs 
The only oral gold antiarthritic compound currently in use is the 
Auranofin, a phosphane complex. It is also highly cytotoxic to cancer 
cells in vitro, and is also reported to be active against psoriasis if used 
topically.[62] 
A common metabolite found in the plasma and urineof patients treated 
with gold drugs is [Au(CN)2]-,[63] an ion which promptly enters cells and 
is capable of inhibiting the oxidative burst of white blood cells. Therfore 
it could therefore be an active metabolite of gold drugs. It also shows 
anti- HIV and anticancer activity. The elevated Au content in the red 
blood cells of smokers receiving gold therapy has been realted to the 
inhalation of HCN through smoke.[64] Simulating the red blood cell 
concentrations, Elder et al.[65] have observed that [Au(CN)2]- reacts with 
GSH to form [Au(SG)2]-, which is very stable. In all probability 
[Au(SG)2]- is to be formed inside the cells both from auranofin and gold 
thiolate drugs, and may be responsible for the inhibition of many enzymes 
such as the Se-enzyme glutathione peroxidase.[66] Compound 20 is a 
strong inhibitor of neutrophil collagenase, a zinc enzyme which includes 
Cys ligands in the metal-binding site.[67, 68] These interactions may be 
useful in joint tissue. GoldI shows a srtrong affinity for thiolate S, but 
binds only weakly to N and O ligands. Hence the proteins containing 
cysteine thiolate groups (mainly those with low pKa values) are targets 
for AuI, but binding of AuI to DNA is poor. Moreover, the thiolate 
exchange reactions are usually very rapid. During therapy, Au levels in 
the blood typically reach 20mm, and Au is transported by albumin bound 
to Cys34.  
Chapter One Introduction Pag.13 
 
The rate of gold binding is regulated by the rate of opening of the cleft 
containing Cys34,[69, 70] and the Au binding seems to induce a “flip-out” 
of this residue.[71] GoldI drugs can strongly bind to thiol groups in DNA-
binding proteins such as the transcription factors Jun-Fos and Jun-Jun, 
allowing the possibility that gold can regulate the activity of transcription 
factor.[72] The oxidation of AuI to AuIII in vivo could be responsible for 
some of the side effects of gold drugs.[73,74] In inflammatory conditions, 
strong oxidants such as H2O2  and ClO- are potentially available in vivo 
and can oxidize the metal centers in auranofin, 20 and 21 to AuIII.[75] 
GoldIII has the unusual capability to deprotonate peptide amide groups 
even at low pH values (e.g. pH 2)[76] and may modify peptide recognition 
by T cells. GoldIII is able tooxidize disulfide bridges in insulin and  
albumin[77] and methionine residues of ribonuclease.[78] 
1.8 Bismute antiulcer Drugs 
Some bismuth complexes have been used for treating gastrointestinal 
disease for at least two centuries.[79] These include alicylate salts,  nitrate, 
sand colloidal bismuth subcitrate, all BiIII compounds. BismuthV is 
usually a powerful oxidant agent. The structures of Bi drugs are widely 
unknown. The coordination number of BiIII is highly variable (3-10), and 
often the coordination geometry is irregular.[80] BiIII is strongly acidic in 
water (first pKa ca. 1.5) and has an high tendency to form stable oxo-
bridged and  hydroxo clusters. 
 The [Bi6O4(OH)4](NO3)6 4H2O complex, known as “magisterium 
bismuti”  since the 17th century was used as a beauty care product, and 
crystallizes at pH values under 1.2.[81] The main understood in structural 
terms are the citrate complexes, for which several X-ray structures have 
been performed,[82] although none has absolutely the same composition as 
the drugs themselves. The dominant aspect is the dimeric [(cit)BiBi(cit)]2- 
unit (H4cit:citric acid), which contains bridging citrate anions. The Bi-
O(alkoxide) bond is reallystrong and  short (2.2 Å), and a stereochemical 
role for the 6s2 lone pair is evident in the structure. These dimers 
aggregate into chains and sheets in the crystal through a network of 
hydrogen bonds involving citrate, counter ions, and water to give 
polymers. Such polymerscould be deposited on the surface of ulcers.  
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BismuthIII citrate complexes seem to be stable in solution in a pH range of 
about 3.5 to 7.5. [BiIII(Hcit)] itself  is solubilized by a variety of 
amines,[83] and the adduct with the organic histamine antagonist 
ranitidine, ranitidine bismuth citrate,[84, 85] has recently been approved as a 
new drug. The antibacterical activity of BiIII against Helicobacter pylori 
seems to be important for its antiulcer activity.[86] This organism is also 
implicated in other diseases such as even cancer.  
The biological activities of BiIII are probably mainly due to binding to 
enzymes and proteins. The binding of BiIII to DNA is unknown, so far. 
There is a poweful correlation between the strength of binding of BiIII to a 
variety of ligands and that of FeIII. Although BiIII (ionic radius 1.03 Å) is 
bigger than FeIII (ionic radius 0.64 Å high spin) it also strongly  binds to 
transferrin, the serum FeIII transport protein.[87] The strength of binding of 
transferrin to BiIII can be related with the high acidity of BiIII. Correlated 
proteins (periplasmic iron-binding proteins) are implicated in Fe uptake 
by some virulent bacteria. 
 BismuthIII can promptly displace ZnII from the metallothionein, Cys-rich 
protein, and bismuth metallothionein is stable even under deeply acidic 
conditions (pH 2).[88] Cysteine and glutathione may have a crucial role in 
the transport of BiIII in cells and biofluids. These thiols can avoid the 
precipitation of colloidal bismuth subcitrate (CBS) at pH 2.0, and animal 
studies have shown that simultaneous oral administration of thiols and 
bismuth salts gives a significant increase in the bismuth concentration in 
blood plasma.[89, 90] The complex [Bi(SG)3] is very stable (lgK.29.6) in a 
wide pH range (2-10) with bindingonly  through the S atom.[91] Exchange 
of GSH between bound and free forms is quite rapid at biological pH (ca. 
1500 s-1). 
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1.9 Anticancer Agents: Platinum 
1.9.1 Clinical Platinum Complexes 
Platinum complexes are currently amongst the most world-widely used 
drugs for the treatment of cancer. Four injectable PtII complexes have 
been approved for clinical use and many other cis-diam(m)ine complexes 
are on clinical trials, including an oral PtIV complex. Today cisplatin (23) 
is one of the most largely used anticancer drugs, along with the second 
generation drug carboplatin [Pt(NH3)2(CBDCA-O,O')] (24). The 
glycolato complex 25 (nedaplatin, 254-S) and oxalato complex 26 
(oxaliplatin, l-OHP, which contains R,R-1,2- diaminocyclohexane, 
DACH) have also been approved for clinical use in Japan and in all the 
countries, respectively. These drugs are particularly effective in 
“cocktail” or combination chemotherapy for treatment of advanced 
colorectal,  lung, and ovarian cancers.[92, 93]  
 
 
Figure 10 Stuctures of Platinum complexes 
The sterically-hindered complex 27 (ZD0473) is active (by oral 
administration and injection) against an acquired cisplatin-resistant cell 
line of a human ovarian carcinoma xenograph,[94] and entered clinical 
trials in 1997. It is certainly less reactive than cisplatin, for example 
binding to plasma proteins  and inducing DNA interstrand crosslinks in 
cells less quickly. The hydrolysis rate of 27 are  at least two to three times 
slower than those of cisplatin (table 1). 
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Table. 1 Rate constants k (Scheme 1) for hydrolysis of the platinum- picoline anticancer 
complex 27 and the  3-picoline analogue at 310 K (0.1m NaClO4), in comparison with 
cisplatin (308 K, 0.32m KNO3) 
 
 
Scheme. 1 Reaction step in the hydrolysis of a(m)mineplatinum complexes 
 
The orally active complex 28 (JM216) is demonstrated to have stronger in 
vitro and in vivo activity compared to cisplatin against small cell lung, 
human cervical, and ovarian carcinoma cell lines.[96] Incubating 28 with 
human plasma, it is transformed into at least six biotransformation 
products, which include the dichloroplatinum(II) complex cis-
[PtCl2(NH3)(cyclohexylamine)] and the monoand dihydroxo PtIV 
complexesas the major metabolite.[97,98]  
Complex 29 (Lobaplatin, D-19466) was approved into clinical trials in 
1992. 
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Figure 11 Structure of Platinum complexes 
The central Pt unit in the trinuclear complex 30 (BBR3464, counteranion 
= NO3-), is capable only of hydrogen-bonding interactions with DNA and  
is reported to be up to 100-fold more potent than cisplatin against human 
tumor cell lines resistant to cisplatin .[99-101] The general charge of 4 
greatly enhances DNA affinity, characterized by long-range interstrand 
cross-linking up to six base pairs apart with significant efficient, 
unwinding and irreversible conversion of B- to Z-DNA. The adducts are 
capable of terminating the DNA synthesis in vitro. The cytotoxic effect of 
the complex is insensitive to the p53 status of cisplatin-resistant cells 
(effective against tumors showing a mutant p53).  
cis-Bis(nonadecanoato)(trans-R,R-1,2-diaminocyclohexane)- platinumII 
31 (N-DDP) is a ipophilic liposome-incorporated cisplatin analogue that 
has demonstrated promising in vivo activity against tumors resistant to 
cisplatin and liver metastases.[102] 
 
  
Figure 12 Structure of Platinum complexes 
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1.9.2 Platination of DNA 
The guanine N7 is the most electron-rich site on DNA (most easily 
oxidized), and the major adducts of platinum drugs with DNA are 1,2-
GpG and 1,2-ApG intrastrand crosslinks. The features of these adducts 
have been widely characterized and reviewed.[ 103] The NMR solution 
structure of cis-[{Pt(NH3)2}2+{d(CCTG*G*TCC)⋅d(GGACCAGG)}] 
(where * denotes Ptbound G) indicates that the B-DNA backbone 
conformation is mainly altered to accommodate the platinated lesion 
(Figure 13).[104]  
 
Figure 13 NMR solution structure of cis-[{Pt(NH3)2}2+{d(CCTG*G*TCC) 
⋅d(GGACCAGG)}] 
A novel X-ray crystal structure of the cisplatin adduct of the duplex 
d(CCTCTG*G*TCTCC)⋅ d(GGAGACCAGAGG) (Figure 4) shows that 
cisplatin bends DNA by 35-40° in the direction of the major groove with 
a dihedral angle of 268 between the two guanine rings.[105,106] The duplex 
acquires a juxtaposition of A-like and B-like helical DNA segments. It is 
notable that the conformation surrounding the GG platination site in the 
solid-state X-ray crystal structure [106] is strongly similar to that in 
solution.[104,107] The Pt ion is removed from the planes of the coordinated 
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G-bases by about 0.8 Å, suggesting the presence of critical strain in this 
lesion. The properties  and nature of minor cisplatin -DNA lesions which 
account for about 10%of the adducts, including 1,3-d(GpNpG) interstrand 
and  intrastrand cross-links and monofunctional adducts, are less well 
know. Interstrand cross-linking of DNA occurs mainly between two 
guanine residues on opposite strands, and requires a distance of 
approximately 3 Å between the two N7 atoms. The most conventional 
interstrand cross-linking sequences are 5'-CG and 3'-CG.[108] In these 
sequences the two guanine residues are separated by at least 7-9 Å; 
therefore a large distortion of double-helical B-DNA is need to achieve 
the cross-linking.  
The solution NMR structure (see Figure 14 on the left) of cis-
[{Pt(NH3)2}2+{d(CATAGCTATG)2}] shows that the duplex endures a 
strong rearrangement at the lesion site, locating the platinum atom in the 
minor groove.[109] The deoxyribose of the platinated G residue is inverted 
so that O4' is pointing in the opposite direction respect to the remaining 
nucleotides. Moreover, the C residue which was initially base-paired to 
the platinated G is extruded and is transformed in extra-helical  
(see Figure 14 on the right). In the solution NMR structure of the 
interstrand cross-linked [{Pt(NH3)2}2+}-{d(CCTCG*CTCTC) 
´d(GAGAG*CGAGG)}], the cis-{Pt- (NH3)2}2+ moiety is also placed in 
the minor groove.[110] The stacking of the two cross-linked guanine 
residues with the surrounding bases forms a bend of 40° towards the 
minor groove. A very similar bend occurs in the X-ray crystal structure of 
this interstrand cross-link. The two cytosin residues are extruded from the 
double helix, and the platinum residue is embedded in a cage of nine 
water molecules. The general mechanism of formation of GG cross-links 
on DNA by cisplatin is evident in Scheme 2. Cisplatin is hydrolyzed to 
give monoaqua and diaqua species with a half-life of 1.7 h at 310 K. The 
aqua complexes are considered to be the active species towards DNA. 
 The finding that the 5'-G monofunctional adduct formed during the 
reaction of cisplatin with the 14-mer DNA duplex 
d(ATACATGGTACATA)  d(TATGTACCATGTAT) is very long lived 
with a half-life of 80 h at 298 K  was unexpected.[111,112] The half-life of 
the two monofunctional G adducts of the GG single strand are similar, 
proposing that the three-dimensional structure of DNA has a role in 
stabilizing the 5'-G adduct either by constraining the position of the 
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incoming 3'-G N7 ligand or by shielding the Cl ligand from hydrolysis. 
Molecular modeling studies prove that hydrogen-bonding between the 
carbonyl groups on DNA and the NH3 ligands plays a main role in 
determining the orientation of the Pt-Cl bonds and their accessibility. 
Molecular mechanics calculations demonstrate that although the chloride 
ligand in the monofunctional adduct faces outward, away from the helix, 
the aqua ligand which replaces it after hydrolysis faces inwards on 
account of its strong hydrogenbonding properties.[112] Modeling of 
transition states is now necessary.  
 
Scheme. 2 Mechanism of reaction of cisplatin with DNA 
 
Kinetic analyses based on HPLC results provide the accurate 
determination of the rates of both platination and chelation steps for 
reactions of cisplatin diaqua with oligonucleotides.[ 113,114] For the double-
stranded oligonucleotide d(TTGGCCAA)2 the formation of the 5'-G 
monoaqua adduct is faster than that of the 3'-G monoadduct, and 
macrochelate ring closure of the 5'-G monoaqua to give the bifunctional 
adduct (half-life of 3.2 h at 293 K) is much slower than that of the 3'-G 
monoadduct. The biological importance of long-lived monofunctional 
adducts on DNA remains to be detected, but these alone may be sufficient 
to kill cells if they are not repaired, which seems to be the case for 
complex 33, the active trans iminoether (see Section 1.9.3).[115] Long-
lived monofunctional adducts may also contribute to the formation of 
DNA- protein cross-links. 
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Figure 14 Crystal structure of  [{Pt(NH3)2}2+}-{d(CCTCG*CTCTC) ´ 
d(GAGAG*CGAGG)}] (on the left) and of  cis-[{Pt(NH3)2}2+{d(CATAGCTATG)2}] (on 
the right) 
The stability of the Pt-N7G bond is demonstrated to be very high, and it 
can be broken only by a very strong nucleophiles such as thiourea or  
cyanide. However, recent studies have found that this bond can be labile 
in certain DNA adducts.  
The adduct trans-{Pt(NH3)2}2+{d(TCTACG*CG*TTCT)}] (1,3-GG 
cross-link) is at neutral pH unstable and rearranges to form the linkage 
isomer trans-[{Pt(NH3)2}2+{d(TCTAC*GCG*TTCT)}] (1,4-CG cross-
link).[116] It was indicated subsequently that intra- and interstrand 
transplatin -DNA adducts undergo isomerization in both double- and 
single-stranded and DNA.[117-119] For instance interstrand cross-links 




Scheme. 3 Rearrangement of a trans-[{Pt(NH3)2}-DNA] intrastrand cross-link (left) to 
an interstrand cross-link (right) 
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The isomerization of the intrastrand d(CCTG*G*TCC) ⋅ d(GGACCAGG) 
cross-link to a d(CCTG*GTCC) ⋅ d(GGACCAGG*) interstrand cross-
link proves that even Pt-N7 bonds in Pt - 1,2-GpG cross-links can be 
destabilized.[ 104] This process seems to be assisted by Cl-. 
1.9.3  Protein Recognition 
In tumor cells the repair of platinated DNA lesions may be protected by a 
class of proteins named HMG high mobility group proteins.[120, 121]  
The protein HMG1 sows three structural domains, two of them, known as 
domains A and B, are positively charged, and the third domain comprises 
a 30-amino-acid stretch of acidic residues at the C terminus site. Several 
NMR structures of HMG domains have been performed.[122,123] Domain B 
of HMG1 consists of three α-helical regions joined by small loops, and 
folded into an L-shaped structure. The two domains, the positively 
charged domain A and the central domain B bind to DNA, while the 
acidic C-terminal domain interacts with histones only. 
The binding affinity of HMG1 towards a series of cisplatin modified 15-
mer DNA duplexes d(CCTCTCN1G*G*- N2TCTTC) 
⋅ d(GAAGAN3CCN4GAGAGG) is strongly dependent on the bases 
adjacent to the Pt lesion.[124] The affinity for HMG1 domain A decreases 
by at least two orders of magnitude in the order N2=dA>T>dC. When 
N1=N2=dA, Pt-DNA binds 100-fold stronger to HMG1 domain A 
(Kd.1.6nM) than to HMG1 domain B (Kd.134nM). The HMG binding 
succed ind increasing the bending of platinated DNA to as much as 
90°.[125] NMR studies of a GG 14-mer platinated with cisplatin show that 
the kinked duplex binds in the elbow region of HMG1 domain A,[126] and 
recent X-ray studies of HMG1 domain A bound to a 16-base-pair DNA 
fragment containing a cisplatin-DNA 1,2-d(GpG) intrastrand crosslink 
suggest that the protein inserts a Phe side chain into the platinum site.  
The linker histone H1, a nuclear protein, also binds much more strongly 
to DNA modified by cisplatin than to transplatin or unmodified DNA.[127] 
Competitive binding of a cisplatin modified 123-base-pair DNA fragment 
suggest that histone H1 binding is stronger than that of HMG1. Also the 
TATA box-binding protein (TBP)/TFIID, a promoter recognition factor 
binds selectively to and is sequestered by cisplatin-damaged DNA. This 
may lead TBP/TFIID away from its normal promoter sequence explaining 
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the inhibition of RNA synthesis.[128] Therefore these proteins may also 
have an important roles in the mechanism of action of platinum 
complexes drugs. 
1.9.4 Active trans Complexes 
Most of the work on the design of platinum anticancer complexes has 
focused on cis-diam(m)ine complexes, since it was demonstrated, years 
ago, that trans-[PtCl2(NH3)2] is inactive. However, the discovery that 
trans-[PtCl2(py)2] (py = pyridine) is strongly cytotoxic has stimulated 
renewed interest in trans complexes.[129] The trans PtIV complex 32 is 
active against both human and murine subcutaneous tumor models,[130] 
and efficiently promotes single-strand breaks and DNA interstrand cross-
links.[131] These properties may explain its unusual cytotoxicity property 
against cisplatin-resistant tumors.[132] Strikingly the corresponding trans 
PtII complexes,without the axial hydroxo groups, are inactive. Direct 
reactions of the PtIV complexes with DNA may be crucial, but in vivo 
reduction could give reactive intermediates. 
Trans-Imino ether platinum complexes such as 33 are more cytotoxic  
than the cis analogues (Ome and Pt are cis with respect to C=N in the Z 
isomer, and trans in the E isomer).[133,134] The mechanism of action of 
these agents seems to be different from that of cisplatin and may be 
correlated to the properties of the imino ether ligands.[135] Although these 
trans complexes react with DNA more slowly than cisplatin, they give the 
same level of DNA binding after 24 hrs. The trans E,E complex is the m 
strongest complex in inhibiting DNA synthesis and cell proliferation, but 
does not induce large local DNA conformational changes.[136] It especially 
forms monofunctional adducts at guanine residues in double-helical DNA 
even after long incubation times (48 hrs at 310 K).[137a] The reactivity 
of the second chloride ligand in the monofunctional adduct is strongly 
reduced. The trans E,E monofunctional adducts are not recognized by 
HMG proteins.[137b,c]  
Pag.24  Studies of novel organo-metallic compounds  E. Sirignano 
 
 
Figure 15 Structures of trans Pt complexes 
1.9.5 Biotransformation  
l-Methionine (L-MetH) may have an important role in the metabolism of 
platinum anticancer drugs. The PtII- L-Met complexes form quickly in 
plasma after injection of cisplatin into rats.[138] The complex [Pt(Met-
S,N)2] has been detected in the urine of patients[139] and exists mainly as 
the cis isomer (cis:trans=87:13) in solution  (Figure 16).[140] 
 
Figure 16 Isomerization of R,R-trans- and S,R-cis-[Pt(Met)2], a metabolit of cisplatin 
HAS, the human serum albumin is a single-chain 66-kDa protein which 
has 17 disulfide bridges and one free thiol group at Cys34, as well as six 
Met residues: M87, M123, M298, M329, M446, and M548. Reaction 
between HAS and cisplatin is believed to be the main route for platinum 
binding in human blood plasma.[141] Recent data suggest that cisplatin 
reacts strongly with methionine residues of albumin, forming a Met- S,N 
macrochelate together with minor adducts with Cys34 and monodentate 
Met-S residues.[142]  
The reaction of carboplatin 24 with l-Met gives way to to a surprisingly 
stable ring-opened intermediate with a half-life of 28 hrs at 310 K.[143] 
Similar ring-opened complexes seems to be present in urine after 
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carboplatin administration.[144] Therefore it can be possible that the 
reaction of carboplatin with Met or its derivatives could give an activation 
pathway for the drug. The binding of the methionine sulfur atom is 
reversible, and it can be displaced by guanine N7. 
Intracellular thiols such as glutathione (the tripeptide g- Glu-Cys-Gly, 
GSH), often present at concentrations of 3-10mM, are capable of 
inactivating platinum drugs. The main product from reaction between 
GSH and cisplatin is a high molecular mass polymer with a Pt:GSH ratio 
of 1:2.[145] The formation of these polymers may be responsible for 
depletion of platinum from the circulation. The active export of cisplatin 
from cells is one of the main mechanisms of resistance, and a GS-X 
pump, an ATP-dependent export pump for GS-conjugates, is able to 
pump out GS-Pt complexes from cancer cells.[146] Reaction between 
cisplatin and the cysteine-rich protein metallothionein (MT) leads to 
displacement of the ammine ligands and gives rise to Pt7-10MT containing 
PtS4 clusters.[147] This gives way to another pathway for the inactivation 
of Pt drugs. 
1.9.6 Photoactivation 
Both PtII and PtIV complexes have long been considered to be 
photoreactive, and there are many field for the application of 
photodynamic reactions in pharmacology and biochemistry. A new 
approach to DNA platination involves the use of iodoplatinum(IV) 
complexes which are activated by visible light.[148] The toxicity of 
trans,cis-[Pt(en)(OAc)2I2] against human bladder cancer cells is enhanced 
(by 35%) when the treated cells are irradiated with light of λ >375 nm. It 
has been shown that visible light can give way to the aquation of this 
complex followed by photoreductive platination of guanosine 
monophosphate, in contrast to the dihydroxo analogue.[149] Reactions of 
iodoplatinum(IV) ethylenediamine complexes with glutathione in the 
absence of light involve the initial attack of thiol on an iodide ligand of 
PtIV to give a reactive chelate ringopened intermediates.[150] Electron 
transfer driven labilization of trans ligands provides a new concept in 
drug design. UV light induced cleavage of both inter and intrastrand 
cross-links involving Pt-G bonds has been observed. Irradiation of DNA 
modified by cisplatin with UV light (λ>300 nm) can produce specific 
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cross-links to the protein HMG1, thought to involve Lys6 in domain B 
with labilization of a - purine bond.[151, 152] 
1.9.7 Octahedral Platinum(IV) Complexes  
Octahedral PtIV complexes show a tendency towards ligands substitution 
by a dissociative mechanism respect to an associative mechanism for PtII, 
with the net result that PtIV compounds are moderately more 
substitutionally inert. This is desirable for lower toxicity and oral 
bioavailability but it is not desirable for DNA intercalation. Despite that, 
most PtIV complexes are showing considerable activity in initial trials, 
with functionality thought to depend on the in vivo reduction of Pt IV to 
PtII, producing reactive intermediates capable of interacting with DNA. In 
order to obtain oral bioavailability and beat cellular resistance, 
reserchears have tried multiple strategies to improve cisplatin properties. 
The reduction of PtIV to PtII compounds by biological agents is crucial to 
exert their antitumor activity. The reduction potential of PtIV complexes 
depends on the type of equatorial and axial ligands [153-160]. Choi et al. in 
another study, proved that the reduction rates which correlate with the 
reduction potentials depend on the electron withdrawing influence of the 
axial ligand [157]. In relation to the studied ethylenediamine-based PtIV 
complexes the fastest reduction rate (OH < OCOCH3 < Cl < OCOCF3) 
corresponds to the most electron withdrawing ligand and correspond to 
the highest observed cytotoxicity. Kelland et al. reported the synthesis of 
about 25 trans-PtIV complexes and their trans-PtII counterparts, and then 
evaluated and compared in vitro as well as in vivo anticancer activity of 
these complexes. The described compounds had the following general 
formula: trans- [(amine)(ammine)Cl2Y2] PtIV (Y =OH or Cl). Two amino 
groups atoms together with two chloride lie in the same plane, in 
equatorial positions. In opposition to them two hydroxide groups or two 
chloride atoms (Y ligands) are the axial ligands,. The anticancer activity 
studies gave very promising results. The complexes were tested in vitro 
against a series of human ovarian carcinoma cell lines, which contained 
tumor cells possessing either acquired (41McisR, CH1cisR and 
A2780cisR) or intrinsic (HX/62 and SKOV-3) resistance to cisplatin. 
Many of the complexes had a comparable anticancer activity respect to 
cisplatin and also did not show acquired cisplatin resistance. Notably, 14 
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complexes showed significant anticancer activity in vivo in the 
subcutaneous murine ADJ/PC6 plasmacytoma model. Among these, 13 
complexes had axial hydroxido ligands and one had axial ethylcarbamate 
ligands, whereas all the platinumII and tetrachloroplatinumIV complexes 
were inactive [161].  
1.9.8 Polynuclear Platinum Complexes  
By the structural point of view, polynuclear platinum complexes are a 
different group. These innovative complexes have two or more platinum 
centers linked by various types of ligand (aromatic, aminoalkane, etc.). 
Thus, polynuclear complexes contravene many structure–activity rules for 
platinum complexes.  Different SARs rules were created for polynuclear 
complexes based on their in vitro cytotoxicity results. One of the 
conditions to obtain good antitcancer activity of the complexes is the 
location of the leaving group, preferably chlorido, in trans position to the 
bridging linker. In the meanwhile, many trans and cis polynuclear 
complexes were synthesized, mainly by Farrell et al. [162-164]. Binuclear 
platinumII complexes with bifunctional spermine, thiourea and modified 
tetraamine linkers have been synthesized and studied. The  secondary, 
protonated, uncoordinating amines in these compounds may give 
additional interaction with DNA by electrostatic interaction and hydrogen 
bonding and thus provide a stronger activity over the parent dinuclear 
agents such as BBR3005 [{trans-PtCl (NH3)2}2-µ-[{trans- 
Pt(NH3)2(H2N(CH2)6NH2)2}](NO3)2 (Fig. 17.-complex 1) [165,166] .  
Trinuclear and tetranuclear platimun complexes have also been 
eavaluated [167,168]. The trinuclear complex BBR3464 (Fig. 17.- complex 
2) is the first example of multinuclear compound which entered clinical 
trials in late 1997. Its preclinical antitumor profile was accentuated by 
remarkable potency, therapeutic doses approximately ten-folds lower that  
cisplatin, and activity in a wide set of solid human cancer [169,170]. 
Currently, BBR3464 is being entered in phase II clinical trials under the 
auspices of Novuspharma SpA. The investigations of phase I trials 
demonstrated that neutropenia and diarrhea were present as dose-limiting 
toxicities. The efficacy of this complex was not limited by neurotoxicity 
nephrotoxicity, or pulmonary toxicity [171]. The complex interacts with 
DNA with a different mechanism respect to cisplatin or other 
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mononuclear platinum complexes [172]. The tetranuclear platinum 
complex (Fig. 17.- complex 3), had low cytotoxic activity perhaps  due to 
problems during trasport across the cell membranes [168]. 
  
Figure 17 Structure of polynuclear platinum complexes 
 
1.10 Palladium Complexes as Alternative Potential 
Antitumor Agents 
 The strong analogy between the coordination chemistry of PtII and PdII 
compounds has encouraged studies of PdII complexs as anticancer 
compounds[173,174]. A crucial factor that might explain is the ligand-
exchange kinetics. The hydrolysis of leaving ligands in palladium 
complexes is too rapid, 105 times faster than their corresponding 
platinum complexes. They dissociate promptly in solution giving very 
reactive species that are unable to reach their pharmacological targets. In 
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considerably stronger activity of palladium complexes suggests that in 
order to develop an antitumor palladium drug it must be stabilized by a 
strongly coordinated nitrogen ligand and a suitable leaving group. If this 
group is acceptably non labile, the drug can maintain its structural 
integrity in vivo for an enough long time. Many simple PdII compounds 
with interesting cytotoxic features have been previously reported such as 
[cis-(NH3)2PdCl2] (Fig. 18- complex 1), [trans-(NH3)2PdCl2] (Fig. 18- 
complex 2), [(1,5-COD)PdCl2], [(Π-C3H5)PdCl2]2 and 
[(cyclopentyl)2PdCl2] Recent progresses in this field have also been based 
on PdII compounds having bidendate ligands as a way to prevent any 
possible cis-trans isomerism [175-177] . 
 
Figure 18 Two palladium (II) compounds with biological properties 
1.10.1 Trans-Palladium(II) Complexes Containing Bulky 
Monodentate Ligands  
Many trans-Pd complexes with interesting activity against cancer cells 
have been prepared. Generally, the strategies that have been used to 
design these compounds were on the window of reactivity usually 
employed for the potential platinum anticancer drugs. A comparative 
study on anticancer activity was carried out between the diethyl-2- 
quinolmethylphosphonate (2-dmqmp) and dihalide PdII complexes of 
monoethyl-2-quinolmethylphosphonate (2-Hmqmp)[178]. The diester 
ligand has two potential donors, the the O from phosphoryl giving the 
complex [trans-(2-dqmp)2PdCl2] and N from quinoline and (Fig. 19- 
complex 1). The complexes of the diester 2-dmqmp were found to be 
more active than those of the monoester-based ligand (2-Hmqmp). This 
may partly be due to the greater leaving activity of the halogen ligands in 
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Figure 19 Trans-palladium (II) complexes containing bulky monodentate ligands 
Fulrani et al., reported the synthesis and cytotoxic studies of some trans-
[(L)2Pd(X)2] complexes (Figure 19 complex 2) (L= N,N-dimethyl-O-
ethylthiocarbamate: DMTC or N-methyl-O-ethylthiocarbamate: MTC, 
X= Cl, Br). Other palladium complexes based on 2-Mercaptopyridines 
(MP) were also synthesized. The [(MP)3Pd(Br)]Br (Fig. 19- complex 3) is 
of potential clinical use since it shows lower IC50 values on LoVo cell 
lines than cisplatin and about the same as its PtII analogue [179].  
PalladiumII complexes containing alkyl phosphonates derived from 
quinoline  and aniline were reported. Most of the aniline compounds (e.g. 
(Fig.19, complex 4)) had cyctotoxic properties in vitro against animal and 
human tumor cell lines. Complexes with naturally occurring compounds 
have also been used. The palladium complex which contains the bulky 
nitrogen ligand harmine (7-methoxy-1-methyl- 911-pyrido[3,4-b]indole, 
trans-[Pd(harmine) (DMSO)Cl2] (Figure 19 complex 5) shows a greater 
cytotoxic activity against K562 and L1210 cell lines than cisplatin [180]. 
Abu-Surrah et al., recently, reported the synthesis and molecular structure 
of a new chiral, enantiometrically pure, trans-palladium(II) complex, 
trans-[2 {(R)-(+)- bornyl-amine}2Cl2] (Fig. 10) that has the bulky amine 
ligand R-(+)-bornyl-amine [181]. The complex had similar anticancer 
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activity against HeLa cells when compared to the activity of the standard 
drugs, cisplatin, carboplatin and oxaliplatin. 
 
Figure 20 Structure of the palladium (II) complex 
1.10.2 PalladiumII Complexes with Bidentate N∩N Ligands  
Dichloro palladiumII complexes with spermine and spermidine were 
reported by Navarro-Ranninger et al. [182]. This type of chelating ligands 
have been utilized because of their relevant biological activity; they are 
involved in differentiation and proliferation of cells in membrane 
stabilization  and DNA replication. Complexes of spermidine (Fig. 21- 
complex 1) show values of IC50 similar to cisplatin, whereas those of 
spermine (Fig. 21- complex 2) have low anticancer activity. 
Ethylendiamine palladiumII complexes with pyridine or its derivatives 
were also reported[183]. The increase of the electron donor properties of 
the substituents mainly lead to an increase of the donor strength of the 
coordinated pyridines, which directly lead to the increase of the cytotoxic 
activity of the palladium compounds. 
 
Figure 21 Palladium(II) complexes with bidentate N∩N Ligands 
Abu-Surrah et al., recently, used an alternative method to prepare the 
enantiometrically pure DACH-based palladiumII complexes [184,185]. In 
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with [cis-Pd(PhNC)2Cl2], a palladiumII starting material that is soluble at 
25°C  in most organic solvents, in CH2Cl2. Following this method, the 
nucleophilic substitution reaction of the complex [cis-Pd(PhNC)2Cl2] 
with (1R,2R)-(-)-1,2-diaminecyclohexane afforded the square planar 
Pd(II) complex [(1R,2R)-(-)-(DACH)PdCl2] (Fig. 22- complex 1) with an  
high yield. The corresponding cationic, aqua complex, 
[(DACH)Pd(H2O)2](NO3)2 (Fig. 22- complex 2) and the oxalate complex 
[(DACH)Pd(C2O4)] (Fig. 22- complex 3) have also been synthesized and 
characterized [186]. A series of other oxaliplatin like complexes such as  
[(DACH)Pd(O-O)] has also been synthesized by Khokhar et al. [187] (O-O: 
malonate, methylmalonate, phenylmalonate, xylate). Unluckly, the 
influence of the different dicarboxylate ligands could not be focused since 
the complexes lack the anticancer activity. This could be related to the 
low stability  and solubility  of the above complexes in solution. 
 
Figure 22 DACH-based palladium (II) complexes 
In order to increase the stability of the palladiumII complexes, two 
chelates forming two rings around the central atom were synthesized and 
studied. Modified amino acids such as py-CH2-accys (Fig. 23- complex 1) 
(accys: N-acetyl-S-methylene-2-(2-pyridine)-L-cysteine) have been used 
[188]. The S,N-chelation mode of these ligands is  important, since only the 
side chain of the aminoacid is involved in metal coordination, whereas the 
aminoacid function remains uncoordinated, leaving this functional group 
accessible for the attachment of other aminoacid or peptides. It has been 
demonstrated that the reactivity of these palladium complexes compete 
with some platinumII complexes. Another study investigated compounds 
having NO3 as a chelate in addition to a bidentate nitrogen ligand [189]. A 
comparison among [(bipy)Pd(NO3)2], [(AMP)Pd(NO3)2], 
[(AEP)Pd(NO3)2], [(DACH)Pd(Meorot)] (bipy = 2,2´-bipyridyl, AMP = 
2-aminomethylpyridine, AEP = 2-aminoethylpyridine, Meorot = 3-
methylorotate) proved that only [(DACH)Pd(Meorot)] (Fig. 23- complex 
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against P388 leukemia. Similarly, [(DACH)Pd(5-fluroorot)] (Fig. 23- 
complex 3) later reported [190], showed a significant anticancer activity. 
These strong chelating ligands, replacing nitro or chloro ligands, induce a 
reduction in the percentage of hydrolysis. 
 
Figure 23 Palladium II complexes bearing two bidentate chelates or tetradentate 
nitrogen ligands 
2-2’-bipyridylamine-based palladiumIIcomplexes having L-alanine or 
glycine have been reported and evaluated [191]. The alanine based complex 
(Fig. 23- complex 4) dysplaied stronger cytotoxic activity against P388 
lymphocytic leukemia cells than the glycine based one. Other aromatic 
ligands such as 1,10-phenanthroline, which is one of the most widely  
used ligands in coordination chemistry, has been utilized in the field of 
antitcancer-transition metal chemistry. Its planar nature allows its 
participation as a DNA intercalator. Several derivatives of it were 
synthesized and used as tetradentate ligands. The activities of [N,N-
dialkyl-1,10- phenanthroline-2,9-dimethamine)Pd(II)] (Fig. 23- complex 
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the nature of the alkyl substituents. The complexe having the bulkiest 
groups showed lower IC50 values than cisplatin [192]. 
1.10.3 Palladium complexes with Biphosphine P∩P Ligands 
Many of the prepared palladiumII complexes showed a moderate 
anticancer activity in vitro compared to the platinum-based drugs because 
of their very high lability in biological fluids [193]. Therefore, it has been 
suggested that the organometallic biphosphine-based cyclopalladated 
complexes which are more stable and less toxic could have in vivo a more 
specific anticancer activity[194]. Many cyclopalladate complexes based on 
biphosphine ligands (Fig. 24) have been synthesized and evaluated for 
their anticancer properties in a murine syngeneic B16F10 melanoma 
model. The ionic complex killed 100% tumor cells even at very low 
concentration (<1.25 µM). Other PdII complexes containing bidentate 
phosphine ligands of the general formula [L2PdXm]n+nX (L= Ph2P-A-
PPh2, A= (CH2)2, (CH2)3, X= Cl, Br, NO3) were synthesized and studied 
for in vitro cytotoxicity, anticancer activity in murine tumor model and 
mechanism of action. The mode of action of these complexes seems tp be 
different from that of cisplatin in relation to the effects on DNA. 
 
 
Figure 24 Palladium (II) complexes with biphosphine P∩P Ligands 
1.10.4 Palladium(II) complexes with N∩S Mixed Donor Ligand 
Khan et al. reported some palladiumII complexes with mixed sulfur-
nitrogen ligands such as substituted pyrimidines (mercapto or amino) and 
methionine [195]. Methionine coordinates to PdII through sulfur and amino 
nitrogen, thus leaving a carboxylic group free. It has been demonstrated 
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that the complex [(methionine)Pd(2-merpy)Cl]Cl (Fig. 25) has IC50 value 
lower than 10 µg/ml, in vitro, so it could be a potential anticancer agent. 
 
Figure 25 Palladium(II) complexes with N∩S Mixed Donor Ligand 
1.10.5 Dinuclear Palladium(II) Complexes  
In the field of dinuclear palladium complexes chemistry, the use of 
strongly coordinated dinitrogen ligands is preferred. The synthesis of 
putrescine and spermine-based dinuclear complexes: [PdCl4(Put)2] and 
[PdCl4(Sperm)2] has been reported by Navarro-Raninger.The complex 
(Fig. 26- complex 1) is a coordination complex with a dimeric nature. In 
the 4 amino groups of the spermine coordinate to two cis-Pd-centers (Fig. 
26- complex 2). The cytotoxicity results showed that the putrescine 
complex is much more reactive respect to the spermidine one [182]. Zhao 
et al. evaluated dinuclear palladium complexes having two functional 
[Pd(en)(pyridine)Cl]+ units bridged by Se or S.[196]. The complexes are 
soluble in water. The Se-Bridged PdII dimmer (Fig. 26- complex 3) has a 
lower IC50 than the S analogue or cisplatin against the HCT8 cancer cells 
Dinuclear cyclopalladated organometallic complexes having biphosphine 
ligands were also studied by Rodrigues et al. [197]. The dimeric PdII 
complex showed to be the most active in vivo compared to the 
corresponding mononuclear complexes. It reduces tumor growth and 
increases animal survival. 
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Figure 26 Structure of multinuclear Palladium complexes 
1.11 Ruthenium (II & III) Complexes as Antitumor 
Agents  
Recently it was demonstrated that ruthenium has several favorable 
chemical properties, suggesting that it may be a strong candidate to 
substitude platinum and to give a basis for rational anticancer drug 
design. Ruthenium is less toxic than platinum and it is believed that the 
remarkable antitumor activity of ruthenium is related to its ability to 
mimic iron in binding to several biomolecules, including albumin and 
serum transferrin. Two RuIII complexes, named trans-
[RuCl4(Im)(DMSO)]ImH (NAMI-A) and trans-[RuCl4(Ind)2]IndH 
(KP1019) are undergoing clinical trials. Whilst KP1019 has cytotoxic 
activity against cancer cells, NAMI-A has anti metastatic activity  being 
relatively non-toxic[198-203]. It has been proposed that the activity of RuIII 
complexes, which are usually relatively inert towards ligand substitution, 
is dependent on in vivo reduction to more labile RuII analogues. Thus, the 
activity of RuII complexes is currently being evaluated. In particular, the 
potential of RuII–(h6-arene) complexes as anticancer agents is under 
investigation since arenes are known to stabilize ruthenium in its 2+ 
oxidation state[203-205]. Half-sandwich (h6-arene) RuII complexes with 
sulfoxide, phosphane, imidazole, chelating amino acidato, and diamine or 
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lability of the Ru–Cl bond and the size of the arene and have a crucial 
role in determining the cytotoxicity of rutheniumII complexes such as 
[(h6-arene)RuCl(LL´)](PF6) with bidentate ligands LL´. Compounds 
having extended polycyclic arenes (e.g. tetrahydroanthracene) and LL´ = 
ethylenediamine (en) are mainly active towards A2780 human ovarian 
cancer cells, whereas those with polar substituents on the arene such as 
COOCH3 (an electronwithdrawing group) or 1,10- phenanthroline (phen),  
or with aromatic diimine ligands such as 2,20-bipyridine (bpy) have  
either poor or no activity. 
 
Figure 27 Structure of the anticancer drug NAMI-A  
Further increases in the size of the polypyridyl ligand (pp) lead, however, 
to a decisive reversal of the latter trend and the in vitro cytotoxicities of 
the complexes [(η6-C6Me6)RuCl(pp)](CF3SO3) (Fig. 28) towards the 
human cell lines HT-29 (colon cancer) and MCF-7 (breast cancer) are 
mainly dependent on the surface area of the aromatic system. For 
example, the IC50 values decreases from 11.1 over 2.12 to 0.13 µM for 
MCF-7 cells as the size of the polypyridyl ligand increases in the order 
dpq < dppz < dppn (dpq = dipyrido- [3,2-f:2´,3´- h]quinoxaline; dppz = 
dipyrido[3,2-a:2´,3´-c]phenazine; dppn = benzo[i]dipyrido[3,2-a:2´,3´-
c]phenazine). These value are related with the cellular uptake efficiency, 
which increases from 1.1 over 146.6 to 906.7 ng(Ru)/mg(protein) within 
the series. The kinetically inert complexes [(η6-C6Me6)Ru{(NH2)2CS}- 
(pp)](CF3SO3)2 (pp = dppz, dppn) (Fig. 29) are also cytotoxic and this 
suggests that specific properties of the large polypyridyl ligands (e.g. 
DNA cleavage and/or intercalation) may be responsible for their 
biological activity. DNA binding studies show that (h6- C6Me6)RuII 
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compounds containing dpq or particularly dppz ligands are good 
metallointercalators but that the dppn ligand is too large to support stable 
intercalation between the base pairs of the double helix [206-214]. The in 
vitro and in vivo assessment of a series of h6-arene ruthenium complexes 
containing a pta ligand (pta = 1,3,5-triaza-7- phosphaadamantane) were 
studied as anticancer agents [215]. In addition to the toluene, para-cymene 
benzene and hexamethylbenzene derivatives, three systems with 
functionalised arene ligands were evaluated. 
All pta complexes were demonstrated to give a pH-dependent DNA 
damage, with the DNA  damage at the typical pH of hypoxic tumor cells, 
whereas little or no damage was observed at characteristic pH values of 
healthy cells. This behavior was correlated to the pta ligand, which can be 
protonated at low pH, and the protonated form was considered to be the 
active agent. Therefore, the introduction of functionalised pendant arms 
on the arene ligand, such as in the below complexes (Fig. 28), did not 
have any significant improvement in the cytotoxicity of the compounds 
(IC50 (TS/A cells) = 66 µM,; 103µM,; 159 µM,) if compared to the h6- 
aromatic hydrocarbon systems. 
 









      dppz
      
      dppn
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Figure 29 Structure of [(η6-C6Me6)Ru{(NH2)2CS}- (pp)](CF3SO3)2 
 
 
Figure 30 Chemical structure of a series of η6- arene ruthenium complexes contraining 
a pta ligand 
1.12 Copper Complexes as Antitumor Agents  
The anticancer activities of a set of simple copper complexes having 
different types of nitrogen donor ligands such as thiosemicarbazone, 
imidazole, purine, benzohydroxamic acid and amino acid ligands have 
been evaluated[216-220]. Some mixed chelate copper-based drugs showed 
greater antineoplastic properties than cisplatin in vitro and in vivo studies 
[221,222]. 
Copper complexes seem to have a mechanism of action certainly different 
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[Cu(malonate)(phen)2] was demonstrated to induce apoptosis in cultured 
mammalian cells and is able to mediate significant cellular oxidative 
stress, interfere with mitochondria respiratory activity in fungal cells and 
promote membrane lipid peroxidation [223,224]. Similar copper chelates of 
phen were studied and also had  high antineoplastic activity by inhibiting  
ATP synthesis and respiration[225]. Moreover, complexes of general 
formula [Cu(phen)]2+ are known to bind to DNA both intercalating and 
non-intercalating, and are known as potent oxidative nucleases but the 
exact structure of [Cu(phen)]2+ when bound to DNA has not been poperly 
characterized [226].  
Recently Devereux et al. have been studing alternative chelating ligands 
such as TBZH and 2-PyBZIMH (Fig. 21). The anti-cancer activity of 
TBZH is mainly increasedif it is bound to a copper centre [227,228] but none 
of the reported complexes have exhibited activity close to that of cisplatin 
so far. Reports of the biological activity of 2-PyBZIMH are scarce with 
no papers published describing the anti-tumor activity of its copper 
complexes. Its use as a ligand in the synthesis of novel PtII and PdII anti-
tumor agents has been reported [219]. In this study thee reserachers did not 
test the free 2-PyBZIMH ligand but found that [Pt(2- PyBZIMH)Cl2] was 
the most efficient anti-cancer agent against eight brain tumour cell lines, 
but the activity was significantly lower than that of cisplatin. 
 
Figure 31 Structure of TBZH and 2-PyrBZIMH ligands 
Recently, Sathisha et al. prepared a complex of CuII with bis(3 
acetylcoumarin) thiocarbohydrazone (Fig. 32). This octahedral distorted 
complex has demonstrated promising cytotoxic activity when screened 
using the in vitro method for certain types of cell lines. 
Bravo-Gómez et al. selected a mixed chelate copperII complex of [Cu(N–
N)(acac)]NO3 and [Cu(N– N)(gly)]NO3 with several substituents on the 
diimine ligand to obtain a quantitative structure–activity relationship 
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complexes of ethyl 2-[bis(2-pyridylmethyl)amino]propionate ligand 
(ETDPA). These complexes are stable in air with the formula of 
[(ETDPA)CuCl2] and [(ETDPA)Cu(phen)](ClO4)2.  
The DNA-binding capability of the two Cu complexes with DNA was 
different. The binding mode of [(ETDPA)CuCl2] is not the classical 
intercalation binding, and the binding mechanism of 
[(ETDPA)Cu(phen)](ClO4)2 with DNA is intercalation. The cytotoxic 
assay shows that the [(ETDPA)Cu(phen)](ClO4)2 is more active on the 
proliferation of cancer cells than the [(ETDPA)CuCl2]. 
 
Figure 32 Proposed structure of the copper complex synthesized by Sathisha et al. 
1.12.1 Other Metal Anticancer Agents 
Tetrahedral bis(diphosphanyl)goldI complexes (see figure 33) are much 
less reactive, than linear AuI antiarthritic complexes for example towards 
thiols. This complex (lactate salt) shows goood activity in a range of 
cancer models. It has a different mechanism of action respect to cisplatin, 
and is targeted to mitochondria, where it destroys membrane potentials. It 
showed to be too cardiotoxic for clinical use, but the introduction of 
pyridylaryl substituents on P increases the hydrophilicity of diphosphane 
bischelated AuI complexes, and produce strong and selective activity 
towards cisplatin resistant and sensitive ovarian tumor cells.[229] It should   
be evaluated whether the cardiotoxicity is reduced.  
Gallium salts are known to exhibit anticancer activity, and GaIII is 
probably delivered to cancer cells through the transferrin, a serum protein. 
Recent interest in gallium salts derives from their synergistic effect with 
cisplatin in the treatment of carcinoma of the urothelium and lung 
cancer.[230] GalliumIII maltolate has entered clinical trials for conditions 



















Figure 33 Structure of Tetrahedral bis(diphosphanyl)gold(I) complex 
1.13 Anticancer Agents: Titanium Complexes 
Among all the evaluated metals– which comprise much of the periodic 
table – complexes of titanium have shown particular promise due to high 
activity against tumors that are resistant to cisplatin combined with low 
toxicity[232-240]. In particular, the titanium complexes 
bis(cyclopentadienide)titanium dichloride (Cp2TiCl2, titanocene 
dichloride, 1) and cis-diethoxybis( 1-phenylbutane-1,3-
dionato)titanium(IV) [(bzac)2- Ti(OEt)2, budotitane, 2] (Fig 34) have 
been the first metal-based chemotherapeutics to reach Phase I clinical 
trials since the development of cisplatin. Although both complexes 
showed promising properties in these preliminary studies, 1 has not 
progressed beyond Phase II due to its low efficacy respect to toxicity 
ratio,[241,242] and 2 has not progressed past Phase I due to formulation 
problems.[243] These difficulties have increased the development of 
titanium complexes that show higher potency and hydrolytic stability.  
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Figure 34 Structure of TDC (1) and Budotitane (2) 
The strong cytotoxic activity of TDC against implanted Ehrlich ascites 
tumors (EAT) in mice was reported in 1979 where cure rates greater than 
80% were observed with little of the heavy-metal toxicity observed for 
cisplatin.[244] In following studies the authors reported the key observation 
that while 1 and vanadocene dichloride showed similar activities against 
EAT in-vivo, the cytotoxicity of TDC was ca. 100 times less than that for 
vanadocene dichloride in-vitro.[245] The reason for the reduced activity 
was hypothesized to be due to the hydrolytic instability of TDC, which 
rapidly forms insoluble aggregates in aqueous solution with eventual 
formation of TiO2, a feature that often occurs with many TiIV complexes 
because of their oxophilic and electron-poor nature. A detailed study of 
the hydrolytic behavior of TDC in neat water at various pH ranges 
showed that at pH 5, following a rapid loss of the first chloride ion, 
complete hydrolysis of both chloro groups occurs with a t1/2 of ca. 50 min, 
while hydrolysis of the Cp ligands is slower (t1/2 ca. 54 h).[246] On the 
other hand, vanadocene dichloride was stable toward hydrolysis at pH 7, 
which certainly explains the difference between the in-vitro and in-vivo 
results for these two complexes. The in-vitro cytotoxicity could be 
resolved by using a galenic formulation,[229] and a subsequent patent 
reported a water-soluble formulation of 1, MKT-4, which allowed the 
intravenous administration during clinical trials.[247] 
In 1982 the anticancer properties of Budotitane (2) were reported, for the 
first time.[248] It shows cytotoxic activity towards animal cancer such as 
EAT and colon tumors.[233,243] During the hydrolysis tests, the addition of 
2 to neat water gave a suspension in which the complex remained 
completely undecomposed.[233] However, if water was added to a solution 
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of 2 in methanol or acetonitrile, rapid hydrolysis ensued. The half-life for 
hydrolysis of the ethoxy groups in water was calculated as t1/2 = 20 s, 
while hydrolysis of the diketonato ligand in acetonitrile/water solutions of 
2 takes places after 2.5 h. The use of smaller diketonato ligands was 
demonstrated to give even a more rapid ligand hydrolysis. NMR studies 
show that 2 exists as the cis isomer.[233] MM3 studies suggest that the 
predominance of the cis compound is primarily due to steric factors. In an 
interesting demonstration of the additional structural complexities that 
can accompany the use of transition metals as drugs, the unsymmetrical 
ligands of 2 can potentially give rise to three sets of enantiomeric cis 
complexes. In CDCl3 solution at 23 °C, 2 exists as a 4:1 mixture of two 
cis isomers. The relative cytotoxicity of these two compounds has not 
been investigated, although the crystal structure of one of them has been 
determined.[249] 
1.13.1 Structure–Activity Relationships of Titanocene Dichloride  
and Related Compounds 
Considerable work has been performed in developing therapeutic 
analogues of 1 by varying the central metal (M), the labile ligands (Cl) 
and the bis-cyclopentadienyl moiety. 
The study of cytotoxic metallocenes other than titanium has been 
described in detail elsewhere.[250] Substitution of the chloro leaving 
ligands has been evaluated in order to obtain analogues with improved 
water solubility, but in general has not been shown to have a deep impact 
on cytotoxicity. For example, titanocenes of the general formula Cp2TiX2 
(X = Cl, Br, NCS, maleate, O2CCl3) all achieved cure rates of 100% in 
mice with fluid EAT, I agreemement with the hypothesis that the 
cytotoxic TiIV compounds is generated from displacement of the labile 
halide ligands in 1.[251,252] In contrast, small changes to the Cp ligand can 
strongly impact the hydrolytic stability and water solubility features of the 
metallocenes and thereby affect the cytotoxic activity. Moreover, it has 
been suggested that substitution can also impact the capability of the 
ligand to intercalate with DNA, although further work are needed to 
establish thismechanism. 
Substitution of one of the hydrogen atoms of the Cp ligand by R [R = Et 
(3), R = Si(CH3)3 (4)] (figure 35) showed to reduce cure rates of mice 
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with fluid EAT to 60– 80%, while substitution of both Cp ligands by R 
reduced cure rates drastically to 10–30%.[232]  
Pentamethyl-substituted titanocenes were reported to be completely 
devoid of cytotoxic activity. The extent to which this lowered activity 
represents the reduced water solubility of these compounds is not sure. 
Studies on the hydrolytic behavior of the methylated metallocene 
complex (C5H4Me)2TiCl2 (5; C5H4Me = 1-methylcyclopentadienide) 
revealed that the CpMe ligands were less promptly hydrolyzed than TDC 
at physiological pH. Furthermore, when the chloride leaving  ligands 
were replaced with glycine in this system 6 (figure 35), water-soluble 
complexes with high hydrolytic stability were obtained at physiological 
pH. The compounds were observed to generate stable complexes with 




Substitution of the Cp ring with electron-poor substituents (R = CO2Me 7) 
(Figure 35) was reported to increase cytotoxicity in a human small-cell 
lung-cancer cell line but revealed lower cytotoxic properties towards a 
number of other studied cancer cells.[254] This could be justified by 
reduced hydrolytic stability due to the  lower ligand-to-metal electron 
donation. 
Many titanocene analogues containing aromatic groups appended to the 
Cp ligand have also been prepared.[240] Although generalizations 
regarding structure–activity relationships are not yet clear, these 
complexes have shown promising in-vitro activity against the LLC-PK 
cell line.  
When tested against a panel of 36 human tumor-cell lines, the most 
promising candidate, titanocene Y (8) (figure 36), was found to have 
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good activity against renal cell cancer. Interestingly, the oxalato complex 
9 (figure 26), possessing a substantially less labile chelating ligand in 
replacement of the chloro groups, was reported to have a 13- fold increase 
in activity relative to 8 during in-vitro studies against the LLC-PK cell 
line,[255] yet in-vivo studies showed quite identical activity if compared to 
to 8.[256] Although the hydrolysis behavior of 8 and 9 was not studied in 
detail, it is possible that differences in the IC50 values of 8 and 9 obtained 
in vitro may in fact reflect the greater hydrolytic stability of 9. In general, 
lower activity was found in analogues where the two Cp units were bound 
by a two-carbon bridge, obtained as mixtures of stereoisomers (10, figure 




Several attempts have been performed to improve the aqueous solubility 
of 1 through appendage of polar side chains to the Cp ligands. For 
instance, titanocenes with alkylammonium hydrochloride moieties gave 
improved aqueous solubility. 
 Compound 11 (figure 37) showed good activity against both A2780 and 
the cisplatin-resistant A2780/CP cell lines.[259] Interestingly, an analogue 
of 11 with a bulkier Cp ligand (12, figure 37) possessed similar 
cytotoxicity.[260] Concurrently, in a parallel study, a significant number of 
similar alkylammonium complexes were prepared and their in-vitro 
cytotoxic properties evaluated against H209, A549, and A2780 cell lines 
in direct comparison with the water soluble synthesis of TDC, MKT-
4.[261] In initial studies an intersting difference in cytotoxicity was found 
between bis(alkylammonium)cyclopentadienide complexes and those 
containing a single alkylammonium Cp ligand. 
However later studies on related compounds, have found that this 
“bis(alkylammonium)” effect is not necessarily general.[262] 





A number of water-soluble and cationic derivatives of TDC have been 
synthesized through incorporation of secondary amide or an ester on to 
the Cp ligand.[263,264] By using an acylation reaction, a diverse array of 
amide and ester-containing titanocenes were prepared. In-vitro studies of 
complexes with the general structure 14 (Figure 38) demonstrated good 
activity against BJAB (leukemia) cell lines.[265] Notably, complex 15 
(Figure 38) possesses a fluorescent aminopyrene unit which may be of 
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1.13.2 Structure–Activity Relationships of Budotitane and Related 
Compounds 
The structure–activity information collected from the preparation of  200 
derivatives of budotitane with the general formula D2MX2 (D = 1,3 
dicarbonyl;M = metal; X = labile ligand) and their activity against the 
sarcoma 180 ascitic tumor model were reported.[233] Among the studied 
metals, the cytotoxic activity decreased in the order Ti>Zr >Hf >Mo >Sn 
>Ge.  
No significant difference in cytotoxicity was found between compounds 
incorporating the leaving groups X (X = F, Br, Cl, OEt), although the OEt 
group was eventually preferred due to its stronger hydrolytic stability. 
 Among the 1,3-dicarbonyl groups reportes, acetylacetonato (acac) 
compounds possessed very low activity, while optimal antitumor activity 
was found for the benzoylacetonato (bzac) ligand. Incorporation of 
donating (OMe) or electron-withdrawing (Cl, NO2) groups on the 
aromatic ring had a marginally deleterious effect upon the observed 
cytotoxic activity, as did the replacement of phenyl for tertbutyl, although 
considerable cytotoxicity was preserved. 
The cytotoxic activity of structurally related mononuclear and 
polynuclear titaniumIV 4-acyl-5-pyrazolonato (16 Figure 39) species 
which are structurally related to 2 were studied.[234,266] The cytotoxic 
acrivity of a tetranuclear species 17 (Figure 39) was encapsulated in a 
liposome to improve its insufficient water solubility and found to display 
cytotoxicity against TA-3 and HEP-2 cell lines in-vitro. Synthetic studies 
found that selectivity for mononuclear compounds could be obtained by 
rigorous absence of moisture during their synthesis. Notably, addition of 
trace water to a solution of the monomeric compound 18 (Figure 39) in 
anhydrous [d6]benzene formed a highly stable species that was 
hypothesized to be hydrolyzed oxo-bridged oligomers retaining the 
chelating ligand within 15 mins, unlike the observations with 
budotitane.[233] 
 




1.13.3 Comparison of the Biological Profiles of Titanocene 
Dichloride  and Budotitane 
In general, the cytotoxic activity profiles of TDC and Budotitane show 
many congruencies. Comparing the in-vivo studies, 1 and 2 have good 
activity against slow-growing tumors of the liver, colon, and kidney, and 
relatively low activity against faster growing cancers such as leukemia. 
Notably, emesis and other symptoms associated with the toxicity of 
cisplatin were not present during clinical trials of 1 and 2. Both 
complexes hydrolyze quickly, and require galenic preparations with 
water-soluble ligands in order to improve water solubility and stability. 
Additionally, both compounds contain a set of aromatic ligands that 
undergo hydrolysis under physiological conditions within several hours. 
The observation that 1 and 2 do not exert their maximal cytotoxic effects 
until  >24 h after administration – in hard contrast to cisplatin – certainly 
leads to the question of how this relates to the half life of ligand 
hydrolysis.[267] In addition, the observation that 1 shows stronger 
cytotoxicity following aging in certain organic co-solvents[268] raises 
questions regarding the peculiar lability required of the active 
compounds. 
While a number of detailed biological studies have been performed on 1, 
analogous biological studies for 2 are largely absent. Although it is 
plausible to hypothesize that 1 and 2 share a similar mechanism of action, 
too little is currently known to draw definite conclusions. The following 
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section will attempt to summarize what is currently known about the 
mechanism  of action of these cytotoxic titanium compounds. 
1.13.4 Mechanistic Aspects of Biological Activity 
Early hypotheses that 1 share a mechanism of action with cisplatin[239] 
have been challenged by the efficacy of 1 against cisplatin-resistant cell 
lines, as well as by the differnt chemical behavior of “soft”, water soluble 
Cl2Pt(NH3)2 with “hard”, hydrolytically unstable Cp2TiCl2 observed in 
aqueous solution under physiological conditions.[241] Nucleic acid 
metabolism appears to be disturbed by titanocene compounds. Analysis of 
the intracellular localization of titanium after treatment of TDC found 
titanium accumulation in cellular regions rich in nucleic acids.[269] 
Interestingly, while cisplatin promptly gives cessation of DNA-metabolic 
activity, TDC does not affect cell transit through the S phase but cells are 
irreversibly unable to perform mitosis.[270] It has been concluded that the 
three main phenomena observed in cells after treatment with TDC – 
specifically, the activation of endogenous viruses, the formation of giant 
cells, and the development of cellular necrosis – are all consistent with an 
interaction of 1 with intracellular DNA.[271] Adducts of TDC (Cp2Ti–
DNA and CpTi–DNA) with calf thymus DNA has been detected through 
spectroscopical studies,[272] as was also supported by model studies with 
particular nucleotides.[273] The specific interaction of the active titanium 
species with DNA remains not clear yet, although an interaction with the 
phosphate backbone has been proposed.[274]  
As far as budotitane is involved, the contribution of the aromatic 
diketonato ligand toward higher cytotoxic activity has led to hypotheses 
concerning DNA intercalation.[233,266]  
However, because of the considerable activity retained when C6H5 is 
replaced by tert-butyl, the uncertain nature of the active species, and the 
lack of biological studies on 2, this proposal remains speculative. 
Another study described the interaction of TDC with topoisomerase II, an 
enzyme catalyzing the opening and rejoining of the DNA phosphate 
backbone during the cell cycle. TDC was reported to be a strong inhibitor 
of topoisomerase II, which may also lead to antiproliferative effects.[275] 
Much recent work has focused on the mechanism thorugh which 
anticancer titanium complexes are transported into cells. Mainly, the 
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question of whether ligands remain attached to the titanium during 
transport into the cell or whether the ligands merely serve to protect the 
titanium center from hydrolysis in the intercellular medium remains a 
critical not answered question. Discovering the mechanism of titanium 
transport would have important implications for the design of more 
effective and potent cytotoxic titanium complexes. 
Observing the increased number of transferrin receptors on the surface of 
tumor cells and the implication of transferrin in transport of metal ions 
such as RuIII and GaIII to cancer cells,[276, 279] it has been proposed that 
transferrin (Tr) is responsible for uptake of titanium from the intercellular 
medium.[ 279-281] Transferrin, the 80 kDa protein responsible for iron 
transport into cells, is present in the intercellular medium at a 
concentration of ca. 35 µ and contains two metal binding domains that 
are about 30% saturated with FeIII in blood plasma. 
Supplementary studies have shown that TiIV binds more strongly to 
human serum transferrin than does FeIII.[282,283] UV/Vis and 1H NMR 
studies support the conclusion that TDC as [Cp2Ti(citrate)2] binds to 
transferrin with complete hydrolysis of the Cp ligands.  
After reaction with transferrin for 30 mins at pH 7, 1H NMR signals 
attributed to bound Cp in TDC completely disappeared, replaced by 
resonance signals characteristic of free cyclopentadiene. Interestingly, at 
low pH (<5.5) titanium was released from Ti2Tr to bind to ATP. In this 
mechanism, TDC, or its analogues,[284,285] could possibly act as a pro-
drug, with the ligands protecting the titanium center from hydrolysis into 
titanium dioxide in the intercellular medium. Although TDC is 
completely hydrolyzed by transferrin in the presence of added citrate, the 
binding of transferrin to the potentially oxo-bridged hydrolysis products 
of TDC may occur with different selectivities and/or rates. 
Notably, however, no such observations were reported for Budotitane or 
its analogous. Moreover, the water-stable tetranuclear titanium complex 
20 based on the diketonato analogue maltol ligand 19 (Figure 40) does 
not donate TiIV to transferrin, even if  is active against HT-29 cell lines in-
vitro with values comparable to that of TDC, unlike other titanocene 
derivatives evaluated in comparison.[286]  
Thus, it would appear that further work is certainly  necessary in 
establishing transferrin as the exclusive agent of active transport for 
cytotoxic titanium complexes. 




A recent paper proposes a different theory for the titanium transport into 
the cells through the action of serum albumin (HSA).[287] HSA, which is 
present in high concentrations in the intercellular medium (ca. 700 µ), 
has a variety of metal-binding sites and has been demonstrated to bind 
intact metal complexes such as contrast agents  and photosensitizers. 
NMR studies proved that, in contrast to albumin-free controls, solutions 
of TDC in the presence of HSA showed no clear signals for either free 
Cp2TiCl2 or cyclopentadiene after many days. Instead, two proton signals 
were formes, and proposed to represent TiIV-bound Cp protons. These 
results certianly suggest that HSA stabilizes the Cp2Ti moiety at 
physiological pH, and that the extent to which albumin binding stabilizes 
complexes may be important for biological activity. 
This was even supported by studies on other metallocene analogues.[288] 
Otherwise, binding studies with the dichloro analogue of Budotitane 
showed less than TDC equiv. of Ti bound to the protein and the presence 
of free ligand in the NMR spectrum. 
It was also reported that while transferrin outcompeted HSA for titanium 
citrate, exchange of Ti from a preformed HSA-Ti complex to transferrin 
was quite slow and incomplete. 
The important feature of this model is that the ligands of the cytotoxic 
titanium complex remain bound, allowing for a biological mechanism 
implicating the ligands in a putative DNA-binding event within the cell. 
An important unanswered question in this model is whether there is a 
mechanism by which the HSA-Ti complex is transported into the cell, or 
whether HSA serves as a protecting group for the active titanium complex 
Chapter One Introduction Pag.53 
 
until it is transported by passive diffusion into the cell. The discovery that 
serum albumin can stabilize otherwise the hydrolytically unstable 
titanium compoundshas, therefore, added a new dimension to the study of 
these compounds. 
It is certainly clear that more studied are needed to improve what is 
known about TiIV complexes as cytotoxic agents. Despite the many years 
since the initial studies regarding the involvement of TiIV metal in 
biological interactions of a therapeutic potential, very little is known 
about the actual important biological interactions involved in the 
cytotoxicity mechanism, as well as about the exact requirements of a 
suitable complex and its attendant ligands. Consequently, only complexes 
of Cp, diketonato, or related ligands have been explored, although some 
recent derivatives demonstrate strongly improved properties. 
Nevertheless, the enormous potential of the TiIV center due to its notably 
low toxicity requires a reinvestigation of its diverse complexes. 
1.13.5 Phase II trial of titanocene dichloride in advanced renal-cell 
carcinoma 
1.13.5.1 Patients and methods 
From May 1995 to June 1996, 14 patients with advanced renal-cell cancer 
(RCC) were recruited into phase II trial. Patients were eligible if they had 
histologically confirmed RCC, bidimensionally measurable meta- static 
or locally recurrent unresectable disease, no prior medical antineoplastic 
cure, a life expectancy of at least 3 months along with a Karnofsky 
performance status of above 70%, and adequate renal, hepatic, and bone 
marrow function. Informed consent was obtained from each patient. The 
patients' characteristics are reported in Table 2. 
Before to study entry, patients had a complete workup, including a 
physical, history examination, blood chemistry, and blood count chest, X-
ray, abdominal ultrasonography. Additional imaging procedures were 
performed as indicated by symptoms or history. 
All patients were treated with titanocene dichloride (provided by Medac, 
Hamburg, Germany) given at 270 mg/m2 on day 1 by i.v. injection. 
Treatment cycles were repeated every 21 days. Patients who achieved 
partial or complete responses or stable disease after two cycles were 
continued on titanocene dichloride until either progression or stabilization 
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of their disease for two cycles. The response to treatment was assessed 
after two cycles of therapy and every 3 months thereafter according to 
WHO response criteria [289]. 
Table. 2 Patients’ characteristics 
 
1.13.5.2 Response 
A total of 11 patients received 2 cycles of titanocene dichloride. One 
patient who presented with stable disease continued the treatment for a 
further two cycles and one patient died due to tumor progression within 4 
weeks. Because of side effects, one patient dropped out of the treatment 
schedule after one cycle. There was no complete or partial response. Two 
patients had metastases in the lung; one of them had been 
nephrectomized. The other patient had bone metastases only. Three 
patients (21%) had stable disease (SD) for 1, 3, and 3 months, 
respectively. All patients with SD had a good performance status 
(Karnofsky index 100%). The remaining ten patients (79%) had shown 
evidence of progression while under treatment with titanocene dichloride. 
The median survival time of all patients amounted to 50 weeks, and the 
overall survival was 43% at 1 year. 
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1.13.5.3 Toxicity 
Mild upper abdominal discomfort with loss of appetite was universally 
experienced for 1-2 days after the administration of titanocene dichloride 
by all patients entered into this study. In eight patients (57%) symptoms 
of vomiting, nausea, and weight loss occurred; three of them suffered 
from grade 3 WHO toxicity and two patients, from grade 2 toxicity. 
Subsequently, the dose of titanocene dichloride was reduced to 75% of 
the original dose in two patients. Although the treatment level had been 
reduced, one patient chose to withdraw from further participation in the 
study. There was no other organ toxicity (see Table 3). Four patients 
(29%) developed an increase in serum creatinine concentration 
corresponding to WHO grade 2 toxicity (maximal 2.6 mg/dl) and three 
patients (21%) developed grade 1 toxicity. The treatment-related increase 
in serum creatinine levels resolved after completion of the therapy. With 
regard to hematologic parameters and chemistry values of liver function, 
no significant difference was detectable between baseline levels and 
control values during the treatment. 
Table. 3 WHO toxicity of tratment with titanocene dichloride (n=14) 
 
 
In conclusion TDC produced responses in proportions too small to justify 
its use in single-agent therapy. 
1.13.6 Methoxy alkyl substituted titanocenes 
Recently, some of us have reported the synthesis and the cytotoxic 
activity of some titanocene derivatives obtained replacing the aryl-
methoxylic group on cyclopentadienyl of titanocene Y with the ethenyl-
methoxy group, in order to have a stronger electron donor effect on the 
cationic species responsible for the cytotoxic activity (fig.41).  
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Figure 41 Bis-[(p-methoxybenzyl)cyclopentadienyl]titanium dichloride (titanocene Y);  
bis-cyclopentadienyl-ethenylmethoxyl-titanium dichloride (T2) and  cyclopentadienyl-
ethenylmethoxyltitanium trichloride (T1) 
We also verified the influence of leaving ligands on the activity by 
substituting chlorine atoms with dimethylamide, oxalate or aminoacid 
groups.[290] 
It is worth noting that in ref. 290, the highest cytotoxic activity was 
reported for half-titanocene complex T1, compared to titanocene T2, 
titanocene Y and cis-platinum. Some of the synthesized compounds 
showed a good cytotoxicity, in particular the complexes bis-
cyclopentadienyl-ethenylmethoxyl-titanium dichloride T2 and 
cyclopentadienyl-ethenylmethoxyl-titanium trichloride T1 gave values 
very similar to cis-platin on MCF-7 cell lines, with the IC50 comparable to 
the ones reported for titanocene Y. Moreover, the half-titanocene 
complex (T1) also showed a good cytotoxic activity, comparable to that of 
cis-platin, on HEK-293 cells. The results of the hydrolysis of our 
titanocenes showed unequivocally that the leaving groups (Cl, N(CH3)2, 
C2O4 or glycine) significantly affect even the hydrolysis rate of 
cyclopentadienyl groups, being chloride and oxalate more stable.[290] 
Thus, the presence of substituents, aryl methoxy group on 
cyclopentadienyl ring in titanocene Y or ethenyl-methoxy group in 
titanocene T2 or in the half-titanocene T1, produces compounds having 
interesting cytotoxic activity. Although generalizations regarding 
structure-activity relationships are not yet clear, we could hypothesize 
that the neutral nucleophilic substituents of cyclopentadienyl (aryl 
methoxy or ethenyl-methoxy group) could intramolecularly coordinate to 
the titanium cation, thus preventing decomposition reactions. On the other 
hand, this hypothesis was suggested for analogous complexes able to give 
polymerization of propene or styrene having microstructures strongly 
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influenced by the possible coordination of neutral substituent of 
cyclopentadienyl at the metal center.[291-293] 
As mentioned above, in the literature several examples of titanocene-
complexes showing cytotoxic activity were reported, but, to the best of 
our knowledge, the cyclopentadienyl-ethenylmethoxyl-titanium 
trichloride represents the first example of half-titanocene complex with 




This chapter introduces the aims  
of this project and provides an extensive  
discussion on the obtained results. 
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2  Aim of the project 
One of the crucial consideration about the application of transition metal 
complexes for chemotherapy is their potential toxicity. The advantage of 
TiIV compounds is their relative biological compatibility, which mostly 
leads to moderate and reversible side effects. However, the hydrolytic 
instability of known TiIV complexes and formation of various different 
species upon water addition makes their clinial use debatable, and 
promote a marked interest in the development of relatively stable TiIV 
complexes with well defined hydrolytic behavior that show considerable 
cytotoxic activity. Strong ligand binding is also of interest to avoid 
complete ligand stripping by transferrin, so that the ligand may be useful  
as a target for structure–activity relationship studies. 
 For a worthier evaluation of the parameters affecting the cytotoxic 
activity and the hydrolytic behaviour, the synthesis and investigation of 
specifically designed complexes based on different strongly coordinating 
ligands has been our main purpose; our main ambition is the synthesis of 
complexes with imroved hydrolytic stability and welldefined hydrolytic 
behavior.  
Therefore, the aim of this study was the synthesis and the characterization 
of some titanocene and half-titanocenes compounds by nuclear magnetic 
resonance (NMR), mass spectroscopy and elemental analysis. All these 
complexes contain different substituents on the Cp ligands, able to 
stabilize the titanium cation by intramolecular or intermolecular 
coordination. Preliminary cytotoxic studies of these titanium-based 
compounds have been carried out, as well. 
Moreover we have evaluated the cytotoxic activity of our pro-ligands, 
fulvene. 
2.1 Ligand and Complex Design 
As the hydrolytic instability of TiIV complexes is one of the  main 
difficulty that needs to be considered, our ligands have been projected to 
enhance stable binding to TiIV and enforce hydrolytic stability. The 
considered parameters are the following:  
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(a) neutral complexes for granting cell penetration by passive diffusion 
and the most stable oxidation state for the TiIV center ;  
(b) inert ligand that will hopefully remain bound to the metal center 
during the biological interactions and allow for activity in a controlled 
manner (see cheme 4) 
(c) the preferred geometry for the TiIV center is tetrahedral;  
(d) complexes of the general structure LTiX3 in order to investigate the 
citotoxic properties of half-titanocene (see scheme 5) 
(e) complexes of the general structure L2TiX2 (see scheme 6) 
(f) two leaving ligands, to enable potential chelate binding to the 
biological target of interest, as happens for cisplatin and as could be 
proposed for titanocene dichloride, both having this characteristic.[233] 
 
  



































Scheme. 5 Structure of synthesized half-titanocene complexes 
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2.2 Synthesis and characterization of aryl-
substituted half-titanocene  
The half-titanocene 1b-6b have been synthesized and fully characterized 
through 1H NMR, 13C NMR, Mass spectroscopy and elemental analisys.  
The aim of these syntheses has been to investigate the cytotoxic activity 
of these compounds, being the cyclopentadienyl-ethenylmethoxyl-
titanium trichloride  (T1,) the first example of half-titanocene complex 
with interesting cytotoxic activity in leterature.[290] 
1b was synthesized in order to verify if the activity was higher for half-
titanocene Y than titanocene Y, as it was for the bis-cyclopentadienyl-
ethenylmethoxyl-titanium dichloride T2 and cyclopentadienyl-
ethenylmethoxyl-titanium trichloride T1.  
2b, 5b and 6b have other methoxyl groups, which may make ligands 
much more coordinating, apart from the methoxyl in position 4.  
3b has a dimethylamino-group in position 4 of the aryl which has strong 
capabilities to bond metal-cation. 
4b has no substituents on the aryl, but the phenyl is of course able to 
coordinate to titanium.   
The synthesis of complexes was carried out according to scheme 7. The 
synthesis of pre-ligands fulvene 1a-6a were carried out as outlined in 
references,[294-297] starting from the suitable and purified following 
general procedures. 
The lithium salt of the ligand was obtained by reacting the suitable 
fulvene with Super Hydride (LiBEt3H) in diethyl ether dry. Then, it was 
isolated and subsequently reacted with one equivalent of TiCl4·2THF in 
dry THF. The reaction product was purified following common 
procedures and isolated in high yield (see Scheme 5).  
Elemental analysis (C, H, N) agreed with the proposed formulation. 1H 
COSY experiments allowed the assignment of all the proton resonances 
of the 1H NMR spectrum, whereas DEPT experiments were useful for the 
attribution of 13C NMR signals (see experimental part). The synthesized 
half-titanocenes were also characterized by mass spectrometry. The mass 
spectra show the molecular ion and the fragmentation of the complexes 
(i.e.: ligand, [ligandTi]). The set of these data allowed us to have an 
unambiguous structural determination, as reported in scheme 5.  
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Figure 42. 1H and 13C NMR spectra of complex 4b 
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2.2.1 Hydrolysis test of complexes 1b-11b 
Hydrolysis stability of the half-titanocene complexes (1b-6b) has been 
determined in aqueous solution, 90% DMSO by 1H NMR spectroscopy, 
in order to correlate the chemical stability and coordination chemistry of 
these complexes with their observed cytotoxic activity. Since we can 
expect that rapid hydrolysis of the leaving group (-Cl) and 
cyclopentadienyl ligands could give way to biologically inactive species, 
active species could be generated if the Cp rings remain metal bound. 
Hydrolysis of aromatic rings of 1b-6b was evaluated by integrating the 
two signals of protons of cyclopentadienyl bonded to metal, as to newly 
formed multiplet of substituted cyclopentadiene. Table 4 reports the 
results of our hydrolysis tests and Fig. 43 shows, as an example, the 
evolution in time of unsaturated region of 1H NMR spectra of 4b. 
Table. 4 Hydrolysis results of 1b-6b complexes in DMSO/D2O solution at rt followed by 
1HNMR 
Complex % Cp rings hydrolysis 
 5 mins 4 hrs 8 hrs 24 hrs 
1b <1 <1 <1 <5 
2b <1 <1 <1 <5 
3b <1 <1 <1 <5 
4b 9 24 40 41 
5b <1 <1 <1 <5 
6b <1 <1 <1 <5 
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Figure 43 1H NMR spectra of 4b at rt in 90% DMSO (A) 5 mins afterthe dissolution, 
 (B) 4.5 hrs after the dissolution, (C) 8.5 hrs after the dissolution and (D) 24 hrs after 
the dissolution. 
All the complexes show an high hydrolytic stability. In particular, the 
cyclopentadienyl rings of  all the complexes are hydrolyzed only for less 
than 5% after 24 hrs, whereas complexes 4b is hydrolyzed for 41%. 
(Table 4). 
These data provide sufficient evidence that the presence of coordinating 
groups on the aryl substituent of the cyclopentadienyl are effective for the 
stabilization of the complexes. Therefore, these coordinating groups 
might be fundamental to increase, if active, their biological effectiveness. 
2.2.2 Cytotoxic tests 
In order to investigate the effects on cancer cell proliferation of the novel 
compounds synthesized, we treated for 5 days MCF7 and SkBr3 breast 
cancer cells with each compound. Cells were also exposed to cisplatin in 
order to compare the anticancer effects of the complexes to this well-
known chemotherapeutic.  
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MCF-7 is a breast cancer cell line isolated in 1970 from a 69-year-old 
Caucasian woman. MCF-7 is the acronym of Michigan Cancer 
Foundation-7, referring to the institute in Detroit where the cell line was 
established in 1973 by Herbert Soule and co-workers.[298]  Of the two 
mastectomies she received, the first revealed the removed tissue to be 
benign. Five years later, a second operation revealed malignant 
adenocarcinoma in a pleural effusion from which was taken cells for 
MCF-7. The woman was treated for breast cancer with radiotheraphy and 
hormonotherapy. 
Prior to MCF-7, it was not possible for cancer researchers to obtain a 
mammary cell line that was capable of living longer than a few months 
MCF-7 cells are useful for in vitro breast cancer studies because the cell 
line has retained several ideal characteristics particular to the mammary 
epithelium. These include the ability for MCF-7 cells to process estrogen, 
in the form of estradiol, via estrogen receptors in the cell cytoplasm. This 
makes the MCF-7 cell line an estrogen receptor (ER) positive control cell 
line. 
In addition to retaining their estrogen sensitivity, MCF-7 cells are also 
sensitive to cytokeratin. They are unreceptive to desmin, endothelin, 
GAP, and vimentin. When grown in vitro, the cell line is capable of 
forming domes and the epithelial like cells grow in monolayers. Growth 
can be inhibited using tumor necrosis factor alpha (TNF alpha), and 
treatment of MCF-7 cancer cells with anti-estrogens can modulate 
insulin-like growth factor finding protein's, which ultimately have the 
effect of a reduction in cell growth. 
Genetically, the MCF-7 line has not been maintained exactly. Originally, 
it was described as having a karyotype containing 85 chromosomes, 
which has since been reduced by 16 chromosomes. Today's cell line has a 
karyotype containing 69 chromosomes. Furthermore, there are genetic 
discrepancies between the MCF-7 cell line from the Michigan Cancer 
Foundation and the ATCC cell line. This indicates that the ATCC cell 
line is of a different source than the other MCF-7 cell lines. 
SkBr3 is a cell line isolated by the Memorial Sloan-Kettering Cancer 
Cells in 1970. It was derived from a pleural effusion due to an 
adenocarcinoma originating in the breast of a 43 year old, caucasian 
female. The cell line over-expresses the HER2 gene product.  
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The SkBr3 line is synonymous (derived from the same patient) with the 
AU565 cell line. 
 
2.2.2.1 Cytotoxicity results  
The effects of each compound on cell viability were determined with the 
MTT assay, which is based on the conversion of MTT to MTT-formazan 
by mitochondrial enzyme. 
 Cells were seeded in quadruplicate in 96-well plates in regular growth 
medium and grown until 70-80% confluence. Cells were washed once 
they had attached and then treated with 10 µM each compound for 
indicated time (for one day up to 5 days). 
 Relative cell viability was determined by MTT assay according to the 
manufacturer’s protocol (Sigma-Aldrich, Milan, Italy). Mean absorbance 
for each drug dose was expressed as a percentage of the control untreated 
well absorbance and plotted vs drug concentration. 
It should be noted that by using the compounds mentioned above, SkBr3 
cells resulted to be more responsive to the treatment compared to MCF7 
cells. 
Among all tested compounds, 4b, 5b and 6b elicited repressive effects on 
the proliferation of both cell lines (Fig. 44). In particular, 4b strongly 
decreased the viability of MCF7 cells after 3 days of treatment, 
whereas 5b showed the highest antitumor activity on SkBr3 cells after 2 
days, being the most active compound on this cell line. In particular 4b, 
5b and 6b showed a strongest cytotoxic effect on MCF7 than cisplatin. 
Moreover 5b showed a similar cytotoxic activity on SkBr3 compared to 
cisplatin.  
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Figure 44 Evaluation of growth responses to 10 µM of 1b-6b in MCF7  and SkBr3  
breast cancer cells, as determined by using the MTT assay. Cell viability was expressed 
as the percentage of cells treated with the different compounds compared to cells treated 
with vehicle. Cells (5–8·104 mL−1) were treated for one day up to 5 days, as indicated 
The cytotoxic activity of complexes 4b and 5b has been tested even 
against NCI-H1299. 
Human non-small-cell lung carcinoma NCI-H1299 clones were grown in 
RPMI1640 medium and they were maintained at 37°C in a humified 
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atmosphere of 5% (v/v) CO2 in air. In order to test cell viability, we use 
MTS assay (Promega, Italy), so cells were plated in 96 wells plates at 
32000 cells/mL and they were allowed to grow for 24 hours. After this 
period, cells were treated for 72 hours with different concentrations of the 
drugs, that were diluted in medium just before their use. Cisplatin was 
removed after 2 hours from the treatment, in order to avoid that some of 
its derivates could damage cells. The data of the survival curves and 
histograms were plotted as percentages of untreated controls. Three 
independent experiments consisted of at least three replicates for each 
point, were conducted. 
 
Figure 45 Curves dose-response of two Human non-small-cell lung carcinoma NCI-
H1299 clones   treated with different concentration of 4b, 5b and Cisplatin 
As it can be seen in figure 45, complex 4b showed a stronger 
antiproliferative effect on WT KRAS clone compared with the effect on 
G12C KRAS clone. Moreover, 4b displayed a similar activity to cisplatin, 
even if its cytotoxic activity is stronger at higher concentrations. Complex 
5b displayed a very similar activity to the one of 4b, because the 
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antiproliferative effect is stronger on WT KRAS clone and it is 
comparable to the one of cisplatin. 
2.3 Synthesis and characterization of titanocene 
derivatives complexes 
In order to verify the cytotoxic activity of half-titanocene, compared to 
the analogous titanocene complexes, we synthesized the titanocene 
derivatives having the same ligands of the more cytotoxic half titanocene 
complexes previously reported (4b and 5b). 
In particular complex 4c was synthesized to test if the ether group, which 
is present on the titanocene Y, on T1 and T2, is necessary to have a 
significant higher cytotoxic activity or if a more labile ligand, having 
greater ability of π–donation, can produce a molecule with likewise 
interesting cytotoxic properties; otherwise its half-titanocene derivatives 
had shown very interesting cytotoxic properties when compared to the 
half-titanocene of the well-known Titanocene Y. 
The complexes have been synthesized starting from fulvcne 4a and 5a. 
The synthesis of the fulvene was carried out as previously outlined for 
their half-titanocene complexes 4b and 5b; the lithium salt was obtained 
by reaction with Super Hydride (LiBEt3H) in dry diethyl ether. Then it 
was isolated and subsequently reacted with half-equivalent of TiCl4·2THF 
in dry THF (see scheme 8). The reaction product was purified following 
common procedures and isolated in high yield. 
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Scheme. 8 Synthetic route for the preparation of complexes 4c and 5c 
 
Complex 4d (1,2-diphenyl-1,2-dicyclopentadienyl-ethane)-titanium-
dichloride was synthesized  in order to have a complex very similar to 4c, 
but with a chelating ligand, which would prevent the intramolecular 
coordination of phenyl groups to metal, and consequently produce a less 
stable complex than 4c.  
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Scheme. 9 Synthetic route for the preparation of complex 4d 
Elemental analysis (C, H, N) agreed with the proposed formulation. 1H 
COSY experiments allowed the assignment of all the proton resonances 
of the 1H NMR spectrum, whereas DEPT experiments were useful for the 
attribution of 13C NMR signals (see experimental part). The synthesized 
half-titanocenes were also characterized by mass spectrometry. The mass 
spectra show the molecular ion and the fragmentation of the complexes 
(i.e.: ligand, [ligandTi]). 
In Fig. 46 the 1H and 13C NMR spectra of complex 4c are reported as an 
example. 
 

















Figure 46 1H (A) and 13C NMR (B) spectra of 4c in THF 
2.3.1 Hydrolysis test of titanocene compounds 
Hydrolytic stability of the titanocene complexes has been determined in 
aqueous solution, 90% DMSO by 1H NMR spectroscopy, in order to 
possibly correlate the chemical stability of these complexes with their 
observed cytotoxic activity. 
Table 5 reports the results of our hydrolysis tests and Fig. 47 shows, as an 
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Table. 5 Hydrolysis results of complexes DMSO/D2O solution at rt followed by 1H NMR 
Complex % Cp rings hydrolysis 
 5 mins 4 hrs 8 hrs 24 hrs 
4c <1 <1 13 40 
4d 25 40 48 60 
5c <1 <1 <1 <5 
 
 
Figure 47 1H NMR spectra of unsaturated region of  4c at RT in 90% DMSO (A) 
5 mins after dissolution, (B) 4 hrs, (C) 8 hrs and (D) 24 hr 
These data confirm the previous ones, being complex 4c the less stable of 
the unbridged aryl titanocene, missing an electron donor group on the 
phenyl ring capable of coordinating to the metal centre; it is worth noting 
that complex 5c, the ansa derivatives, is muh less stable of its unbridged 
related compound 4c, being already hydrolyzed for 25% after 5 minutes. 
It can be justified considering that the bridge between the two benzilic 
carbons prevents the coordination of the phenyl ring on the metal centre, 
making it less stable. 
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2.3.2 Cytotoxic activity 
In order to investigate the effects on cancer cell growth of the compounds 
synthesized, MCF7 and SkBr3 breast cancer cells were used as model 
systems. Cells were treated for 5 days with each compound and were also 
exposed to cisplatin, in order to compare the anticancer effects of the 
chemicals used to this well-known chemotherapeutic. In dose-response 
and time course experiments, most of the tested compounds showed the 
capability to inhibit, in a dose-dependent manner, the proliferation of both 
cell lines, just after a 24 hour treatment). 
 
Figure 48 . Evaluation of cell growth treating MCF7 and SKBr3 breast cancer cells 
with tested compounds, as determined by using the MTT assay. Cells (5–8·104 mL−1) 
were treated for one day up to 5 days with increasing concentrations of tested 
compounds, as indicated. Cell viability was expressed as the percentage of cells treated 
with the different compounds compared to cells treated with vehicle. IC50 values were 
calculated by probit analysis (P<0.05, χ2 test). 
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 Among all tested titanocene derivatives, complexes 4c elicited strong 
repressive effects on the proliferation of both cell lines (Table 6). In 
particular, complex 4 showed quite similar patterns of response across the 
two cancer cell models (with IC50 values of 10 µM in both cell lines after 
24 h treatment). Moreover 4c inhibited the proliferation of MCF7 cells 
more strongly compared to cisplatin. 
The low activity of complex 4d can be justified considering that the 
bridge between the two benzilic carbons prevents the coordination of the 
phenyl ring on the metal centre, making it less stable, and therefore less 
active.  
Complexes with an alkyl group on the linker between Cp ring and phenyl 
group show a lower activity. 
Table. 6 Cytotoxic activity of tested compounds on MCF7 and SkBr3 breast cancer cells 
after one 24hrs treatment, as determined by using the MTT assay. IC50 values were 
calculated by probit analysis (P<0.05, χ2 test). 
Compound Cell lines (IC50 values) 
MCF-7       SKBr3 
4c 10 (±3) 10 (±1) 
4d 27 (±6) 25 (±5) 
5c n.d n.d 
Cisplatin 29 (±8) 10 (±2) 
 
Complex 4c has been then tested against NCI-H1299 with the previously 
reported method. 
Human non-small-cell lung carcinoma NCI-H1299 clones were grown in 
RPMI1640 medium and they were maintained at 37°C in a humified 
atmosphere of 5% (v/v) CO2 in air. In order to test cell viability, we use 
MTS assay (Promega, Italy), so cells were plated in 96 wells plates at 
32000 cells/mL and they were allowed to grow for 24 hours. After this 
period, cells were treated for 72 hours with different concentrations of the 
drugs, that were diluted in medium just before their use. Cisplatin was 
removed after 2 hours from the treatment, in order to avoid that some of 
its derivates could damage cells. The data of the survival curves and 
histograms were plotted as percentages of untreated controls. Three 
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independent experiments consisted of at least three replicates for each 
point, were conducted. 
In Figure 49, we can see that 4c showed a stronger antiproliferative 
activity both on WT KRAS clone and on G12C KRAS clone compared to 
cisplatin. However, the effect is higher on WT KRAS clone. 
 
Figure 49 Curves dose-response of two Human non-small-cell lung carcinoma NCI-
H1299 clones  treated with different concentration of 4c and Cisplatin 
The cytotoxic activity of complex 4c was evaluated even against others 
cell lines with the following method. 
A375 (melanoma cell line), A549 (human lung alveolar basal epithelial 
cell) and HEK-293 (3.5 104 cells/well) were plated on 96-well microtiter 
plates and allowed to adhere at 37°C in a 5% CO2 atmosphere for 2 h. 
Thereafter, the medium was replaced with fresh one (50 µL) and a 75 µL 
of 1:4 serial dilution of each tested compound was added, and then the 
cells incubated for further 72 h. Cis-Platinum was used as reference drug. 
 Mitochondrial respiration, an indicator of cell viability, was assessed by 
the mitochondrial-dependent reduction of MTT to formazan and cells 
viability was assessed accordingly to the method of Mosman. Briefly 25 
mL of MTT (5 mg/mL) was added and the cellswere incubated for an 
additional 3 h. Thereafter, cells were lysed and the dark blue crystals 
solubilised with 100 mL of a solution containing 50% (v:v) N,N-
dimethylformamide, 20% (w:v) SDS with an adjusted pH of 4.5. The 
optical density (OD) of each well was measured with a microplate 
spectrophotometer (Titertek Multiskan MCC/340) equipped with a 620 
nm filter. The viability of each cell line in response to treatment with 
tested compounds and 6-mercaptopurine was calculated as: % dead cells 
=100-(OD treated/OD control) ×100 
Pag.82  Studies of novel organo-metallic compounds  E. Sirignano 
 
Table. 7 The cytotoxic activity of compounds was evaluated as IC50 (µM): 
the concentration of compound that affords cell growth by 50% as compared to control 
on the following cell lines: A375 (melanoma cell line), A549 (human lung alveolar basal 




Cell line (IC50, µM) 
A375              A549       HEK-293 
4c 12 (±4) 70 (±8) >100 
TDC >100 >100 >100 
Cisplatin 22 (±8) 12 (±2) 67(±5) 
 
2.4 Synthesis and characterization of alkyl-
substituted titanocene 
In order to enforce our hypothesis about the efficacy of a coordinating 
group to stabilize the metal center, we decided to synthesize complexes 
8b and 8c. These compounds have a strong electron-donor group on the 
Cp ring (a tert-butyl group) able to strengthen the sigma bond (σ bond) 
between Cp ring and the metal center, but no capability of coordination to 
the Ti centre 
Complexes 7b and 7c have been synthesized and fully characterized 
through 1 H NMR, 13C NMR and elemental anlisys. 
The synthesis of 7b and 7c were carried out by reaction of the lithium salt 
of the ligand (7a) with one equivalent of TiCl4 to obtain 8b, or half 
equivalent of TiCl4 to obtain 8c (see scheme 9) 
The reaction of 6,6-dimethylfulvene with acetone in dry diethyl ether at 
low temperature produced tert-butylcyclopentadiene (7a). Then, the 
ligand reacted with BuLi to form the correspondinh lithium salt which 
was isolated and then reactes with one equivalent or half quivalent of 
TiCl4 in dry THF. The complexes were purified following common 
procedures and isolated in good yield. 
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Scheme 9. Synthetic route for the preparation of complex 7b.7c 
2.4.1 Hydrolysis test  
Hydrolysis stability of the complexes (7b and 7c) has been determined in 
aqueous solution, 90% DMSO by 1H NMR spectroscopy, as well. Table 8 
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Table. 8 Hydrolysis results of 8b-8ccomplexes in 
DMSO/D2O solutionat rt followed by 1HNMR 
Complex % Cp rings hydrolysis 
 5 mins 4 hrs 8 hrs 24 hrs 
7b <1 58 76 >99 
7c <1 52 59 72 
 
As can be easily visualized through the table 5, complex 7b showed a 
moderate instability after 24 hrs, which almost total hydrolysis, whereas 
complex 7c proved to be more stable. 
These data enforce our hypothesis that a coordinating groups on the 
cyclopentadienyl ring is necessary for the stabilization of the complexes, 
especially for half titanocene complexes, whose metal centre is more 
electron poor compared to titanocene derivative. 
2.4.2 Cytotoxic activity 
As for the previous complexes, these compunds have been tested on the 
same cell lines (MCF-7 ans SKBr3), but their observed citotoxicity was 
quite low if compared to Cisplatin (see table 9).  
Table. 9 Cytotoxic activity of tested compounds on MCF7 and SkBr3 breast cancer cells 
after one 24h treatment, as determined by using the MTT assay. IC50 values were 




MCF-7    SKBr3 
7b >100 >100 
7c >100 >100 
Cisplatin 29 (±8) 10 (±2) 
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2.5 Synthesis and characterization of ethoxybenzyl-
cyclopentadienyl titanocene 
As indicated by our results, the presence of a coordinating group, such as 
phenyl or ether one, is necessary to stabilize the active species and 
generate a cytotoxic complex. This conclusion is supported by the lower 
activity of complex 4d (three times less cytotoxic than the unbridged 
complex 4c), in which the bridge beetwen the Cp ligands prevent the 
coordination of phenyl group on the metal centre, and of the lack of 
activity of complex 7c,with no coordinating group in its structure. 
Moreover, the position of the phenyl ring and of the ether group may 
influence the activity, as can been easily seen through the half-titanocene 
2b and 5b; these two complexes have two methoxylic groups, but in 
different positions and this lead to different cytotoxic activity, being 
complex 5b more cytotoxic than 2b, perhaps because of a stronger 
coordinating capability of the methoxy group in position 2, compared to 
the one in position 3. 
In order to investigate an alternative arrangement of the phenyl group and 
of the ether group we decided to synthesized complexes 8b-8c, in which 
the phenyl ring and the ether group can more easily coordinate the metal 
centre, being the whole complex much more flebible.  
As can be easily verified, this ligand may stabilize the titanium cation 
either with oxygen atom or with phenyl ring. 
Moreover, complexes 8b-c allowed to test the effect of phenoxy group, 
instead of methoxy one present in T1 and T2, on the effectiveness of this 
titanocene and half-titanocene. 
Complexes 8d and 8e were synthesized so as to have different leaving 
groups on titanocene, compared to chloride, and this could improve the 
activity of the complexes, by means of favorable pharmacokinetic 
properties. 
The synthesis of 8b and 8c were carried out in good yields by reaction of 
the lithium salt of the ligand Li[C5H4-CH2CH2OPh] with one equivalent 
of TiCl4 or half an equivalent respectively. 
The synthesis of (bis-2-cyclopentadienyl-ethoxy-benzene)-titanium-bis-
glycine [C5H4-CH2CH2OPh]2Ti(gly)2 (8d) was carried out by the reaction 
of 8c with two equivalents of glycine in methanol containing 1% of water 
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(see scheme 10).  
Instead, the synthesis of (bis-2-cyclopentadienyl-ethoxy-benzene)-
titanium-oxalate [C5H4CH2CH2OPh]2Ti(C2O4) (8e) was performed by 
reaction of 8c with silver-oxalate in dry THF (see Scheme 10). 
 All the synthesized complexes were purified following common 
procedures and isolated in good yield. Elemental analysis (C, H, N) were 
in agreement with the proposed formulae. 1H COSY experiments allowed 
the assignment of all the proton resonances of the 1H NMR spectrum, 
whereas DEPT experiments were useful for the attribution of 13C NMR 
signals. The synthesized titanocenes were also characterized by mass 
spectrometry. 
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Scheme. 10 Synthetic route for the preparation of complexes 8b-8e 
 
2.5.1 Hydrolysis test 
Even for these complexes, hydrolytic stability has been determined in 
aqueous solution, 90% DMSO by 1H NMR spectroscopy. Table 10 
reports the results of our hydrolysis tests with. All the complexes show an 
high hydrolytic stability. In particular, the cyclopentadienyl rings of 
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Table. 10 Hydrolysis results of 8b-8ccomplexes in  
DMSO/D2O solutionat rt followed by 1HNMR 
Complex % Cp rings hydrolysis 
 5 mins 4 hrs 8 hrs 24 hrs 
8b <1 <1 <1 <5 
8c <1 <1 <1 <5 
8d <1 <1 <1 <5 
8e <1 <1 <1 <5 
 
2.5.2 Cytotoxic activity 
The synthesized compounds have been evaluated for their cytotoxic 
potential against two human breast cancer cell lines. Most of these 
compounds showed significant anti-proliferative effects compared to 
cisplatin when tested against both MCF7 and SkBr3 cells in MTT assays. 
Cells were treated for 5 days with each compound and were also exposed 
to cisplatin, in order to compare the anticancer effects of the chemicals 
used to this well-known chemotherapeutic. In dose-response and time 
course experiments, most of the tested compounds showed the capability 
to inhibit, in a dose-dependent manner, the proliferation of both cell lines, 
just after a 24 hour treatment.  
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Figure 50 Evaluation of cell growth treating MCF7 and SKBr3 breast cancer cells with 
tested compounds, as determined by using the MTT assay. Cells (5–8·104 mL−1) were 
treated for one day up to 5 days with increasing concentrations of tested compounds, as 
indicated. Cell viability was expressed as the percentage of cells treated with the 
different compounds compared to cells treated with vehicle. IC50 values were calculated 
by probit analysis (P<0.05, χ2 test). 
Among all tested titanocene derivatives, complexes 8c and 8e elicited 
strong repressive effects on the proliferation of both cell lines (Table 11). 
Complex 8e exhibited stronger antiproliferative effects in SkBr3 cells 
with respect to those elicited in MCF7 cells (IC50 values of 9 µM in 
MCF7 and 6 µM in SkBr3 cells) after a one-day-treatment (Table 11). 
Remarkably, a 24-hour-treatment with complex 8e (10 µM) was able to 
fully prevent SkBr3 cell growth (Fig. 50). Finally, it should be pointed 
out that complexes 8c and 8e inhibited the proliferation of MCF7 cells 
more strongly compared to cisplatin (Fig. 50). 
Complex 8d showed a good cytotoxic activity only against SkBr3, 
whereas the half-titanocene 8b was active only at very high concentration 
(>100 µM). 
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Table. 11 Cytotoxic activity of tested compounds on MCF7 and SkBr3 breast cancer 
cells after one 24h treatment, as determined by using the MTT assay. IC50 values were 
calculated by probit analysis (P<0.05, χ2 test). 
Complex Cell line (IC50, µM) 
MCF-7        SKBr3        HEK-293 
8b >100 >100 >100 
8c 10 (±2) 10 (±1) >100 
8d >100 38 (±5) >100 
8e 9 (±1) 6 (±2) >100 
TDC >100 >100 >100 
Tit. Y 72 (±9) >100 >100 
Cisplatin 29 (±8) 10 (±2) 67(±5) 
 
Moreover, complexes 8c and 8e were tested again NCI-H1299. 
Human non-small-cell lung carcinoma NCI-H1299 clones were grown in 
RPMI1640 medium and they were maintained at 37°C in a humified 
atmosphere of 5% (v/v) CO2 in air. In order to test cell viability, we use 
MTS assay (Promega, Italy), so cells were plated in 96 wells plates at 
32000 cells/mL and they were allowed to grow for 24 hours. After this 
period, cells were treated for 72 hours with different concentrations of the 
drugs, that were diluted in medium just before their use. Cisplatin was 
removed after 2 hours from the treatment, in order to avoid that some of 
its derivates could damage cells. The data of the survival curves and 
histograms were plotted as percentages of untreated controls. Three 
independent experiments consisted of at least three replicates for each 
point, were conducted 
 





Figure 51. Curves dose-response of two Human non-small-cell lung carcinoma  
NCI-H1299 clones treated with different concentration of 8c, 8e and Cisplatin 
 
In Figure 51, the dose-response curve of 8c showed again a similar 
activity to cisplatin and a stronger effect of the drug on WT KRAS clone. 
Morevoer complex 8e is the only titanocene complex that showed a 
similar activity on WT KRAS clone and G12C KRAS clone. 
2.6 Synthesis and characterization of titanocene 
and half-titanocene derivatives having a methyl 
group on the linker between Cp ring and 
phenyl group 
In order to investigate the importance of the linker between the Cp ring 
and the phenyl ring, we synthesized and fully characterized complexes 
9b-9c, 10b-10c and 11b-11c. 
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Scheme. 11 Synthetic route for the preparation of complexes 9b-11b and 9c-11c 
 
These complexes have the same ligand of the most active compounds 
previously reported, and in addition  a methyl group on the linker 
between Cp rings and phenyl group in order to obtain  even a more 
lipophilic complex. 
The synthesis has been carried out according the same method used for 
complexes 1b-6b, starting from the suitable acetophenone, as shown in 
scheme 11. 
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All the synthesized complexes were purified following common 
procedures and isolated in good yield. Elemental analysis (C, H, N) were 
in agreement with the proposed formulae. 1H COSY experiments allowed 
the assignment of all the proton resonances of the 1H NMR spectrum, 
whereas DEPT experiments were useful for the attribution of 13C NMR 
signals. The synthesized titanocenes were also characterized by mass 
spectrometry. 
2.6.1 Hydrolysis test 
Even for these complexes, hydrolytic stability has been determined in 
aqueous solution, 90% DMSO by 1H NMR spectroscopy. 
Table 12 reports the results of our hydrolysis tests. All the complexes  
show an hydrolytic stability, whereas complexes 9b and 9c are the less 
stable ones. These data agree with those previously reported.  
 
Table. 12 Hydrolysis results of complexes in  
DMSO/D2O solution at rt followed by 1H NMR. 
Complex % Cp rings hydrolysis 
 5 mins 4 hrs 8 hrs 24 hrs 
9b  15 30 55 55 
9c 14 35 52 55 
10b <1 <1 <1 <5 
10c <1 <1 <1 <5 
12 <1 <1 <1 <5 
11c <1 <1 <1 <5 
 
2.6.2 Cytotoxic activity 
The synthesized compounds have been evaluated for their cytotoxic 
potential against the same human breast cancer cell lines. 
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Table. 13 Cytotoxic activity of tested compounds on MCF7 and SkBr3 breast 
 cancer cells after one 24h treatment, as determined by using the MTT assay. 
 IC50 values were calculated by probit analysis (P<0.05, χ2 test). 
 
Complex Cell line (IC50, µM) 
MCF-7        SKBr3 
9b >50 >50 
9c >50 >50 
10b >50 >50 
10c >50 >50 
11b >50 >50 
11c >50 >50 
TDC >100 >100 
Tit. Y 72 (±9) >100 
Cisplatin 29 (±8) 10 (±2) 
 
Cells were treated for 5 days with each compound and were also exposed 
to cisplatin, in order to compare the anticancer effects of the chemicals 
used to this well-known chemotherapeutic. In dose-response and time 
course experiments, most of the tested compounds showed the capability 
to inhibit, in a dose-dependent manner, the proliferation of both cell lines, 
just after a 24-hour treatment. 
As snown in table 13, complexes 9b-11b and 9c-11c show no significant 
activity when tested against the same cell lines. 
2.7 Synthesis and characterization of naphtyl-
substituted complexes 
Complexes 12b and 12c have the naphtyl ring instead of the phenyl ring 
and the methoxy group in the same position of Titanocene Y; the naphtyl 
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and phenyl groups have similar coordination properties but very different 
steric hindrance. 
The synthesis was carried out starting from the suitable benzaldehide, as 
shown in scheme 12. 
 
 
Scheme. 12. Synthetic route for the preparation of complexes 12b and 12c 
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2.7.1 Hydrolysis test 
Even for these complexes, hydrolytic stability has been determined in 
aqueous solution, 90% DMSO by 1H NMR spectroscopy. 
Table 14 reports the results of our hydrolysis tests with. All the 
complexes show an hydrolytic stability even after 24 hours. 
Table. 14 Hydrolysis results of complexes in DMSO/D2O solution 
 at rt followed by 1H NMR. 
Complex % Cp ring hydrolysis 
5 mins      4hrs      8 hrs       24 hrs 
12b <1 <1 <1 <5 
12c <1 <1 <1 <5 
 
2.7.2 Cytotoxic activity 
The synthesized compounds have been evaluated for their cytotoxic 
potential against the same human breast cancer cell lines but their 
cytotoxicity is lower if compared to cisplatin. 
Table. 15 Cytotoxic activity of tested compounds on MCF7 and SkBr3  
breast cancer cells after one 24h treatment, as determined by using the MTT assay.  
IC50 values were calculated by probit analysis (P<0.05, χ2 test). 
Complex Cell line (IC50, µM) 
MCF-7             SKBr3 
12b >50 >50 
12c >50 >50 
TDC >100 >100 
Titanocene Y 72 (±9) >100 
Cisplatin 29 (±8) 10 (±2) 
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2.8 Cytotoxic activity of fulvene 
All the synthesized fulvene have been tested for their cytotoxic acitivity 
against five cancer cell lines: MCF-7, SkBr3, Ishikawa, LnCap and A549. 
In addition to the well known MCF7 and SkBr3 cell lines, we tested them 
against: 
• Ishikawa cell line: the cell line Ishikawa was established from an 
endometrial adenocarcinoma from a 39 year old woman. The cells 
induced well differentiated adenocarcinoma in athymic nude mice. 
Estrogen and progesterone receptors were demonstrated both in 
cell culture and in induced tumours. Ishikawa has been reported to 
produce corticotropin-releasing hormone, placental alkaline 
phosphatase and chorionic gonadotrophin, and responded to 
steroid hormones.  
• LnCap cell line: LNCaP cells are androgen-sensitive human 
prostate adenocarcinoma cells derived from the left 
supraclavicular lymph node metastasis from a 50-year-old 
caucasian male in 1977. They are adherent epithelial cells growing 
in aggregates and as single cells. High-affinity specific androgen 
and estrogen receptors are present in the cytosol and nuclear 
fractions 
• A549 cell line: A549 cells are adenocarcinomic human alveolar 
basal epithelial cells. The A549 cell line was first developed in 
1972 by D. J. Giard, et al. through the removal and culturing of 
cancerous lung tissue in the explanted tumor a of 58-year-old 
caucasian male. In nature, these cells are squamous and 
responsible for the diffusion of some substances, such as water 
and electrolytes, across the alveoli of lungs. They are able to 
synthesize lecithin and contain high level of desaturated fatty 
acids, which are important to maintain the membrane 
phospholipids in cells 
With the aim of investigating the effects on cancer cell growth of the 
newly synthesized compounds, we evaluated by MTT tests their cytotoxic 
potential against a panel of f the ive human tumor cell lines.  
MCF7 breast and A549 lung cancer cells were maintained in DMEM/F-
12 supplemented with 10% fetal bovine serum (FBS), 100 mg/ml 
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penicillin/streptomycin and 2 mM L-glutamine (Life Technologies, 
Milan, Italy). LNCaP prostate and SkBr3 breast cancer cells were 
cultured inRPMI-1640 medium with and without phenol red respectively, 
supplemented with 10% FBS, 100 mg/ml penicillin/streptomycin and 2 
mM L-glutamine (Life Technologies, Milan, Italy). Ishikawa endometrial 
cancer cells were maintained in MEM supplemented with 10% FBS, 100 
mg/ml penicillin/streptomycin, 2 mM L-glutamine and 1% Non-Essential 
Amino Acids Solution (Life Technologies, Milan, Italy).  
The effects of each compound on cell viability were determined with the 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] 
assay, which is based on the conversion of MTT to MTT-formazan by 
mitochondrial enzyme.27 Cells were seeded in quadruplicate in 96-well 
plates in regular growth medium and grown until 70–80% confluence. 
Cells were washed once they had attached and then treated with 
increasing concentrations each compound for 1day in regular medium 
supplemented with 1% FBS. Relative cell viability was determined by 
MTT assay according to the manufacturer’s protocol (Sigma–Aldrich, 
Milan, Italy). Mean absorbance for each drug dose was expressed as a 
percentage of the control untreated well absorbance and plotted versus 
drug concentration. IC50 values represent the drug concentrations that 
reduced the mean absorbance at 570 nm to 50% of those in the untreated 
control wells. 
Cells were treated for 24 hrs with each compound and were also exposed 
to cis-diamminedichloroplatinum(II) (cisplatin), in order to compare the 
anticancer effects of the chemicals synthesized to this widely used anti-
cancer chemotherapy drug. As cisplatin is used to treat among others 
testicular, ovarian, bladder, head and neck, esophageal, small and non-
small cell lung, breast, cervical, stomach and prostate cancers, we 
employed breast MCF7 and SkBr3, endometrial Ishikawa, prostate 
LnCaP and lung A549 cancer cells as model systems. The in vitro 
cytotoxic activity measurements indicated that most of the compounds 
studied are able to inhibit the proliferation of the five cell lines.  
As reported in table x. compounds 1a-6a and 12a show a significant 
cytotoxic activity on all the cell lines, being the Ishikawa the most 
sensitive and the LnCap the less one. 
In particular, among the investigated compounds, 5a exhibited the most 
powerful antiproliferative activity against all the human tumor cell lines 
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evaluated. Interestingly, the aforementioned compound showed higher 
inhibitory effects on cell growth than to cisplatin.  
It should be noted that 3a did not exhibit any antiproliferative potential, 
whereas 11a just blocked the proliferation of MCF7 breast cancer cells, 
confirming the importance of both two methoxy groups in 2’ and 4’ 
position. The inability of this compound to block the proliferation of 
SkBr3, Ishikawa, LnCaP and A549 cells might be related to the presence 
of the methyl group in position 6.  
Table. 16 Cytotoxic activity of tested compounds on breast MCF7 and SkBr3, 
endometrial Ishikawa, prostate LnCaP and lung A549 cancer cells, after 24 h treatment, 
as determined by using the MTT assay. IC50 values were calculated by probit analysis  
(P<0.05, χ2 tst). 
Compound IC50 (µM) 
MCF7 SkBr3 Ishikawa LnCaP A549 
1a 14(±2) 13(±4) 15(±2) 10(±4) 12(±4) 
2a 10(±1) 13(±2) 9(±3) 11(±2) 13(±5) 
3a >50 >50 >50 >50 >50 
4a 15(±3) 4(±1) 11(±3) 7(±1) 15(±4) 
5a 8 (±2) 9(±2) 3(±1) 5(±2) 5(±1) 
6a 11(±3) 10(±2) 9(±3) 5(±2) 25(±4) 
9a 15(±2) 35(±6) 10(±2) >50 >50 
10a 6(±1) 15(±2) 6(±2) >50 22(±4) 
11a 10(±1) >50 >50 >50 >50 
12 a 30(±5) >50 9(±1) 8(±1) 13(±2) 
1a hydro 10(±2) >50 10(±3) 12(±2) >50 
Cisplatin 22 (±6) 12 (±1) 14(±3) 10(±1) 12(±2) 

Chapter Three 
This chapter contains a summary of the performed work  
 together with the main conclusions. 
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3 Conclusions 
We have synthesized and characterized several ligands and titanium 
complexes. All the complexes have been tested in order to value their 
hydrolytic behavior. 
The synthesized compounds have been evaluated for their cytotoxic 
potential against cancer cell lines. Most of these compounds showed 
significant anti-proliferative effects compared to cisplatin  
 As indicated by our results : 
• the presence of a coordinating group, such as phenyl or ether 
one, is necessary to stabilize the active species, delay 
hydrolysis and generate a cytotoxic complex 
• the ether groups are important  to improve the hydrolysis 
stability but are not necessary to have a significant cytotoxic 
activity  
• a more labile ligand, as the benzyl group, having greater 
ability of π–donation, produce complexes  with interesting 
cytotoxic properties;   
• lower activity was found in the analogues where the two Cp 
units were bound by a two-carbon bridge (4d) 
• half-titanocene showed lower cytotoxic activity compared to 
their titanocene analogues 
• the labile ligands (Cl) do  not have a strong impact on 
cytotoxic activity 
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• a methyl group on the linker between Cp ring and the phenyl 
group  decrease the cytotoxic activity 
• small steric hyndrance alla round the complex is favored 
• the proligands show interesting cytotoxic activity but are not 
related to complexes cytotoxicity 
• further study are needed to understand  the exact mechanism 
through which these compounds exercise their action. 
 
We strongly believe that the real merit of TiIV complexes for clinical 




This chapter contains all the experimental data 
 relative to the synthesis, and thecharacterizations 
 of all the ligands and complexes.  
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4 Experimental section 
4.1 General procedure 
All manipulations were carried out under oxygen- and moisture-free 
atmosphere in an MBraun MB 200 glove-box. All the solvents were 
thoroughly deoxygenated and dehydrated under argon by refluxing over 
suitable drying agents, while NMR deuterated solvents (Euriso-Top 
products) were kept in the dark over molecular sieves. TiCl4, TitaniumIV 
chloride tetrahydrofuran complex and all chemicals were obtained from 
Aldrich chemical Co. and used without further purification. 
Cyclopentadiene was obtained by freshly cracked dicyclopentadiene. 
Silver oxalate was prepared by following the reported procedure.[255] 
The elemental analyses for C and H were recorded on a ThermoFinnigan 
Flash EA 1112 series and performed according to standard 
microanalytical procedures. 1H NMR, homodecoupled 1H NMR, 1H 
COSY and 13C NMR spectra were recorded at 298 K on a Bruker Avance 
300 Spectrometer operating at 300 MHz (1H) and 75 MHz (13C) and 
referred to internal tetramethylsilane. Molecular weights were determined 
by ESI mass spectrometry. ESI-MS analysis in positive and negative ion 
mode, were made using a Finnigan LCQ ion trap instrument, 
manufactured by Thermo Finnigan (San Jose, CA, USA), equipped with 
the Excalibur software for processing the data acquired. The sample was 
dissolved in acetonitrile and injected directly into the electrospray source, 
using a syringe pump, which maintains constant flow at 5 µl /min. The 
temperature of the capillary was set at 220°C. GC analyses were carried 
out with a GC-MS 7890A/5975C spectrometer (Agilent Technologies) 
equipped with an OPTIMA 17MS column  and a mass-selective detector.  
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4.2  Synthesis of ligands 
4.2.1 Synthesis of 6-p-(methoxyphenyl) fulvene  (1a ) 
The synthesis was carried out under nitrogen. Pyrrolidine (2.5 ml, 30.0 
mmol) was added to as olution of p-methoxy-benzaldehyde (2.4 ml, 20 
mmol) and Cyclopentadiene (4.1 ml, 50.0 mmol) in 30 ml of methanol. 
After addition, the colour of the solution immediately turned from 
colourless to red-orange. Large amounts of an orange solid precipitated 
out the solution. When TLC analysisi showed only one product band after 
15 min, acetic acid (1.8 ml, 32.0 mmol) was added. The reaction mixture 
was diluted with 20 ml of a mixture of diethyl eher and water (1:1). The 
resultant organic layer was separated and the aqueous layer was washed 
with diethyl ether (3 x 20 ml). The combined organic extracts were 
washed with a satured aqueous NaCl solution. The organic solution was 
dried over magnesium sulfate. When the solvent was removed under 
reduced pressure, 3.6 g of an orange product were obtained (98%yield) 
1H NMR (δ ppm CDCl3, 250 MHz): 6.70, 6.64, 6.45, 6.30 (C5H4, 4H m); 
7.53, 7.50, 6.71, 6.88, 6.85  (C6H4, 4H m); 3.75 ((OCH3)2, 6H s); 7.10 
(Ph-CH-Cp, 1H s) 
4.2.2 Synthesis of 6-(3’,4’- dimethoxyphenyl)fulvene (2a) 
The synthesis was carried out under nitrogen. Pyrrolidine (2.5 ml, 30.0 
mmol) was added to as olution of 3,4-dimetoxy-benzaldehyde (2.0 g, 10 
mmol) and Cyclopentadiene (5 ml, 75.0 mmol) in 30 ml of methanol. 
After addition, the colour of the solution slowly turned from colourless to 
red-orange. After 20 hours no solid precipitated out the solution; acetic 
acid (1.8 ml, 32.0 mmol) was added. The reaction mixture was diluted 
with 20 ml of a mixture of diethyl eher and water (1:1). The resultant 
organic layer was separated and the aqueous layer was washed with 
diethyl ether (3 x 20 ml). The combined organic extracts were washed 
with a satured aqueous NaCl solution. The organic solution was dried 
over magnesium sulfate. When the solvent was removed under reduced 
pressure, 2.05 g of a red product were obtained (99% yield). 
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1H NMR (δ ppm CDCl3 , 250 MHz 6.73, 6.69, 6.50, 6.34 (C5H4, 4H m); 
6.93,6.90.6.79  (C6H3, 3H m); 3.94 ((OCH3)2, 6H s); 7.19 (Ph-CH-Cp, 1H 
s) 
4.2.3 Synthsis of 6-(p-N, N-Dimethylanilinyl) fulvene (3a) 
The synthesis was carried out under nitrogen. Pyrrolidine (2.5 ml, 30.0 
mmol) was added to as olution of p-(N, N-dimethylamino)benzaldehyde 
(3.0 g, 30 mmol) and Cyclopentadiene (4.1 ml, 50.0 mmol) in 30 ml of 
methanol. After addition, the colour of the solution immediately turned 
from colourless to red-orange. Large amounts of an orange solid 
precipitated out the solution. When TLC analysisi showed only one 
product band after 15 min, acetic acid (1.8 ml, 32.0 mmol) was added. 
The reaction mixture was diluted with 20 ml of a mixture of diethyl eher 
and water (1:1). The resultant organic layer was separated and the 
aqueous layer was washed with diethyl ether (3 x 20 ml). The combined 
organic extracts were washed with a satured aqueous NaCl solution. The 
organic solution was dried over magnesium sulfate. When the solvent was 
removed under reduced pressure, 3.6 g of an orange product were 
obtained (90% yield) 
1H NMR (δ ppm CDCl3, 250 MHz): 6.79, 6.63, 6.43, 6.31 (C5H4, 4H m); 
7.58, 7.55, 6.71, 6.88 (C6H4, 4H m); 3.03 (N(CH3)2, 6H s); 7.13 (Ph-CH-
Cp, 1H s) 
4.2.4 Synthesis of 6-phenylfulvene (4a) 
The synthesis was carried out under nitrogen. Pyrrolidine (2.5 ml, 30.0 
mmol) was added to as olution of benzaldehyde (2.03 ml, 20 mmol) and 
Cyclopentadiene (4.1 ml, 50.0 mmol) in 30 ml of methanol. After 
addition, the colour of the solution slowly turned from colourless to red-
orange. After 20 hours no solid precipitated out the solution; acetic acid 
(1.8 ml, 32.0 mmol) was added. The reaction mixture was diluted with 20 
ml of a mixture of diethyl eher and water (1:1). The resultant organic 
layer was separated and the aqueous layer was washed with diethyl ether 
(3 x 20 ml). The combined organic extracts were washed with a satured 
aqueous NaCl solution. The organic solution was dried over magnesium 
sulfate. When the solvent was removed under reduced pressure, 3.17 g of 
a red oil were obtained (97% yield). 
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1H NMR  (δ ppm CDCl3, 250 MHz): 6.70, 6.52, 6.36, 6.33 (C5H4, 4H m); 
7.61, 7.59, 7.43,7.40, 7.36 (C6H5, 5H m); 7.24 (Ph-CH-Cp, 1H s) 
4.2.5 Synthesis of 6-(2’,4’- dimethoxyphenyl)fulvene (5a) 
The synthesis was carried out under nitrogen. Pyrrolidine (1.3 ml, 
15mmol) was added to as olution of 2,4-dimethoxy-benzaldehyde (2.0 g, 
10 mmol) and Cyclopentadiene (2.1 ml, 26.0 mmol) in 30 ml of 
methanol. After addition, the colour of the solution slowly turned from 
colourless to red-orange. After 4.5 hours no solid precipitated out the 
solution; acetic acid (1.8 ml, 32.0 mmol) was added. The reaction mixture 
was diluted with 20 ml of a mixture of diethyl eher and water (1:1). The 
resultant organic layer was separated and the aqueous layer was washed 
with diethyl ether (3 x 20 ml). The combined organic extracts were 
washed with a satured aqueous NaCl solution. The organic solution was 
dried over magnesium sulfate. When the solvent was removed under 
reduced pressure, 2.05 g of a red product were obtained (96% yield). 
1H NMR   (δ ppm CDCl3, 250 MHz): 6.58, 6.55, 6.48, 6.37 (C5H4, 4H m); 
7.63, 7.61, 7.52  (C6H3, 3H m); 3.87 ((OCH3)2, 6H s); 6.65(Ph-CH-Cp, 
1H s) 
4.2.6  Synthesis of 6 (2’,4’,6’-trimethoxyphenyl)fulvene (6a) 
The synthesis was carried out under nitrogen. Pyrrolidine (1.3 ml, 15 
mmol) was added to as olution of 2,4,6-trimethoxy-benzaldehyde (1.7 g, 
10 mmol) and Cyclopentadiene (2.1 ml, 26.0 mmol) in 30 ml of 
methanol. After addition, the colour of the solution slowly turned from 
colourless to red-orange. After 4.5 hours no solid precipitated out the 
solution; acetic acid (1.8 ml, 32.0 mmol) was added. The reaction mixture 
was diluted with 20 ml of a mixture of diethyl eher and water (1:1). The 
resultant organic layer was separated and the aqueous layer was washed 
with diethyl ether (3 x 20 ml). The combined organic extracts were 
washed with a satured aqueous NaCl solution. The organic solution was 
dried over magnesium sulfate. When the solvent was removed under 
reduced pressure, 2.31 g of a red product were obtained (95% yield). 
1H NMR   (δ ppm CDCl3, 250 MHz): 6.45, 6.43, 6.38, 6.32 (C5H4, 4H m); 
6.15  (C6H2, 2H m); 3.86, 3.81 (OCH3)3, 9H s); 7.18(Ph-CH-Cp, 1H s) 
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4.2.7 Synthesis of (tert-butyl) cyclopentadiene (7a ) 
The synthesis was carried out under nitrogen. Pyrrolidine (2.5 ml, 30.0 
mmol) was added to a solution of acetone (0.45 ml, 6.0 mmol) and 
Cyclopentadiene (1.2 ml, 15.0 mmol) in 20 ml of methanol. When TLC 
analysisi showed only one product band after 12 min, acetic acid (1.8 ml, 
32.0 mmol) was added. The reaction mixture was diluted with 20 ml of a 
mixture of diethyl eher and water (1:1). The resultant organic layer was 
separated and the aqueous layer was washed with diethyl ether (3 x 20 
ml). The organic solution was dried over magnesium sulfate. When the 
solvent was removed under reduced pressure 1.3 g of an orange-red 
product  (6,6-dimethyl-fulvene) were obtained (81% yield). 
1g of 6,6-dimethyl-fulvene (9.4 mmol), were dissolved in 50 ml of dry 
diethyl ether to give a red solution. 7 ml of methyllithium solution (1.6 M 
in diethyl ether, 11 mmol) were added drop-wise at -78° C, giving a 
brown solution. The solution was warmed up to room temperature and 
left stirred overnight to give a white precipitate and a yellow solution. 
Afterwards the mixture was quenched with cold water. The organic 
product was extracted by 3x80 ml ether fraction.  
The solution was dried over magnesium sulphate and the solvent was 
removed at reduced pressure to yield 1.14 g of a red orange oil (yield 
99%). 
1H NMR (δ ppm CDCl3, 250 MHz): 1.22 [ C5H5-C(CH3)3, 9H, m ]; 2.97 [ 
C4H4-CH-C(CH3)3, 1H, s]; 6.01-6.66 [ C5H5-C(CH3)3, 5H, m]. 
13C NMR (δ ppm CDCl3, 62.89 MHz): 29.6[ C5H5-C(CH3)3]; 30.8 [ C5H5-
C(CH3)3]; 39.9 [ (C4H4-CH)C(CH3)3]; 122.2-133.4 [ C5H5-C(CH3)3]. 
4.2.8 Synthesis of 1-[(2-(cyclopentadienyl)ethoxy]benzene (8a) 
5.23 ml of 1-(2-chloroethoxy)benzene (38.45 mmol), previously distilled 
on CaH2, were dissolved in 50 ml of dry THF to give a colourless 
solution. 25 ml of a 2M solution in THF of sodium cyclopentadienide 
were added drop-wise at -78° C. The solution was warmed up to room 
temperature and left stirred overnight to give a white precipitate and a 
dark pink solution. Afterwards the mixture was quenched with methanol 
and cold water. The organic product was extracted by 3x50 ml ether 
fraction. The solution was dried over magnesium sukphate and the 
solvent was removed at reduced pressure to yield a brown oil (yield 89%) 
Chapter Four Experimental Section Pag.111 
 
1H NMR  (δ ppm CDCl3, 250 MHz): 2.88 [ C5H5-(CH2CH2OC6H5), 2H,t];  
4.14 [ C5H5-(CH2CH2OC6H5), 2H,t]; 3.01[C4H4-CH-
(CH2CH2OC6H5),1H, m]; 6.17-6.52- [C4H4-CH-(CH2CH2OC6H5), 4H , 
m];   6.92-7.32 [C5H5 -(CH2CH2OC6H5), 5H,m]. 
13C NMR  (δ ppm C6D6, 62.89 MHz): 30.1 [ C5H5-(CH2CH2OPh)]; 67.8 [ 
C5H5-(CH2CH2OPh)]; 44.1[ C4H4-CH-(CH2CH2OPh)] ; 114.8-120.9-
128.1-129.7-134.4-134.9-159.1 [C4H4 –CH-(CH2CH2OPh)] 
GC-MS: 186.1 [M+] 
4.2.9  Synthesis of 6-methyl-6-phenyl-fulvene (9a) 
The synthesis was carried out under nitrogen. Pyrrolidine (2.5 ml, 30.0 
mmol) was added to as olution of acetophenone (2.40 g, 20 mmol) and 
Cyclopentadiene (4.1 ml, 50.0 mmol) in 30 ml of methanol. After 
addition, the colour of the solution turned from colourless to red-orange. 
After 20 hours, acetic acid (1.8 ml, 32.0 mmol) was added. The reaction 
mixture was diluted with 20 ml of a mixture of diethyl eher and water 
(1:1). The resultant organic layer was separated and the aqueous layer 
was washed with diethyl ether (3 x 20 ml). The combined organic extracts 
were washed with a satured aqueous NaCl solution. The organic solution 
was dried over magnesium sulfate. The crude product was purified by 
column cromatography over silica gel anda mixture of n-hexane/ethyl 
acetate (9:1) as the eluent, yielding 1.05 g (31% yield). 
1H NMR  (δ ppm CDCl3, 250 MHz): 6.65, 6.63, 6.53, 6.47 (C5H4, 4H m); 
7.39 (C6H5, 5H m); 2.54 (CH3, 3H s) 
 
4.2.10  Synthesis of 6-methyl-6-(4’-methoxyphenyl)fulvene (10a) 
The synthesis was carried out under nitrogen. Pyrrolidine (2.5 ml, 30.0 
mmol) was added to as olution of 4’-methoxyacetophenone (3.00 g, 20 
mmol) and Cyclopentadiene (4.1 ml, 50.0 mmol) in 30 ml of methanol. 
After addition, the colour of the solution turned from colourless to red-
orange. After 20 hours, acetic acid (1.8 ml, 32.0 mmol) was added. The 
reaction mixture was diluted with 20 ml of a mixture of diethyl eher and 
water (1:1). The resultant organic layer was separated and the aqueous 
layer was washed with diethyl ether (3 x 20 ml). The combined organic 
extracts were washed with a satured aqueous NaCl solution. The organic 
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solution was dried over magnesium sulfate. The crude product was 
purified by column cromatography over silica gel anda mixture of n-
hexane/ethyl acetate (9:1) as the eluent, yielding 0.71 g (20% yield). 
1H NMR  (δ ppm CDCl3, 250 MHz): 6.63, 6.54, 6.45, 6.23 (C5H4, 4H m); 
7.38, 7.31, 6.95, 6.91 (C6H4, 4H m); 2.52 (CH3, 3H s) 3.83 ((OCH3) 3H s) 
4.2.11 Synthesis of 6-methyl-6-(2’,4’-dimethoxyphenyl)fulvene (11a) 
The synthesis was carried out under nitrogen. Pyrrolidine (2.5 ml, 30.0 
mmol) was added to as olution of 2’,4’-methoxyacetophenone (3.60 g, 20 
mmol) and Cyclopentadiene (4.1 ml, 50.0 mmol) in 30 ml of methanol. 
After addition, the colour of the solution turned from colourless to red-
orange. After 20 hours, acetic acid (1.8 ml, 32.0 mmol) was added. The 
reaction mixture was diluted with 20 ml of a mixture of diethyl eher and 
water (1:1). The resultant organic layer was separated and the aqueous 
layer was washed with diethyl ether (3 x 20 ml). The combined organic 
extracts were washed with a satured aqueous NaCl solution. The organic 
solution was dried over magnesium sulfate. The crude product was 
purified by column cromatography over silica gel anda mixture of 
petroleum spirit/ethyl acetate (8:2) as the eluent, yielding 1.01 g (22% 
yield). 
1H NMR  (δ ppm CDCl3, 250 MHz): 6.47, 6.43, 6.40, 6.06 (C5H4, 4H m); 
7.04, 6.64, 6.56(C6H3, 3H m); 2.50 (CH3, 3H s) 3.85, 3.73 ((OCH3)2 6H 
s); 
4.2.12 Syhthesis of 6-(4’-methoxynaphtalyl)fulvene (12a) 
The synthesis was carried out under nitrogen. Pyrrolidine (2.5 ml, 30.0 
mmol) was added to as olution of 6-methoxy-2naphtaldehyde (2.4 g, 20 
mmol) and Cyclopentadiene (4.1 ml, 50.0 mmol) in 30 ml of methanol. 
After addition, the colour of the solution immediately turned from 
colourless to red-orange. Large amounts of an orange solid precipitated 
out the solution and after 16 hours acetic acid (1.8 ml, 32.0 mmol) was 
added. The reaction mixture was diluted with 20 ml of a mixture of 
diethyl eher and water (1:1). The resultant organic layer was separated 
and the aqueous layer was washed with diethyl ether (3 x 20 ml). The 
combined organic extracts were washed with a satured aqueous NaCl 
solution. The organic solution was dried over magnesium sulfate. When 
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the solvent was removed under reduced pressure, 0.69 g of an orange 
product were obtained (18% yield) 
1H NMR (δ ppm CDCl3, 250 MHz): 6.36, 6.38, 6.53, 6.69 (C5H4, 4H m); 
7.97, 7.79, 7.75, 7.18, 7.15, 7.14 (C10H6, 4H m); 3.95 ((OCH3) 3H s); 
7.34 (Ph-CH-Cp, 1H s) 
4.3 Synthesis of half-titanocene complexes 
4.3.1 Synthesis of [(4-methoxybenzyl)cyclopentadienyl]-titanium 
(IV)trichloride (1b) 
LiBEt3H (7 ml of a 1.0 M solution in THF) was concentrated by removal 
of the solvent by heating it to 60° C under a vacuum of 10-2  mbar for 40 
minutes and to 90° C for other 20 minutes. The concentrated reagent was 
dissolved in diethyl ether (50 ml) and was transferred to a solution of 1a  
(1.13g, 6.1 mmol) in diethyl ether (60 ml). The solution was stirred (12 
h), during which time the lithium cyclopentadienide intermediate   
precipitated from the solution and the colour of the solution changed from 
red to yellow. After stirring, the precipitate was allowed to settle and was 
filtered to remove the filtrate. The white lithium salt  was then collected 
on a frit and washed with diethyl ether (25 ml), dried briefly in vacuo and 
transferred to a Schlenk flask under nitrogen. 
0.350 g (1.83 mmol) of the lithium cyclopentadienide intermediate were 
dissolved in 20 ml of dry THF to give a colourless solution. 0.19 ml(18.3 
mmol) of TiCl4 were added at 0°C  to give a dark red solution. The 
solution was refluxed for 19 hours and then cooled. The solvent was 
removed under reduced pression. The remaining residue was extracted 
with dichlorometane (30 ml) and filtered through celite to remove the 
LiCl. The black filtrate was washed twice with hexane  (20 ml) and then 
dried under reduced pression to give a black solid. 
 1H NMR (δ ppm, CD2Cl2, 300 MHz): 3.78 [3H, C5H4-CH2-C6H4-OCH3], 
4.01 [2H, C5H4-CH2-C6H4-OCH3], 6.8 [4H,C5H4-CH2-C6H4-OCH3], 6.83-
7.01 [4H, C5H4-CH2-C6H4-OCH3 ]. 
13C NMR (δ ppm, CD2Cl2, 75 MHz): 55.9 [ C5H4-CH2-C6H4-OCH3 ], 45.0 
[C5H4-CH2-C6H4-OCH3], 114.0- 128.7-130.0-132.0-135.9-147.8-158.6 
[C5H4-CH2-C6H4-OCH3]. 
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Elemental analysis : Calcd. for  C14H16Cl3OTi (%): C 47.43, H 4.55. 
Found (%): C 47.81, H 4.54. 
Mass (E.I., 70 eV., m/z): 273 [L-TiCl-Li]•+, 186 [L]•+. 
4.3.2 Synthesis of  [(3,4-dimethoxybenzyl)-cyclopentadienyl]-
titanium-trichloride (2b) 
LiBEt3H (7 ml of a 1.0 M solution in THF) was concentrated by removal 
of the solvent by heating it to 60° C under a vacuum of 10-2  mbar for 40 
minutes and to 90° C for other 20 minutes. The concentrated reagent was 
dissolved in diethyl ether (50 ml) and was transferred to a solution of 1a  
(1g, 4.7 mmol) in diethyl ether (60 ml). The solution was stirred (12 h), 
during which time the lithium cyclopentadienide intermediate   
precipitated from the solution and the colour of the solution changed from 
red to yellow. After stirring, the precipitate was allowed to settle and was 
filtered to remove the filtrate. The white lithium salt  was then collected 
on a frit and washed with diethyl ether (25 ml), dried briefly in vacuo and 
transferred to a Schlenk flask under nitrogen. 
TiCl4 (0.24 ml, 2.26 mmol) was added to 20 ml of dry THF . The solution 
turned immediately from colourless to pale yellow. 0.5 g (2.26 mmol) of 
the lithium cyclopenadienide intermediate were dissolved in 20 ml of dry 
THF and added dropwise  to the solution containing the TiCl4.The 
solution turned from yellow to dark red during addition. After this 
addition, the mixture was refluxed overnight and then cooled. The colour 
of the solution became finally brown.The solvent was removed under 
reduced pression. The remaining residue was extracted with 
dichlorometane (30 ml) and filtered twice through celite to remove the 
LiCl. The black filtrate was washed twice with hexane  (20 ml) and then 
dried under reduced pression to give a brown solid. 
 1H NMR (δ ppm, THF-d8 300 MHz): 3.73 [6H,C5H4-CH2-C6H3-
(OCH3)2], 3.98 [2H, C5H4-CH2-C6H3-(OCH3)2 ], 6.29-6.42 [ 4H,C5H4-
CH2-C6H3-(OCH3)2], 6.71-6.84 [3H, C6H3-(OCH3)2]. 
13C NMR (δ ppm, CD2Cl2, 75 MHz): 55.5 [C5H4-CH2-C6H3-(OCH3)2 ], 
36.8 [C5H4-CH2-C6H3-(OCH3)2], 112.2, 113,3 115.4 120.8 122.5 132.8 
137.1 149.2 150.3 [C5H4-CH2-C6H3-(OCH3)2]. 
Elemental analysis : Calcd. for  C15H18Cl3O2Ti (%): C 46.85, H 4.72. 
Found (%): C 46.91, H 4.74 
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Mass (E.I., 70 eV., m/z): 286 [L-Ti-Na]•+. 
4.3.3 Synthesis of  [(4-(N,N-dimethylbenzanilido)-
cyclopentadienyl]-titanium-trichloride  (3b) 
LiBEt3H (6.2 ml of a 1.0 M solution in THF) was concentrated by 
removal of the solvent by heating it to 60° C under a vacuum of 10-2 mbar 
for 40 minutes and to 90° C for other 20 minutes. The concentrated 
reagent was dissolved in diethyl ether (50 ml) and was transferred to a 
solution of 1a  (1.15g, 5.8 mmol) in diethyl ether (60 ml). The solution 
was stirred (12 h), during which time the lithium cyclopentadienide 
intermediate   precipitated from the solution and the colour of the solution 
changed from red to yellow. After stirring, the precipitate was allowed to 
settle and was filtered to remove the filtrate. The white lithium salt  was 
then collected on a frit and washed with diethyl ether (25 ml), dried 
briefly in vacuo and transferred to a Schlenk flask under nitrogen. 
TiCl4·2 THF (0.564 g) was added to 20 ml of dry THF. The solution 
turned immediately from colourless to pale yellow. 0.35 g of the lithium 
cyclopenadienide intermediate were dissolved in 20 ml of dry THF and 
added dropwise to the solution containing the TiCl4.The solution turned 
from yellow to red during addition. After this addition, the mixture was 
refluxed overnight and then cooled. The solvent was removed under 
reduced pression. The remaining residue was extracted with toluene (30 
ml) and filtered twice through celite to remove the LiCl. The dark red 
filtrate was washed twice with hexane  (20 ml) and then dried under 
reduced pression to give a red solid. 
 1H NMR (δ ppm, THF-d8,, 300 MHz): 2.98 [6H, C5H4-CH2-C6H4-
N(CH3)2 ], 3.89 [2H, C5H4-CH2-C6H4-N(CH3)2], 6.45-6.67 [4H,C5H4-
CH2-C6H4-N(CH3)2], 7.10-7.31 [4H, C5H4-CH2-C6H4-N(CH3)2]. 
13C NMR (δ ppm, THF-d8, 75 MHz): 41.7 [C5H4-CH2-C6H4-N(CH3)2 ], 
33.1 [ C5H4-CH2-C6H4-N(CH3)2], 115.9-117.6-119.2-128.7-130.7-136.0-
137.1 [C5H4-CH2-C6H4-N(CH3)2]. 
Elemental analysis : Calcd. for  C15H19Cl3NTi (%): C 49.02, H 5.21, N 
3.81. Found (%): C 49.12, H 5.17, N 3.79. 
Mass (E.I., 70 eV., m/z): 371 [L-TiCl3-Na]•+ 
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4.3.4 Synthesis of [(benzyl)-cyclopentadienyl]-titanium-trichloride 
(4b) 
LiBEt3H (9.7 ml of a 1.0 M solution in THF) was concentrated by 
removal of the solvent by heating it to 60° C under a vacuum of 10-2 mbar 
for 40 minutes and to 90° C for other 20 minutes. The concentrated 
reagent was dissolved in diethyl ether (50 ml) and was transferred to a 
solution of 1a  (1.g, 6.5 mmol) in diethyl ether (60 ml). The solution was 
stirred (12 h), during which time the lithium cyclopentadienide 
intermediate precipitated from the solution and the colour of the solution 
changed from red to yellow. After stirring, the precipitate was allowed to 
settle and was filtered to remove the filtrate. The white lithium salt was 
then collected on a frit and washed with diethyl ether (25 ml), dried 
briefly in vacuo and transferred to a Schlenk flask under nitrogen. 
TiCl4· 2 THF (0.617g, 1.86 mmol) was added to 20 ml of dry THF. The 
solution turned immediately from colourless to pale yellow. 0.300 g (1.86 
mmol) of the lithium cyclopenadienide intermediate were dissolved in 30 
ml of dry THF and added dropwise to the solution containing the 
TiCl4.The solution turned from yellow to red during addition. After this 
addition, the mixture was refluxed overnight and then cooled. The solvent 
was removed under reduced pression. The remaining residue was 
extracted with dichlorometane (30 ml) and filtered twice through celite to 
remove the LiCl. The filtrate was washed twice with hexane  (20 ml) and 
then dried under reduced pression to give a dark red solid. 
1H NMR (δ ppm, THF-d8 300 MHz):  4.06 [2H, C5H4-CH2-C6H5], 6.33-
6.45 [4H, C5H4-CH2-C6H5], 7.22-7.24 [9H, C5H4-CH2-C6H5 ]. 
13C NMR (δ ppm, THF-d8 75 MHz): 36.7 [C5H4-CH2-C6H5], 110.9-
115.1-122.6-128.0-128.6-140.6 [C5H4-CH2-C6H5]. 
Elemental analysis : Calcd. for  C13H14Cl3Ti (%): C 48.12, H 4.35. Found 
(%): C 48.17, H 4.32. 
Mass (E.I., 70 eV., m/z): 242 [L-Ti-K]•+, 163 [L-Li] •+ 
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4.3.5 Synthesis of [(2,4-di-methoxybenzyl)-cyclopentadienyl]-
titanium-trichloride (5b) 
LiBEt3H (7 ml of a 1.0 M solution in THF) was concentrated by removal 
of the solvent by heating it to 60° C under a vacuum of 10-2 mbar for 40 
minutes and to 90° C for other 20 minutes. The concentrated reagent was 
dissolved in diethyl ether (50 ml) and was transferred to a solution of 1a  
(1g, 4.7 mmol) in diethyl ether (60 ml). The solution was stirred (12 h), 
during which time the lithium cyclopentadienide intermediate   
precipitated from the solution and the colour of the solution changed from 
red to yellow. After stirring, the precipitate was allowed to settle and was 
filtered to remove the filtrate. The white lithium salt was then collected 
on a frit and washed with diethyl ether (25 ml), dried briefly in vacuo and 
transferred to a Schlenk flask under nitrogen. 
TiCl4·2 THF (0.75g, 2.26 mmol) was added to 20 ml of dry THF. The 
solution turned immediately from colourless to pale yellow. 0.5 g (2.26 
mmol) of the lithium cyclopenadienide intermediate were dissolved in 20 
ml of dry THF and added dropwise to the solution containing the 
TiCl4.The solution turned from yellow to dark red during addition. After 
this addition, the mixture was refluxed overnight and then cooled. The 
colour of the solution became finally brown. The solvent was removed 
under reduced pression. The remaining residue was extracted with 
dichlorometane (30 ml) and filtered twice through celite to remove the 
LiCl. The filtrate was washed twice with hexane  (20 ml) and then dried 
under reduced pression to give a brown solid. 
 1H NMR (δ ppm, THF-d8 300 MHz): 3.72-3.76 [6H,C5H4-CH2-C6H3-
(OCH3)2], 3.90 [2H, C5H4-CH2-C6H3-(OCH3)2 ], 6.28-6.29 [ 4H,C5H4-
CH2-C6H3-(OCH3)2], 6.40-6.46-7.01 [3H,C5H4-CH2-C6H3-(OCH3)2] 
13C NMR (δ ppm, CD2Cl2, 75 MHz): 55.4-55.5[C5H4-CH2-C6H3-
(OCH3)2], 31.8 [C5H4-CH2-C6H3-(OCH3)2], 99.1-104.8-116.6-121.9-
123.3-131.4-137.6-159.2-161.0 [C5H4-CH2-C6H3-(OCH3)2]. 
Elemental analysis : Calcd. for  C15H18Cl3O2Ti (%): C 46.85, H 4.72. 
Found (%): C 46.91, H 4.74. 
Mass (E.I., 70 eV., m/z): 286 [L-Ti-Na]•+. 
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4.3.6 Synthesis of [(2,4,6-tri-methoxybenzyl)-cyclopentadienyl]-
titanium-trichloride (6b) 
LiBEt3H (6 ml of a 1.0 M solution in THF) was concentrated by removal 
of the solvent by heating it to 60° C under a vacuum of 10-2  mbar for 40 
minutes and to 90° C for other 20 minutes. The concentrated reagent was 
dissolved in diethyl ether (50 ml) and was transferred to a solution of 1a  
(1g, 4.1 mmol) in diethyl ether (60 ml). The solution was stirred (12 h), 
during which time the lithium cyclopentadienide intermediate   
precipitated from the solution and the colour of the solution changed from 
red to yellow. After stirring, the precipitate was allowed to settle and was 
filtered to remove the filtrate. The white lithium salt was then collected 
on a frit and washed with diethyl ether (25 ml), dried briefly in vacuo and 
transferred to a Schlenk flask under nitrogen. 
TiCl4·2 THF (0.504 g, 1.52 mmol) was added to 20 ml of dry THF. The 
solution turned immediately from colourless to pale yellow. 0.380 g(1.52 
mmol) of the lithium cyclopenadienide intermediate were dissolved in 30 
ml of dry THF and added dropwise  to the solution containing the 
TiCl4.The solution turned from yellow to dark red during addition. After 
this addition, the mixture was refluxed overnight and then cooled..The 
solvent was removed under reduced pression. The remaining residue was 
extracted with dichlorometane (30 ml) and filtered twice through celite to 
remove the LiCl. The black filtrate was washed twice with hexane  (20 
ml) and then dried under reduced pression to give a black solid. 
 1H NMR (δ ppm, THF-d8 300 MHz): 3.72-3.77 [9H,C5H4-CH2-C6H2-
(OCH3)3], 3.90 [2H, C5H4-CH2-C6H2-(OCH3)3 ], 6.30-6.34 [4H,C5H4-
CH2-C6H2-(OCH3)3], 6.47 [2H, C5H4-CH2-C6H2-(OCH3)3]. 
13C NMR (δ ppm, THF-d8 75 MHz): 54.7 [C5H4-CH2-C6H2-(OCH3)3], 
31.05 [C5H4-CH2-C6H2-(OCH3)3], 98.4-104.0-115.8-122.5-130.6-137.7-
158.3-160.3[C5H4-CH2-C6H2-(OCH3)3]. 
Elemental analysis : Calcd. for  C16H20Cl3O3Ti (%): C 46.36, H 4.86. 
Found (%): C 46.39, H 4.84. 
Mass (E.I., 70 eV., m/z): 317 [L-Ti-Na]•+. 
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4.3.7 Synthesis of (tert-butyl-cyclopentadienyl)-titanium (IV) 
trichloride (7b) 
To a solution of neutral ligand 14a (0.500 g, 4.1 mmol) in dry n-hexane  
(30 mL), 1,4 ml of n-BuLi (2.5 M solution in hexane, 2.35 mmol) was 
slowly added at 0° C. The solution was warmed up to room temperature 
and left stirred overnight, obtaining a yellow lithium intermediate which 
was washed twice with hexane, dried under reduced pressure and isolated 
in good yield. Afterward to a solution of the lithium intermediate (0.110g, 
0.85 mmol) in 30 ml of dry at -78° C 0.08 mL (0.85 mmol) of TiCl4 were 
added, The solution turned from yellow to dark red during addition. After 
this addition, the mixture was refluxed overnight and then cooled.The 
solvent was removed under reduced pression. The remaining residue was 
extracted with dichlorometane (30 ml) and filtered twice through celite to 
remove the LiCl. The black filtrate was washed twice with hexane  (20 
ml) and then dried under reduced pression to give a brown solid (0.070 g, 
30% yield) 
1H NMR  (δ ppm toluol, 250 MHz): 1.26 [C5H4-C(CH3)3, 9H , s];  5.80-
6.08 [ C5H4-C(CH3)3, 4H , s] 
13C NMR (δ ppm toluol, 62.89 MHz): 31.4 [C5H4-C(CH3)3]; 32 [C5H4-
C(CH3)3];116-121-149 [C5H4-C(CH3)3]. 
4.3.8 Synthesis of (2-cyclopentadienyl-ethoxy-benzene)-titanium-
(IV) trichloride (8b) 
To a solution of neutral ligand (1.0 g, 5.37 mmol) in dry THF (40 mL), a 
stoichiometic amount of n-BuLi (2.5 M solution in hexane, 2.149 mL) 
was slowly added at 0°C. The solution was warmed up to room 
temperature and left stirred overnight, obtaining a yellow lithium 
intermediate. Afterward the solution was treated at -78 °C with 0.59 mL 
(5.37 mmol) of TiCl4 and stirred overnight. The solvent was then 
removed under reduced pression. The remaining residue was extracted 
with dichlorometane (30 ml) and filtered through celite to remove the 
LiCl. The black filtrate was washed twice with hexane (20 ml) and then 
dried under reduced pressure to give a black solid (yield 65%) 
1H NMR  (δ ppm CDCl3, 250 MHz): 3.23 [C5H4-(CH2CH2OPh), 2H,t];  
4.21 [ C5H4-(CH2CH2OPh), 2H,t]; 6.44 [ C5H4-(CH2CH2OPh), 4H , s];   
6.87-7.1 [C5H4 -(CH2CH2OPh), 6H,m]. 
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13C NMR  (δ ppm, C6D6, 62.89 MHz): 25.7 [ C5H4-(CH2CH2OPh)]; 71.9 [ 
C5H4-(CH2CH2OPh)];114.7- 115.1- 115.9- 121.3- 123.7- 130.0- 130.2- 
159.7 [C5H4 -(CH2CH2OPh)]. 
Elemental analysis: Calcd. for  C13H13Cl3OTi (%): C 46.00, H 3.86. 
Found (%): C 46.21, H 3.84. 
Mass data (E.I., 70 eV., m/z): 233 [L-Ti]•+.310 [L-TiCl2-Li]•+. 
4.3.9 Synthesis of 3-(phenylethyl)cyclopentadienyl-titanium(IV) 
trichloride (9b) 
LiBEt3H (10 ml of a 1.0 M solution in THF) was concentrated by removal 
of the solvent by heating it to 60° C under a vacuum of 10-2 mbar for 40 
minutes and to 90° C for other 20 minutes. The concentrated reagent was 
dissolved in diethyl ether (50 ml) and was transferred to a solution of 1a  
(0.84g, 5 mmol) in diethyl ether (60 ml). The solution was stirred (12 h), 
during which time the lithium cyclopentadienide intermediate   
precipitated from the solution and the colour of the solution changed from 
red to yellow. After stirring, the precipitate was allowed to settle and was 
filtered to remove the filtrate. The white lithium salt was then collected 
on a frit and washed with diethyl ether (25 ml), dried briefly in vacuo and 
transferred to a Schlenk flask under nitrogen. 
TiCl4·2 THF (0.13g, 0.4 mmol) was added to 20 ml of dry THF. The 
solution turned immediately from colourless to pale yellow. 0.070g (0.4 
mmol) of the lithium cyclopenadienide intermediate were dissolved in 30 
ml of dry THF and added dropwise to the solution containing the 
TiCl4.The solution turned from yellow to dark red during addition. After 
this addition, the mixture was refluxed overnight and then cooled..The 
solvent was removed under reduced pression. The remaining residue was 
extracted with dichlorometane (30 ml) and filtered twice through celite to 
remove the LiCl. The black filtrate was washed twice with hexane  (20 
ml) and then dried under reduced pression to give a dark brown solid. 
1H NMR (δ ppm THF-d8, 300 MHz): 1.58 [3H, C5H4-CH(CH3)-
C6H4(OCH3)], 4,45 [1H, C5H4-CH(CH3)-C6H5] 6.35, 6.43 [4H, C5H4-
CH(CH3)-C6H5)], 7.17, 7.18, 7.21, 7.23 [5H, C5H4-CH(CH3)-C6H5]. 
13C NMR (δ ppm, THF-d8, 75 MHz): 23.9 [C5H4-CH(CH3)-
C6H4(OCH3)], 43.6 [C5H4-CH(CH3)-C6H5] 109.2, 114.8, 120.1, 127.5, 
127.8, 138.8 [C5H4-CH(CH3)-C6H5]. 
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Elemental analysis: Calcd. for  C13H12Cl3Ti (%): C 48.42, H 3.75. Found 
(%): C 48.21, H 3.74. 
Mass (E.I., 70 eV., m/z): 286 [L-Ti-Cl2]•+ 
4.3.10 Synthesis of [3-(4-
methoxyphenylethyl)cyclopentadienyl]titanium(IV) 
trichloride (10b) 
LiBEt3H (7.2 ml of a 1.0 M solution in THF) was concentrated by 
removal of the solvent by heating it to 60° C under a vacuum of 10-2 mbar 
for 40 minutes and to 90° C for other 20 minutes. The concentrated 
reagent was dissolved in diethyl ether (50 ml) and was transferred to a 
solution of 1a  (0.71g, 3.6 mmol) in diethyl ether (60 ml). The solution 
was stirred (12 h), during which time the lithium cyclopentadienide 
intermediate   precipitated from the solution and the colour of the solution 
changed from red to yellow. After stirring, the precipitate was allowed to 
settle and was filtered to remove the filtrate. The white lithium salt was 
then collected on a frit and washed with diethyl ether (25 ml), dried 
briefly in vacuo and transferred to a Schlenk flask under nitrogen. 
TiCl4·2 THF (0.149 g, 0.45 mmol) was added to 20 ml of dry THF. The 
solution turned immediately from colourless to pale yellow. 0.090g (0.45 
mmol) of the lithium cyclopenadienide intermediate were dissolved in 30 
ml of dry THF and added dropwise to the solution containing the 
TiCl4.The solution turned from yellow to dark red during addition. After 
this addition, the mixture was refluxed overnight and then cooled..The 
solvent was removed under reduced pression. The remaining residue was 
extracted with dichlorometane (30 ml) and filtered twice through celite to 
remove the LiCl. The black filtrate was washed twice with hexane  (20 
ml) and then dried under reduced pression to give a dark brown solid 
(yield 44.2%) 
1H NMR (δ ppm, C6D6, 300 MHz): 3.30 [3H, C5H4-CH(CH3)-
C6H4(OCH3)], 1.58 [3H, C5H4-CH(CH3)-C6H4(OCH3)], 4,63 [1H, C5H4-
CH(CH3)-C6H4(OCH3)] 5.45, 5.75 [4H, C5H4-CH(CH3)-C6H4(OCH3)], 
6.37, 6.46, 6.74, 7.04 [4H, C5H4-CH(CH3)-C6H4(OCH3)]. 
13C NMR (δ ppm, C6D6, 75 MHz): 55.0 [C5H4-CH(CH3)-C6H4(OCH3)], 
23.2 [C5H4-CH(CH3)-C6H4(OCH3)], 40.6 [C5H4-CH(CH3)-C6H4(OCH3)], 




Elemental analysis: Calcd. for  C14H14Cl3OTi (%): C 47.70, H  4.00. 
Found (%): C 47.81, H 3.94. 
Mass (E.I., 70 eV., m/z): 317 [L-Ti-Cl2]•+ 
4.3.11 Synthesis of [3-(2,4-
dimethoxyphenylethyl)cyclopentadienyl]titanium(IV) 
trichloride (11b) 
LiBEt3H (8.8 ml of a 1.0 M solution in THF) was concentrated by 
removal of the solvent by heating it to 60° C under a vacuum of 10-2 mbar 
for 40 minutes and to 90° C for other 20 minutes. The concentrated 
reagent was dissolved in diethyl ether (50 ml) and was transferred to a 
solution of 1a  (1g, 4.4 mmol) in diethyl ether (60 ml). The solution was 
stirred (12 h), during which time the lithium cyclopentadienide 
intermediate   precipitated from the solution and the colour of the solution 
changed from red to yellow. After stirring, the precipitate was allowed to 
settle and was filtered to remove the filtrate. The white lithium salt was 
then collected on a frit and washed with diethyl ether (25 ml), dried 
briefly in vacuo and transferred to a Schlenk flask under nitrogen. 
TiCl4·2 THF (0.28 g, 0.85 mmol) was added to 20 ml of dry THF. The 
solution turned immediately from colourless to pale yellow. 0.200 g (0.85 
mmol) of the lithium cyclopenadienide intermediate were dissolved in 30 
ml of dry THF and added dropwise to the solution containing the 
TiCl4.The solution turned from yellow to dark red during addition. After 
this addition, the mixture was refluxed overnight and then cooled.The 
solvent was removed under reduced pression. The remaining residue was 
extracted with dichlorometane (30 ml) and filtered twice through celite to 
remove the LiCl. The black filtrate was washed twice with hexane  (20 
ml) and then dried under reduced pression to give a brown solid (yield 
40.875%). 
1H NMR (δ ppm, C6D6, 300 MHz): 3.22 3.23 [6H, C5H4-CH(CH3)-
C6H3(OCH3)2], 1.7 [3H, C5H4-CH(CH3)-C6H3(OCH3)2], 5.06 [1H, C5H4-
CH(CH3)-C6H3(OCH3)2] 5.92, 6.33, 6.43, 6.54, 6.61, 6.91 [7H, C5H4-
CH(CH3)-C6H3(OCH3)2]. 
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13C NMR (δ ppm, C6D6, 75 MHz): 54.3 55.2 [C5H4-CH(CH3)-
C6H3(OCH3)2], 23.7 [C5H4-CH(CH3)-C6H3(OCH3)2], 30.5 [C5H4-
CH(CH3)-C6H3(OCH3)2], 98.6-103.7-114.5-120.8-121.4-131.4-136.4-
150.2-160.1 [C5H4-CH(CH3)-C6H3(OCH3)2]. 
Elemental analysis: Calcd. for C15H16Cl3O2Ti (%): C 47.10, H  4.22. 
Found (%): C 47.11, H 4.19. 
Mass (E.I., 70 eV., m/z): 347 [L-Ti-Cl2]•+ 
4.3.12 Synthesis of [(4-methoxynaphtalyl)cyclopentadienyl] titanium 
(IV) trichloride (12b) 
LiBEt3H (8.1 ml of a 1.0 M solution in THF) was concentrated by 
removal of the solvent by heating it to 60° C under a vacuum of 10-2 mbar 
for 40 minutes and to 90° C for other 20 minutes. The concentrated 
reagent was dissolved in diethyl ether (50 ml) and was transferred to a 
solution of 1a  (0.69g, 2.9 mmol) in diethyl ether (60 ml). The solution 
was stirred (12 h), during which time the lithium cyclopentadienide 
intermediate   precipitated from the solution and the colour of the solution 
changed from red to yellow. After stirring, the precipitate was allowed to 
settle and was filtered to remove the filtrate. The white lithium salt was 
then collected on a frit and washed with diethyl ether (25 ml), dried 
briefly in vacuo and transferred to a Schlenk flask under nitrogen. 
TiCl4·2 THF (0.27 g, 0.82 mmol) was added to 20 ml of dry THF. The 
solution turned immediately from colourless to pale yellow. 0.200 g (0.82 
mmol) of the lithium cyclopenadienide intermediate were dissolved in 30 
ml of dry THF and added dropwise to the solution containing the 
TiCl4.The solution turned from yellow to dark red during addition. After 
this addition, the mixture was refluxed overnight and then cooled..The 
solvent was removed under reduced pression. The remaining residue was 
extracted with dichlorometane (30 ml) and filtered twice through celite to 
remove the LiCl. The black filtrate was washed twice with hexane  (20 
ml) and then dried under reduced pression to give a black solid . 
1H NMR   (δ ppm THF-d8, 300 MHz): 6.38, 6.46 (C5H4, 4H m); 7.66, 
7.64, 7.60, 7.34, 7.16. 7.07 (C10H6, 6H m); 3.85 ((OCH3) 3H s); 4.19 (Ph-
CH2-Cp, 2H s) 
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13C NMR (δ ppm CD2Cl2, 75 MHz): 104.9, 124.1, 125.4, 128.1, 128.7, 
129.3, 132.5, 147.0, 155.9 (C5H4 and C10H6); 55.9 ((OCH3) 3H s); 35.1 
(Ph-CH2-Cp, 2H s) 
Elemental analysis: Calcd. for C17H14Cl3OTi (%): C 52.55, H  3.63. 
Found (%): C 52.78, H 3.65. 
Mass (E.I., 70 eV., m/z): 353 [L-Ti-Cl2]•+ 
4.4 Synthesis of titanocene derivatives 
4.4.1 Synthesis of bis-[(benzyl)-cyclopentadienyl]-titanium-
dichloride (4c) 
LiBEt3H (9.8 ml of a 1.0 M solution in THF) was concentrated by 
removal of the solvent by heating it to 60° C under a vacuum of 10-2  
mbar for 40 minutes and to 90° C for other 20 minutes. The concentrated 
reagent was dissolved in diethyl ether (50 ml) and was transferred to a 
solution of 4a  (1g, 6.5 mmol) in diethyl ether (60 ml). The solution was 
stirred (12 h), during which time the lithium cyclopentadienide 
intermediate   precipitated from the solution and the colour of the solution 
changed from red to yellow. After stirring, the precipitate was allowed to 
settle and was filtered to remove the filtrate. The white lithium salt  was 
then collected on a frit and washed with diethyl ether (25 ml), dried 
briefly in vacuo and transferred to a Schlenk flask under nitrogen. 
TiCl4·2 THF (0.308g, 0.93 mmol) was added to 20 ml of dry THF. The 
solution turned immediately from colourless to pale yellow. 0.300 g (1.86 
mmol) of the lithium cyclopenadienide intermediate were dissolved in 30 
ml of dry THF and added via cannula to the solution containing the 
TiCl4.The solution turned from yellow to red during addition. After this 
addition, the mixture was refluxed overnight and then cooled. The solvent 
was removed under reduced pression. The remaining residue was 
extracted with dichlorometane (30 ml) and filtered twice through celite to 
remove the LiCl. The filtrate was washed twice with hexane  (20 ml) and 
then dried under reduced pression to give a dark red solid (yield 55%). 
1H NMR (δ ppm, THF-d8, 250 MHz):  4.06 [C5H4-CH2-C6H5, 2H, s], 
6.33-6.44 [C5H4-CH2-C6H5, 4H, m], 7.22- 7.24 [C5H4-CH2-C6H5, 5H, m]. 
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13C NMR (δ ppm, THF-d8, 62.89 MHz):  36.7 [C5H4-CH2-C6H5],  110.9-
115.1-122.6-128.0-128.6-140.6[C5H4-CH2-C6H5]. 
Elemental analysis: Calcd. for  C24H20Cl2Ti (%): C 67.48, H 4.72. Found 
(%): C 67.39, H 4.77. 
Mass data (E.I., 70 eV., m/z): 426 [L2-TiCl2-Li]•+  ; 357 [L2-Ti]•+. 
4.4.2 Synthesis of [1,2-Di(cyclopentadienyl)-1,2-bis1,2-
di(phenyl)ethanediyl]titanium-dichloride) (4d) 
TiCl4·2 THF (1.076g, 3,24 mmol) was added to 20 ml of dry toluene 
containing 10% dry THF. The solution turned immediately from 
colourless to pale yellow. The mixture was stirred and cooled down to -
78° C, followed by drop wise addition of n-butyl lithium (4 ml, 6,48 
mmol). The solution turned from yellow to brown during addition. After 
this addition the mixture was allowed to warm up slowly to room 
temperature. The colour of the solution became finally black. After 20 h, 
stirring at r.t, a solution of phenyl-fulvene (6.48 mmol, 1g) in 10 ml of 
dry toluene was added to the TiCl2·2 THF solution at r.t under nitrogen. 
Then it was stirred under reflux for another 20 hours. 10 ml of the solvent 
were removed and then the remaining mixture was filtered through celite. 
The solvent was then removed under vacuum and washed with 
dichlorometane and finally twice with hexane to give a dark brown solid 
(yield 49%). 
1H NMR (δ ppm, CDCl3, 250 MHz):  5.54 [trans-C5H4-CH2-C6H5, 2H, s], 
4.85[cis-C5H4-CH2-C6H5 2H, s], 6.20-6.37 [C5H4-CH2-C6H5,4H, m], 6.89-
7.29 [C5H4-CH2-C6H5, 5H, m]. 
13C NMR (δ ppm, CDCl3, 62.89 MHz):  54.2 [trans-C5H4-CH2-C6H5], 
51.0 [cis-C5H4-CH2-C6H5], 110.0-113.4-117.1-127.5-128.1-128.3-128.6-
133.8-138.3[C5H4-CH2-C6H5]. 
Mass (E.I., 70 eV, m/z): 433.04 [L2-TiCl2-Li]•+. 
Elemental analysis: Calcd. for  C24H20Cl2Ti (%): C 67.48, H 4.72. Found 
(%): C 67.39, H 4.77. 
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4.4.3 Synthesis of bis-[(2,4 dimethoxybenzyl)-cyclopentadienyl] 
titanium (IV) dichloride (5c) 
LiBEt3H (7 ml of a 1.0 M solution in THF) was concentrated by removal 
of the solvent by heating it to 60° C under a vacuum of 10-2 mbar for 40 
minutes and to 90° C for other 20 minutes. The concentrated reagent was 
dissolved in diethyl ether (50 ml) and was transferred to a solution of 4a  
(1g, 4.7 mmol) in diethyl ether (60 ml). The solution was stirred (12 h), 
during which time the lithium cyclopentadienide intermediate   
precipitated from the solution and the colour of the solution changed from 
red to yellow. After stirring, the precipitate was allowed to settle and was 
filtered to remove the filtrate. The white lithium salt was then collected 
on a frit and washed with diethyl ether (25 ml), dried briefly in vacuo and 
transferred to a Schlenk flask under argon. 
TiCl4·2 THF (0.308 g, 0.93 mmol) was added to 20 ml of dry THF. The 
solution turned immediately from colourless to pale yellow. 0.300 g (1.35 
mmol) of the lithium cyclopenadienide intermediate were dissolved in 30 
ml of dry THF and added via cannula to the solution containing the 
TiCl4.The solution turned from yellow to red during addition. After this 
addition, the mixture was refluxed overnight and then cooled. The solvent 
was removed under reduced pression. The remaining residue was 
extracted with dichlorometane (30 ml) and filtered twice through celite to 
remove the LiCl. The filtrate was washed twice with hexane  (20 ml) and 
then dried under reduced pression to give a dark red solid (yield 55%). 
1H NMR (δ ppm, C6D6 300 MHz): 3.32-3.38 [6H,C5H4-CH2-C6H3-
(OCH3)2], 4.25 [2H, C5H4-CH2-C6H3-(OCH3)2 ], 6.19-6.29 [ 4H,C5H4-
CH2-C6H3-(OCH3)2], 6.38-6.46-7.11 [3H,C5H4-CH2-C6H3-(OCH3)2]. 
13C NMR (δ ppm, CD2Cl2, 300 MHz): 55.1-55.2[C5H4-CH2-C6H3-
(OCH3)2], 31.8 [C5H4-CH2-C6H3-(OCH3)2], 99.4-104.6-115.7-121.7-
123.0-131.7-137.2-159.0-160.7 [C5H4-CH2-C6H3-(OCH3)2]. 
Elemental analysis : Calcd. for  C28H28Cl2O4Ti (%): C 61.45, H 5.16. 
Found (%): C 61.91, H 5.17. 
Mass (E.I., 70 eV., m/z): 499 [L-Ti-Na]•+. 
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4.4.4 Synthesis of bis(tert-butyl-cyclopentadienyl) titanium (IV) 
dichloride (7c) 
To a solution of neutral ligand 14a (0.518 g, 4.2 mmol) in dry THF (50 
mL), 2.6 ml of n-BuLi (2.5 M solution in hexane, 2.35 mmol) was slowly 
added at -78° C. The solution was warmed up to room temperature and 
left stirred overnight, obtaining a yellow lithium intermediate. Afterward 
the solution was treated at -78° C with 0.23 mL (2.1 mmol) of TiCl4 and 
stirred overnight. The solvent was removed under reduced pression. The 
remaining residue was extracted with dichlorometane (30 ml) and filtered 
twice through celite to remove the LiCl. The black filtrate was washed 
twice with hexane  (20 ml) and then dried under reduced pression to give 
a brown solid. (0.060g, 36% yield) 
1H NMR (δ ppm toluol, 250 MHz): 1.27 [C5H4-C(CH3)3, 9H , s]; 5.81-
6.09 [C5H4 -C(CH3)3 ,4H ,s]. 
13C NMR (δ ppm toluol, 62,89 MHz): 30.89 [C5H4-C(CH3)3]; 31.4 [C5H4-
C(CH3)3]; 117.7-119.4-149.1 [ C5H4-C(CH3)3]. 
Elemental analysis : Calcd. for  C19H24Cl2Ti (%): C 61.45, H 5.16. Found 
(%): C 61.91, H 5.17. 
Mass (E.I., 70 eV., m/z): 288 [L-Ti-Cl]•+. 
4.4.5 Synthesis of  (bis-2-cyclopentadienyl-ethoxy-benzene)-
titanium (IV) dichloride  (8c) 
To a solution of neutral ligand (0.45 g, 2.41 mmol) in dry THF  (40 mL), 
a stoichiometic amount of n-BuLi (2.5 M solution in hexane, 1.5 mL) was 
slowly added at 0 °C. The solution was warmed up to room temperature 
and left stirred overnight, obtaining a yellow lithium intermediate. 
Afterward the solution was treated at -78 °C with 0.13 mL (1.21 mmol) of 
TiCl4 and stirred overnight. The solvent was then removed under reduced 
pressure. The remaining residue was extracted with dichloromethane (30 
mL) and filtered through celite to remove the LiCl. The black filtrate was 
washed twice with hexane (20 mL) and then dried under reduced pressure 
to give a black solid (yield 37%). 
 1H NMR (δ ppm THF-d8 300 MHz,) δ 3.58 [t, 4H, C5H4-
(CH2CH2OC6H5)], 4.68 [t, 4H, C5H4-(CH2CH2O C6H5)], 6.75-6.85 [m, 
Pag.128  Studies of novel organo-metallic compounds  E. Sirignano 
 
8H, C5H4-(CH2CH2OC6H5),], 6.90-7.10 [m, 10H, C5H4-
(CH2CH2OC6H5)].  
13C NMR (δ ppm 75 MHz, C6D6) δ 25.1 [C5H4-(CH2CH2OC6H5)], 67.5 
[C5H4-(CH2CH2OC6H5)], 114.0, 114.9, 128.9 [C5H4-(CH2CH2OC6H5)], 
115.2, 118.6, 120.2, 157.8, 159.4 [C5H4-(CH2CH2OC6H5)].  
Elemental analysis Calcd for C26H26Cl2O2Ti (%): C, 63.83; H, 5.36. 
Found (%): C, 64.02; H 5.32. 
Mass (E.I., 70 eV, m/z): 496 [L2-TiCl2-Li]•+.  
4.4.6 Synthesis of (bis-2-cyclopentadienyl-ethoxy-benzene)-
titanium-bis-glycine  (8d) 
In a round-bottom flask 50 mg of (bis-2-cyclopentadienyl-ethoxy-
benzene)-titanium-dichloride (0.16 mmol) was dissolved in 30 mL of 
methanol (containing 1% of water). To this brown solution 17 mg of 
glycine (0.23 mmol) was added at room temperature and the mixture was 
stirred for 4 h. The solvent was removed in vacuum, obtaining a 
red/orange solid, the yield was quantitative.  
1H NMR (δ ppm 300 MHz, DMSO-d6) δ 3.16 [t, 4H, C5H4-
(CH2CH2OC6H5)], 4.11 [t 4H, C5H4-(CH2CH2OC6H5)], 6.70-7.20 [m, 
18H, C5H4-(CH2CH2OC6H5)]; 3.30 [s, 4H, Ti-OCO-CH2-NH2]  
13C NMR (δ ppm 75 MHz, THF-d8) δ 29.7 [C5H4-(CH2CH2OC6H5)], 68.3 
[C5H4-(CH2CH2OC6H5)], 112.5, 114.3, 120.5, 129.1, 130.0, 159.5, 160.2 
[C5H4-(CH2CH2OC6H5)], 185.6 [Ti-OCO-CH2-NH2], 47.1 [Ti-OCO-CH2-
NH2].  
Elemental analysis Calcd for C30H34N2O6Ti (%): C, 63.61; H 6.05. Found 
(%): C, 63.45; H 6.09. 
4.4.7 Synthesis of (bis-2-cyclopentadienyl-ethoxy-benzene)-
titanium-oxalate  (8e)  
Oxalic acid dihydrate (0.80 g, 6.33 mmol) was dissolved in ethanol (30 
mL) to give a colourless solution. To this solution, freshly distilled 
triethylamine (0.90 mL, 12.64 mmol) was added, which remained 
colourless. Silver nitrate (1.16 g, 6.80 mmol) was dissolved in acetonitrile 
(5 mL) and ethanol (30 mL) to give a colourless solution. The two 
solutions were added and shielded from light exposure and stirred for two 
hours. When the stirring was stopped, the white precipitate was allowed 
Chapter Four Experimental Section Pag.129 
 
to stand for one more hour. The solution was filtered, and the white solid 
was dried in vacuo whilst being shielded from thelight 
Silver oxalate (0.04 g, 0.12 mmol) and (bis-2-cyclopentadienyl-ethoxy-
benzene)-titanium-dichloride (0.04 g, 0.08 mmol) were dissolved in THF 
(30 mL) in a round-bottom flask, shielded from the light. The solution 
was left stirring for 24 h at room temperature. The suspension was gravity 
filtered to give a red-orange colored filtrate. The solvent was removed in 
vacuum and a red-orange solid was obtained (yield 59.4%). 
 1H NMR (δ ppm 300 MHz, THF-d8) δ 3.16 [t, 4H, C5H4-
(CH2CH2OC6H5)], 4.07 [t, 4H, C5H4-(CH2CH2O C6H5)], 6.73-7.16 [m 
18H, C5H4-(CH2CH2OC6H5)]. 
 13C NMR (δ ppm 75 MHz, C6D6) δ 30.8 [C5H4-(CH2CH2OC6H5)], 68.3 
[C5H4-(CH2CH2OC6H5)], 115.4, 116.2, 119.7, 121.2, 130.0, 130.2, 134.0, 
159.1 [C5H4-(CH2CH2OC6H5)], 160.2 [Ti-C2O4]. 
 Anal. Calcd for C28H26O6Ti (%): C, 66.41; H 5.18. Found (%): C, 66.21; 
H 5.21. 
4.4.8 Synthesis of bis-[3-(phenylethyl)cyclopentadienyl]-
titanium(IV) dichloride (9c) 
The lithium intermediate was obtained by the first step of the synthesis of 
9b 
TiCl4·2 THF (0.094g, 0.28 mmol) was added to 20 ml of dry THF. The 
solution turned immediately from colourless to pale yellow. 0.100g (0.56 
mmol) of the lithium cyclopenadienide intermediate were dissolved in 30 
ml of dry THF and added dropwise to the solution containing the 
TiCl4.The solution turned from yellow to dark red during addition. After 
this addition, the mixture was refluxed overnight and then cooled..The 
solvent was removed under reduced pression. The remaining residue was 
extracted with dichlorometane (30 ml) and filtered twice through celite to 
remove the LiCl. The black filtrate was washed twice with hexane  (20 
ml) and then dried under reduced pression to give a dark red solid 
1H NMR (δ ppm, THF-d8, 300 MHz): 1.58 [3H, C5H4-CH(CH3)-
C6H4(OCH3)], 4,44 [1H, C5H4-CH(CH3)-C6H5] 6.35, 6.40 [4H, C5H4-
CH(CH3)-C6H5)], 7.16, 7.18, 7.20, 7.23 [5H, C5H4-CH(CH3)-C6H5]. 
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13C NMR (δ ppm, THF-d8, 75 MHz): 22.9 [C5H4-CH(CH3)-
C6H4(OCH3)], 43.4 [C5H4-CH(CH3)-C6H5] 110.2, 115.1, 120.4, 127.0, 
127.8, 139.1 [C5H4-CH(CH3)-C6H5]. 
Elemental analysis Calcd for C26H24Cl2Ti (%): C, 68.60; H, 5.31. Found 
(%): C, 68.62; H 5.32. 
Mass (E.I., 70 eV, m/z): 384 [L2-Ti]•+.  
4.4.9 Synthesis of bis-[3-(4-
methoxyphenylethyl)cyclopentadienyl]titanium(IV) dichloride 
(10c) 
The lithium intermediate was obtained by the first step of the synthesis of 
10b 
TiCl4·2 THF (0.074g, 0.23 mmol) was added to 20 ml of dry THF. The 
solution turned immediately from colourless to pale yellow. 0.093g (0.46 
mmol) of the lithium cyclopenadienide intermediate were dissolved in 30 
ml of dry THF and added dropwise to the solution containing the 
TiCl4.The solution turned from yellow to dark red during addition. After 
this addition, the mixture was refluxed overnight and then cooled..The 
solvent was removed under reduced pression. The remaining residue was 
extracted with dichlorometane (30 ml) and filtered twice through celite to 
remove the LiCl. The black filtrate was washed twice with hexane  (20 
ml) and then dried under reduced pression to give a dark red solid (yield 
38.2%) 
1H NMR (δ ppm, C6D6, 300 MHz): 3.28 [6H, C5H4-CH(CH3)-
C6H4(OCH3)], 1.58 [6H, C5H4-CH(CH3)-C6H4(OCH3)], 4.6 [2H, C5H4-
CH(CH3)-C6H4(OCH3)] 5.44, 5.81 [8H, C5H4-CH(CH3)-C6H4(OCH3)], 
6.37, 6.45, 6.75, 7.04 [8H, C5H4-CH(CH3)-C6H4(OCH3)]. 
13C NMR (δ ppm, C6D6, 75 MHz): 54.6 [C5H4-CH(CH3)-C6H4(OCH3)], 
21.9 [C5H4-CH(CH3)-C6H4(OCH3)], 40.2 [C5H4-CH(CH3)-C6H4(OCH3)], 
113.8-114.2-115.7-119.6-120.3-129.1-138.3-142.7-158.7 [C5H4-
CH(CH3)-C6H4(OCH3)]. 
Elemental analysis Calcd for C28H28Cl2O2Ti (%): C, 65.26; H, 5.48. 
Found (%): C, 65.32; H 5.42. 
Mass (E.I., 70 eV, m/z): 479 [L2-Ti-Cl]•+.  
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4.4.10 Synthesis of bis-[3-(2,4-
dimethoxyphenylethyl)cyclopentadienyl]titanium(IV) 
dichloride (11c) 
The lithium intermediate was obtained by the first step of the synthesis of 
11b 
TiCl4·2 THF (0.141g, 0.42 mmol) was added to 20 ml of dry THF. The 
solution turned immediately from colourless to pale yellow. 0.200g (0.84 
mmol) of the lithium cyclopenadienide intermediate were dissolved in 30 
ml of dry THF and added dropwise to the solution containing the 
TiCl4.The solution turned from yellow to dark red during addition. After 
this addition, the mixture was refluxed overnight and then cooled..The 
solvent was removed under reduced pression. The remaining residue was 
extracted with dichlorometane (30 ml) and filtered twice through celite to 
remove the LiCl. The black filtrate was washed twice with hexane  (20 
ml) and then dried under reduced pression to give a dark red solid (yield 
37.3%). 
1H NMR (δ ppm, C6D6, 300 MHz): 3.20 3.32 [12H, C5H4-CH(CH3)-
C6H3(OCH3)2], 1.7 [6H, C5H4-CH(CH3)-C6H3(OCH3)2], 5.07 [2H, C5H4-
CH(CH3)-C6H3(OCH3)2] 5.70, 5.92 [8H, C5H4-CH(CH3)-C6H3(OCH3)2], 
6.28, 6.30, 6.88 [6H, C5H4-CH(CH3)-C6H3(OCH3)2]. 
13C NMR (δ ppm, C6D6, 75 MHz): 52.1 53.2 [C5H4-CH(CH3)-
C6H3(OCH3)2], 23.3 [C5H4-CH(CH3)-C6H3(OCH3)2], 38.8 [C5H4-
CH(CH3)-C6H3(OCH3)2], 98.4-103.5-115.8-121.3-122-136.3-135.5-
153.0-159.6 [C5H4-CH(CH3)-C6H3(OCH3)2]. 
Elemental analysis Calcd for C30H32Cl2O4Ti (%): C, 62.63; H, 5.61. 
Found (%): C, 62.59; H 5.59. 
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4.4.11 Synthesis of bis-[(4-methoxynaphtalyl)cyclopentadienyl] 
titanium (IV) dichloride (12c) 
The lithium intermediate was obtained by the first step of the synthesis of 
12b 
TiCl4·2 THF (0.13g, 0.41 mmol) was added to 20 ml of dry THF. The 
solution turned immediately from colourless to pale yellow. 0.200 g(0.82 
mmol) of the lithium cyclopenadienide intermediate were dissolved in 30 
ml of dry THF and added dropwise  to the solution containing the 
TiCl4.The solution turned from yellow to dark red during addition. After 
this addition, the mixture was refluxed overnight and then cooled..The 
solvent was removed under reduced pression. The remaining residue was 
extracted with dichlorometane (30 ml) and filtered twice through celite to 
remove the LiCl. The black filtrate was washed twice with hexane  (20 
ml) and then dried under reduced pression to give a black solid 
1H NMR   (δ ppm CD2Cl2, 300 MHz): 6.38, 6.35 (C5H4, 4H m); 7.68, 
7.67, 7.59, 7.34, 7.17, 7.01 (C10H6, 6H m); 3.88 ((OCH3) 3H s); 3.90 (Ph-
CH2-Cp, 2H s) 
13C NMR   (δ ppm CD2Cl2, 75 MHz): 105.4, 124.3,125.2, 128.0, 128.8, 
129.4, 132.8, 146.8, 156.1 (C5H4 and C10H6); 55.2 ((OCH3) 3H s); 34 (Ph-
CH2-Cp, 2H s) 
Elemental analysis Calcd for C34H28Cl2O2Ti (%): C, 69.53; H, 4.80. 
Found (%): C, 69.58; H 4.79. 




 [1] a) P. J. Sadler, Adv. Inorg. Chem. 1991, 36, 1 -48; b) 
Metallopharmaceuticals (Top. Biol. Inorg. Chem. Vol. 1 and 2), Springer, 
Heidelberg,1999. 
[2] Zijian Guo and Peter J. Sadler Angew. Chem. Int. Ed. 1999, 38, 1512-
1531 
[3]  Ismail Warad, Ala’a F. Eftaiha, Mohammed A. Al-Nuri, Ahmad I. 
Husein, Mohamed Assal, Ahmad Abu-Obaid, Nabil Al-Zaqri, Taibi Ben 
Hadda, Belkheir Hammouti J. Mater. Environ. Sci. 2013 ,4, 542-557 
[4] See reviews on Bioinorganic Enzymology: Chem. Rev. 1996, 96. 
[5] T. W. Redpath, Br. J. Radiol. 1997, 70, S70 -S80. 
[6] S.Aime, M. Botta,G. Ermondi,Magn. Reson. Imaging 1992, 10, 849-
854. 
[7] J. A. Peters, J. Huskens, D. J. Raber, Prog. Nucl. Magn. Reson. Spec. 
1996, 28, 283-350. 
[8] F. Uggeri, S. Aime, P. L. Anelli, M. Botta, M. Brocchetta, C. De 
Haen, G. Ermondi, M. Grandi, P. Paoli, Inorg. Chem. 1995, 34, 633-642. 
[9] S. M. Rocklage, W. P. Cacheris, S. C. Quay, K. N. Raymond, 
Inorg.Chem. 1989, 28, 477-485. 
[10] B. Gallez, G. Bacic, H. M. Swartz, Magn. Reson. Med. 1996, 35, 14-
19. 
[11] C. F. G. C. Geraldes, A. D. Sherry, R. D. Brown, S. H. Koenig, 
Magn. Reson. Med. 1986, 3, 242-250. 
[12] M. Schaefer, Met. Based Drugs 1997, 4, 159-171. 
[13] E. Deutsch, W. Bushong, K. A. Glavan, R. C. Elder, V. J. Sodd, K. 
L. Scholz, D. L. Fortman, S. J. Lukes, Science 1981, 214, 85-86. 
[14] J. F. Kronauge, A. S. Leon, E. S. Verdera, H. S. Balter, E. T. Leon, 
F. Mut, M. C. Oliveira, F. A. Garcia, B. L. Holman, A. Davison, A. G. 
Jones, J. Nucl. Med. 1992, 33, 1949-1957. 
[15] R. T. Maguire, V. L. Pascucci, A. N. Maroli, J. V. Gulfo, Cancer 
1993, 72, 3453-3462. 
[16] L. S. Zuckier, G. L. De Nardo, Semin. Nucl. Med. 1997, 27, 10-29. 
[17] R. K. Hom, J. A. Katzenellenbogen, Nucl.Med. Biol. 1997, 24, 485-
498 




[19] D. W. Cagle, T. P. Thrash, M. Alford, L. P. F. Chibante, G. J. 
Ehrhardt, L. J. Wilson, J. Am. Chem. Soc. 1997, 118, 8043 ± 8047. 
[20] J. L. Clement, P. S. Jarrett, Met. Based Drugs 1994, 1, 467-482. 
[21] S. P. Fricker, Toxicol. in Vitro 1994, 8, 879-881. 
[22] T. N. C. Wells, P. Scully, G. Paravicini, A. E. I. Proudfoot, M. A. 
Payton, Biochemistry 1995, 34, 7896-7903. 
[23] J. D. Berman, Clin. Infect. Dis. 1997, 24, 684-703. 
[24] G. Cantos, C. L. Barbieri, M. Iacomini, P. A. J. Gorin, L. R. 
Travassos, Biochem. J. 1993, 289, 155-160. 
[25] W. L. Roberts, J. D. Berman, P. M. Rainey, Antimicrob. Agents 
Chemother. 1995, 39, 1234-1239. 
[26] Z. I. Cabantchik, H. Glickstein, J. Golenser, M. Loyevsky, A. 
Tsafack, Acta Haematol. 1996, 95, 70-77. 
[27] J. O. Ojwang, R. W. Buckheit, Y. Pommier, A. Mazumder, K. 
Devreese, J. A. Este, D. Reymen, L. A. Pallansch, C. Lackmansmith, T. 
L.Wallace, E. De Clercq, M. S. McGrath, R. F. Rando, Antimicrob. 
Agents Chemother. 1995, 39, 2426-2435. 
[28] J. S. Bishop, J. K. Guycaffey, J. O. Ojwang, S. R. Smith, M. E. 
Hogan, P. A. Cossum, R. F. Rando, N. Chaudhary, J. Biol. Chem. 1996, 
271, 5698-5703. 
[29] E. De Clercq, N. Yamamoto, R. Pauwels, M. Baba, D. Schols, H. 
Nakashima, J. Balzarini, Z. Debyser, B. A. Murrer, D. Schwartz, D. 
Thornton, G. Bridger, S. Fricker, G. Henson, M. Abrams, D. Picker, 
Proc. Natl. Acad. Sci. USA 1992, 89, 5286-5290. 
[30] K. Devreese, V. Kofler-Mongold, C. Leutgeb, V. Weber, K. 
Vermeire, S. Schacht, J. Anne, E. De Clercq, R. Datema, G. Werner, J. 
Virol. 1996, 70, 689-696. 
[31] G. A. Donzella, D. Schols, S.W. Lin, J. A. Este, K. A. Nagashima, P. 
J. Maddon, G. P. Allaway, T. P. Sakmar, G. Henson, E. De Clercq, J. P. 
Moore, Nature Med. 1998, 4, 72-77. 
[32] M. M. Hardy, A. G. Flickinger, D. P. Riley, R. H.Weiss, U. A. Ryan, 
J. Biol. Chem. 1994, 269, 18535 -18540 
[33] K. M. Faulkner, S. I. Liochev, I. Fridovich, J. Biol. Chem. 1994, 269, 
23471. 




[35] C. Szabo, B. J. Day, A. L. Salzman, FEBS Lett. 1996, 381, 82 ± 86. 
[36] P. R. Gardner, D.-D. H. Nguyen, C. W. White, Arch. Biochem. 
Biophys. 1996, 325, 20-28. 
[37] D. P. Riley, R. H. Weiss, J. Am. Chem. Soc. 1994, 116, 387-388. 
[38] D. P. Riley, P. J. Lennon, W. L. Neumann, R. H. Weiss, J. Am. 
Chem. Soc. 1997, 119, 6522-6528. 
[39] S. C. Black, C. S. Schasteen, R. H. Weiss, D. P. Riley, E. M. 
Driscoll, B. R. Lucchesi, J. Pharmacol. Exp. Ther. 1994, 270, 1208-1215. 
[40] S. Melov, J. A. Schneider, B. J. Day, D. Hinerfield, P. Coskun, S. S. 
Mirra, J. D. Crapo, D. C. Wallace, Nature Genet. 1998, 18, 159-163. 
[41] I. H. Tuzel, J. Clin. Pharmacol. 1974, 14, 494-503. 
[42] M. Hale, Am. J. Nurs. 1990, 90, 61-63. 
[43] C. Glidewell, I. L. Johnson, Inorg. Chim. Acta 1987, 132, 145-147. 
[44] A. R. Butler, A. M. Calsey-Harrison, C. Glidewell, I. L. Johnson, J. 
Reglinski, W. E. Smith, Inorg. Chim. Acta 1988, 151, 281-286. 
[45] N. A. Davies, M. T.Wilson, E. Slade, S. P. Fricker, B. A. Murrer, N. 
A. Powell, G. R. Henderson, Chem. Commun. 1997, 47-48. 
[46] B. A. Fricker, E. Slade, N. A. Powell, O. J. Vaughan, G. R. 
Henderson, B. A. Murrer, I. L. Megson, S. K. Bisland, F. W. Flitney, Br. 
J. Pharmacol. 1997, 122, 1441-1449. 
[47] Y. Shechter, S. J. D. Karlish, Nature 1980, 286, 556 - 558. 
[48] G. R. Dubyak, A. Kleinzeller, J. Biol. Chem. 1980, 255, 5306-5312. 
[49] J. H. McNeill, V. G. Yuen, H. R. Hoveyda, C. Orvig, J. Med. Chem. 
1992, 35, 1489-1491. 
[50] V. G. Yuen, C. Orvig, J. H. McNeill, Can. J. Physiol. Pharmacol. 
1995, 73, 55-64. 
[51] P. Caravan, L. Gelmini, N. Glover, F. G. Herring, H. Li, J. H. 
McNeil, S. J. Rettig, I. A. Setyawati, E. Shuter, Y. Sun, A. S. Tracey, V. 
G. Yuen, C. Orvig, J. Am. Chem. Soc. 1995, 117, 12759-12770. 
[52] Y. Sun, B. R. James, S. J. Rettig, C. Orvig, Inorg. Chem. 1996, 35, 
1667-1673. 
[53] C. M. Davis, J. B. Vincent, Biochemistry 1997, 36, 4382 -4385. 
[54] C. M. Davis, A. C. Royer, J. B. Vincent, Inorg. Chem. 1997, 36, 
5316-5320 
[55] C. F. Shaw III in Gold Progress in Chemistry, Biochemistry and 
Technology (Ed.: H. Schmidbaur), Wiley, New York, 1999, pp. 259 - 308 
[56] M. A. Mazid, M. T. Razi, P. J. Sadler, G. N. Greaves, S. J. Gurman, 
 
 
M. H. J. Koch, J. C. Phillips, J. Chem. Soc. Chem. Commun. 1980, 1261-
1262. 
[57] R. C. Elder, K. Ludwig, J. N. Cooper, M. K. Eidsness, J. Am. Chem. 
Soc. 1985, 107, 5024 -5025. 
[58] R. Bau, J. Am. Chem. Soc. 1998, 120, 9380 -9381. 
[59] A. A. Isab, P. J. Sadler, J. Chem. Soc. Dalton Trans. 1981, 1657-
1663. 
[60] I. Schröter, J. Strähle, Chem. Ber. 1991, 124, 2161-2164. 
[61] A. A. Isab, P. J. Sadler J. Chem. Soc. Chem. Commun. 1976, 1051-
1052. 
[62] K. F. Helm, J. G. Marks, J. J. Leyden, C. Guzzo, G. G. Krueger, T. 
W. Griffiths, C. E. M. Griffiths, J. Am. Acad. Dematol. 1995, 33, 517-
519. 
[63] R. Rudkowski, G. Graham, G. D. Champion, J. B. Ziegler, Biochem. 
Pharmacol. 1990, 39, 1687-1695. 
[64] G. G. Graham, T. M. Haavisto, P. J. McNaught, J. Rheumatol. 1982, 
9, 527-531. 
[65] R. C. Elder, W. B. Jones, Z. Zhao, J. G. Dorsey, K. Tepperman, Met. 
Based Drugs 1994, 1, 363-374. 
[66] J. R. Roberts, C. F. Shaw III, Biochem. Pharmacol. 1998, 55, 1291-
1299. 
[67] S. K. Mallya, H. E. vanWart, J. Biol. Chem. 1989, 264, 1594-1601. 
[68] R. M. Snyder, C. K. Mirabelli, S. T. Crooke, Semin. Arthritis Rheum. 
1987, 17, 71-80. 
[69] J. Christodoulou, P. J. Sadler, A. Tucker, Eur. J. Biochem. 1994, 
225, 363-368. 
[70] C. F. Shaw III, A. A. Isab, J. D. Hoeschele, M. Starich, J. Locke, P. 
Schulteis, J. Xiao, J. Am. Chem. Soc. 1994, 116, 2254-2260. 
[71] J. Christodoulou, P. J. Sadler, A. Tucker, FEBS Lett. 1995, 376, 1-5. 
[72] M. L. Handel, C. K. W. Watts, A. DeFazio, R. O. Day, R. L. 
Sutherland, Proc. Natl. Acad. Sci. USA 1995, 92, 4497-4501. 
[73] D. Schuhmann, M. Kubickamuranyi, J. Mirtschewa, J. Gunther, P. 
Kind, E. Gleichmann, J. Immunol. 1990, 145, 2132-2139. 
[74] S. L. Best, P. J. Sadler, Gold Bull. 1996, 29, 87-93. 
[75] C. F. Shaw III, S. Schraa, E. Gleichmann, Y. P. Grover, L. 
Dunemann, A. Jagarlamudi, Met. Based Drugs 1994, 1, 351-362. 
[76] S. L. Best, T. K. Chattopadhyay, M. I. Djuran, R. A. Palmer, P. J. 
 
 
Sadler, I. Sovago, K. Varnagy, J. Chem. Soc. Dalton Trans. 1997, 2587-
2596. 
[77] P. L.Witkiewicz, C. F. Shaw III, J. Chem. Soc. Chem. Commun. 
1981, 1111-1112. 
[78] A. A. Isab, P. J. Sadler, Biochim. Biophys. Acta 1977, 492, 322-330 
[79] G. F. Baxter, Chem. Br. 1992, 28, 445-448. 
[80] a) H. Sun, H. Li, P. J. Sadler, Chem. Ber. 1997, 130, 669-681. 
[81] F. Lazarini, Cryst. Struct. Commun. 1979, 8, 69-74. 
[82] a) W. A. Herrmann, E. Herdtweck, L. Pajdla, Inorg. Chem. 1991, 30, 
2579-2581; b) E. Asato, W. L. Driessen, R. A. G. de Graaf, F. B. 
Hulsbergen, J. Reedijk, Inorg. Chem. 1991, 30, 4210-4218; c) E. Asato, 
K. Katsura, M. Mikuriya, T. Fujii, J. Reedijk, Inorg. Chem. 1993, 32, 
5322-5329; d) P. J. Barrie, M. I. Djuran, M. A. Mazid, M. McPartlin, P. J. 
Sadler, I. J. Scowen, H. Sun, J. Chem. Soc. Dalton Trans. 1996, 2417-
2422. 
[83] P. J. Sadler, H. Sun, J. Chem. Soc. Dalton Trans. 1995, 1395-1401. 
[84] J. W. Clitherow (Glaxo), GB-B 2220937A, 1990. 
[85] L. F. Lacey, N. M. Frazer, O. N. Keene, J. T. L. Smith, Eur. J. Clin. 
Pharmacol. 1994, 47, 177-180. 
[86] S. P. Lee, Res. Commun. Chem. Pathol. 1981, 34, 359. 
[87] a) H. Li, P. J. Sadler, H. Sun, J. Biol. Chem. 1996, 271, 9483 ± 9489; 
b)H. Li, P. J. Sadler, H. Sun, Eur. J. Biochem. 1996, 242, 387-393. 
[88] H. Sun, H. Li, P. J. Sadler, unpublished results. 
[89] D. R. Williams, J. Inorg. Nucl. Chem. 1977, 39, 711-714. 
[90] D. Chaleil, F. Lefevre, P. Allain, G. J. Martin, J. Inorg. Biochem. 
1981, 15, 213-221. 
[91] P. J. Sadler, H. Sun, H. Li, Chem. Eur. J. 1996, 2, 701-708. 
[92] N. Uchida, H. Kasai, Y. Takeda, R. Maekawa, K. Sugita, T. 
Yoshioka,Anticancer Res. 1998, 18, 247-252. 
[93] J. L. Misset, Br. J. Cancer 1998, 77, S4, 4-7. 
[94] F. I. Raynaud, F. E. Boxall, P. M. Goddard, M. Valenti, M. Jones, B. 
A. Murrer, M. Abrams, L. R. Kelland, Clin. Cancer Res. 1997, 3, 2063-
2074. 
[95] Y. Chen, Z. Guo, S. Parsons, P. J. Sadler, Chem. Eur. J. 1998, 4, 
672-676. 
[96] L. R. Kelland, G. Abel, M. J. McKeage, M. Jones, P. M. Goddard, 
M.Valenti, B. A. Murrer, K. R. Harrap, Cancer Res. 1993, 53, 2581-2586. 
 
 
[97] F. I. Raynaud, P. Mistry, A. Donaghue, G. K. Poon, L. R. Kelland, 
B. A. Murrer, K. R. Harrap, Cancer Chemother. Pharmacol. 1996, 
38,155-162. 
[98] F. I. Raynaud, F. E. Boxall, P. Goddard, C. F. Barnard, B. A. Murrer, 
L. R. Kelland, Anticancer Res. 1996, 16, 1857-1862. 
[99] N. Farrell, Y. Qu, J. Kasparkova, V. Brabec, M. Valsecchi, E. Menta, 
R. D. Domenico, M. Conti, G. Da Re, A. Lotto, S. Spinelli, Proceedings 
of the 88th Annual Meeting American Association for Cancer Reserach 
(San Diego, CA) 1997, Vol. 38, No. 2077, pp. 310. 
[100] G. Pratesi, F. C. Giuliani, D. Polizzi, S. Righetti, C. Manzotti, G. 
Pezzoni, N. Farrell, F. Zunino, Proceedings of the 88th Annual Meeting 
American Association for Cancer Reserach (San Diego, CA) 1997, Vol. 
38, No. 2078, pp. 310. 
[101] G. Pratesi, F. C. Giuliani, D. Polizzi, S. Righetti, C. Manzotti, G. 
Pezzoni, N. Farrell, F. Zunino, Proceedings of the 88th Annual Meeting 
American Association for Cancer Reserach (San Diego, CA) 1997, Vol. 
38, No. 2079, pp. 310. 
[102] A. R. Khokhar, S. Albaker, T. Brown, R. Perez-Soler, J. Med. 
Chem. 1991, 34, 325-329. 
[103] For example: a) J. Reedijk, Chem. Commun. 1996, 801-806; b) D. 
Yang, A. H.-J. Wang, Prog. Biophys. Mol. Biol. 1996, 66, 81-111; c) T. 
W. Hambley, Coord. Chem. Rev. 1997, 166, 181-223; d) P. AugeÂ, J. 
Kozelka, Transition Met. Chem. 1997, 22, 91-96. 
[104] D. Yang, S. S. G. E. van Boom, J. Reedijk, J. H. van Boom, A. H.-
J. Wang, Biochemistry 1995, 34, 12 912-12920 
[105] P. M. Takahara, A. C. Rosenzweig, C. A. Frederick, S. J. Lippard, 
Nature 1995, 377, 649-652. 
[106] P. M. Takahara, C. A. Frederick, S. J. Lippard, J. Am. Chem. Soc. 
1996, 118, 309-321. 
[107] A. Gelasco, S. J. Lippard, Biochemistry 1998, 37, 9230 ± 9239. 
[108] M. A. Lemaire, A. Schwartz, A. R. Rahmount, M. Leng, Proc. Natl. 
Acad. Sci. USA 1991, 88, 1982-1985. 
[109] H. Huang, L. Zhu, B. R. Reid, G. P. Drobny, P. B. Hopkins, 
Science 1995, 270, 1842-1845. 
[110] F. Paquet, C. Perez, M. Leng, G. Lancelot, J.-M. Malinge, J. 
Biomol. Struct. Dyn. 1996, 14, 67-77. 
[111] S. J. Berners-Price, K. J. Barnham, U. Frey, P. J. Sadler, Chem. 
 
 
Eur. J. 1996, 2, 1283-1291. 
[112] F. Reeder, Z. Guo, P. del S. Murdoch, A. Corazza, T. W. Hambley, 
S. J. Berners-Price, J.-C. Chottard, P. J. Sadler, Eur. J. Biochem. 1997, 
249, 370-382. 
[113] F. Gonnet, F. Reeder, J. Kozelka, J. C. Chottard, Inorg. Chem. 
1996, 35, 1653-1658. 
[114] F. Reeder, F. Gonnet, J. Kozelka, J. C. Chottard, Chem. Eur. J. 
1996, 2, 1068-1076. 
[115] V. Brabec, O. Vrana, O. Novakova, V. Kleinwachter, F. P. Intini, 
M. Coluccia, G. Natile, Nucleic Acids Res. 1996, 24, 336-341. 
[116] K. M. Comess, C. E. Costello, S. J. Lippard, Biochemistry 1990, 29, 
2102-2110. 
[117] R. Dalbies, D. Payet, M. Leng, Proc. Natl. Acad. Sci. USA 1994, 
91, 8147-8151. 
[118] R. Dalbies, M. Boudvillain, M. Leng, Nucleic Acids Res. 1995, 23, 
949-953. 
[119] C. Perez, M. Leng, J. M. Malinge, Nucleic Acids Res. 1997, 25, 896 
-903. 
[120] M. M. McA_Nulty, S. J. Lippard, Nucleic Acids Mol. Biol. 1995, 9, 
264-284. 
[121] J. P. Whitehead, S. J. Lippard, Met. Ions Biol. Syst. 1996, 32, 687-
726. 
[122] H. M. Weir, P. J. Kraulis, C. S. Hill, A. R. C. Raine, E. D. Laue, J. 
O. Thomas, EMBO J. 1993, 12, 1311-1319. 
[123] C. M. Read, P. D. Cary, C. Crane-Robinson, P. C. Driscoll, D. G. 
Norman, Nucleic Acids Res. 1993, 21, 3427-3436. 
[124] S. U. Dunham, S. J. Lippard, Biochemistry 1997, 36, 11428-11436. 
[125] C. S. Chow, J. P. Whitehead, S. J. Lippard, Biochemistry 1994, 33, 
15124-15130. 
[126] S. J. Berners-Price, A. Corazza, Z. Guo, K. J. Barnham, P. J. Sadler, 
Y. Ohyama, M. Leng, D. Locker, Eur. J. Biochem. 1997, 243, 782-791. 
[127] J. Yaneva, S. H. Leuba, K. van Holde, J. Zlatanova, Proc. Natl. 
Acad. Sci. USA 1997, 94, 13448-13451. 
[128] P. Vichi, F. Coin, J.-P. Renaud, W. Vermeulen, J. H. J. 
Hoeijmakers, D. Moras, J.-M. Egly, EMBO J. 1997, 16, 7444-7456. 
[129] M. van Beusichem, N. Farrell, Inorg. Chem. 1992, 31, 634-639. 
[130] L. R. Kelland, C. F. J. Barnard, I. G. Evans, B. A. Murrer, B. R. C. 
 
 
Theobald, S. B. Wyer, P. M. Goddard, M. Jones, M. Valenti, A. Bryant, 
P. M. Rogers, K. R. Harrap, J. Med. Chem. 1995, 38, 3016-3024. 
[131] K. J. Mellish, C. F. J. Barnard, B. A. Murrer, L. R. Kelland, Int. J. 
Cancer 1995, 62, 717-723. 
[132] P. M. Goddard, R. M. Orr, M. R. Valenti, C. F. J. Barnard, B. A. 
Murrer, L. R. Kelland, K. R. Harrap, Anticancer Res. 1996, 16, 33-38. 
[133] M. Coluccia, A. Nassi, F. Loseto, A. Boccarelli, M. A. Mariggio, D. 
Gordano, F. P. Intini, P. Caputo, G. Natile, J. Med. Chem. 1993, 36, 510-
512. 
[134] R. Cini, P. A. Caputo, F. P. Intini, G. Natile, Inorg. Chem. 1995, 34, 
1130-1137. 
[135] M. Coluccia, A. Boccarelli, M. A. Mariggio, N. Cardellicchio, 
P.Caputo, F. P. Intini, G. Natile, Chem. Biol. Int. 1995, 98, 251-266. 
[136] M. Coluccia, M. A. Mariggio, A. Boccarelli, F. Loseto, N. 
Cardellicchio, P. Caputo, F. P. Intini, C. Pacifico, G. Natile, Platinum and 
Other Metal Coordination Compounds in Cancer Chemotherapy 2 (Eds.: 
H. M. Pinedo, J. H. Schornagel ), Plenum, New York, 1993, pp. 27-36. 
[137] a) V. Brabec, O. Vrana, O. Novakova, V. Kleinwachter, F. P. Intini, 
M. Coluccia, G. Natile, Nucleic Acids Res. 1996, 24, 336 ± 341; b) V. 
Brabec, personal communication; c) R. Zaludova, A. Zakovska, J. 
Kasparkova, Z. Balcarova, O. Urana, M. Coluccia, G. Natile, V. Brabec, 
Mol. Pharm. 1997, 52, 354-361. 
[138] W. W. Alden, A. J. Repta, Chem. Biol. Interact. 1984, 48, 121-126. 
[139] C. M. Riley, L. A. Sternson, A. J. Repta, S. A. Slyter, Anal. 
Biochem. 1983, 130, 203-214. 
[140] P. del S. Murdoch, J. D. Ranford, P. J. Sadler, S. J. Berners-Price, 
Inorg. Chem. 1993, 32, 2249-2255. 
[141] N. Nagai, R. Okuda, M. Kinochita, H. Ogata, J. Pharm. Pharmacol. 
1996, 48, 918-924. 
[142] A. I. Ivanov, J. Christodoulou, J. A. Parkinson, K. J. Barnham, 
A.Tucker, J. Woodrow, P. J. Sadler, J. Biol. Chem. 1998, 273, 14721-
14730. 
[143] K. J. Barnham, M. I. Djuran, P. del S. Murdoch, J. D. Ranford, P. J. 
Sadler, Inorg. Chem. 1996, 35, 1065-1072. 
[144] K. J. Barnham, U. Frey, P. del S. Murdoch, J. D. Ranford, P. J. 
Sadler, D. R. Newell, J. Am. Chem. Soc. 1994, 116, 11175-11176. 




[146] T. Ishikawa, C. D. Wright, H. Ishizuka, J. Biol. Chem. 1994, 269, 
29085-29093. 
[147] D. C. Lemkuil, D. Nettesheim, C. F. Shaw III, D. H. Petering, J. 
Biol. Chem. 1994, 269, 24792-24797. 
[148] N. A. Kratochwil, M. Zabel, K. J. Range, P. J. Bednarski, J. Med. 
Chem. 1996, 39, 2499-2507. 
[149] N. A. Kratochwil, J. A. Parkinson, P. J. Bednarski, P. J. 
Sadler,Angew. Chem. 1999, 111, 1566-1569; Angew. Chem. Int. Ed. 
1999, 38, 1460-1463. 
[150] N. A. Kratochwil, Z. Guo, P. del S. Murdoch, J. A. Parkinson, P. J. 
Bednarski, P. J. Sadler, J. Am. Chem. Soc. 1998, 120, 8253-8254. 
[151] D. Payet, M. Leng, Met. Based Drugs 1995, 2, 137-141. 
[152] S. A. Kane, S. J. Lippard, Biochemistry 1996, 35, 2180-2188. 
[153] Galanski M., Keppler B., Anti-Cancer Agents Med. Chem.,2007, 
55.  
[154] Łakomska I., Wojtczak A., Sitkowski J., Kozerski L., Szłyk E., 
Polyhedron, 2008, 27,  2765.  
[155] Hall M., Hambley T., Coord. Chem. Rev., 2002. 232,  49.  
[156] Weaver E., Bose R., J. Inorg. Biochem., 2003, 93, 231.  
[157] Choi S., Filotto C., Bisanzo M., Delaney S., Lagasee D., Whiworth 
J., Jusko A., Li C., Wood N., Willingham J., Schwenker A., Spaulding K., 
J. Inorg. Chem., 1998, 37,  2500.  
[158] Hambley T., Battle A., Deacon G., Lawrenz E., Fallon G., 
Gatehouse B.M., Webster L., Rainone S., J. Inorg. Biochem.,1999, 77, 3.  
[159] Ellis L., Er H., Hambley T., Aust. J. Chem.,1995, 48,  793.  
[160] Song R., Mook K., Sohn Y., Bull. Korean Chem. Soc., 2000, 21, 
1000.  
[161] Kelland L., Barnard C., Evans I., Murrer B., Theobald B., Wyer S., 
Goddard P., Jones M., Valenti M., Bryant A., Rogers P., Harrap K., J. 
Med. Chem., 1995, 38, 3016.  
[162] Farrell N., del Ameida S., Skov K., J. Am. Chem. Soc., 1988, 110, 
5018.  
[163] Farrell N., Qu Y., J. Inorg. Chem.,1989, 28, 3416.  
[164] Farrell N., Qu Y., Hacker M., J. Med. Chem., 1990, 33, 2179.  
[165] Bierbach U., Hambly T., Farrell N., J. Inorg. Chem., 1998, 37,  708.  
 
 
[166] Rauter H., Di Domenico R., Menta E., Oliva A., Qu Y., Farrell N., 
J. Inorg. Chem., 1997, 36, 3919.  
[167] Qu Y., Farrell N., Kasparkova J., Brabcc V., J. Inorg. 
Biochem.,1997, 67, 174.  
[168] Jansen B., Van der Zwan J., Reedijk J., den Dulk H., Brouwer J., 
Eur. J. Inorg. Chem., 1999, 9, 1429.  
[169] Di Blasi P., Bernareggi A., Beggiolin G., Piazzoni L., Mernta E., 
Formento M., Anticancer Res., 1998, 18, 3113.  
[170] Perego P., Caserini C., Gatti L., Garenini N., Romanelli S., Supino 
R., Colangelo D., Viano L., Leone R., Spinelli S., Pezzoni G., Mazotti C., 
Farell N., Zunino F., Mol. Pharm., 1999, 55,  528.  
[171] Judson I., Kelland L., Drugs, 2000, 59,  29.  
[172] Perego P., Gatti L., Caserini C., Supino R., Colangelo D., Leone R., 
Spinelli S., Farell N., Zunino F., J. Inorg. Biochem., 1999, 77, 59.  
[173] Maitlis P., The Organic Chemistry of Palladium in Organometallic 
Chemistry, A series of monographs, P. Maitlis, F. Stone, R. West. Eds: 
Academic Press Inc. New York, 1971, 1.  
[174] Rau T., van Eldik R., In Metal Ions in Biological Systems, Sigel H., 
Sigel A., Ed. Marcel Dekker New York, 1996, 31, 339.  
[175] Ghaham R., Williams D., J. Inorg. Nucl. Chem., 1979, 41, 1245.  
[176] Butour J., Wimmer S., Wimmer F., Castan P., Chem. Biol. 
Interact.,1997, 11, 165.  
[177] Mansuri-Torshizi H., Srivastava T., Parekh H., Chitnis M., J. Inorg. 
Biochem., 1992, 45, 135.  
[178] Tusel-Bozic L., Matijasic I., Bocelli G., Calestani G., Furlani A., 
Scarcai V., Papaioannou A. A., J. Chem. Soc. Dalton Trans., 1991, 2, 
195.  
[179] Carrara M., Berti T., D´Ancona S., Cherchi V., Sindellari L., 
Anticancer Res., 1996, 17, 975.  
[180] Al-Allaf A., Rashan L., Eur. J. Med. Chem., 1998, 33,  817.  
[181] Abu-Surrah A., Klinga M., Leskelä M., Kristalloger. NCS, 2002, 
217, 257.  
[182] Navarro-Ranninger C., Pérez J., Zamora F., Gonzalez V., Masaguer 
J., Alono C., J. Inorg. Biochem., 1993, 52, 37.  
[183] Zhao G., Lin H., Yu P., Sun H., Su X., Chen Y., J. Inorg. Biochem., 
1999, 73, 145.  
 
 
[184] Abu-Surrah A., Kettunen M., Lappalainen K., Piironen U., Klinga 
M., Leskelä M. M., Polyhedron, 2002, 21, 2653.  
[185] Abu-Surrah A., Lappalainen K., Piironen U., Lehmus P., Repo T., 
Leskelä M., J. Organomet. Chem., 2002, 648, 55.  
[186] Abu-Surrah A., Al-Allaf T., Klinga M., Leskelä M., M. Polyhedron, 
2003, 22, 1529.  
[187] Khokhar A., Lumetta G., J. Inorg. Chem. Acta, 1988,  225.  
[188] Rau T., Alsfasser R., Zahl A., Van Eldik R., J. Inorg. Chem., 1998, 
37, 4223.  
[189] Wimmer F., Wimmer S., Castan P., Cros S., Johnson N., Colacio-
Rodrigez E., Anticancer Res., 1989, 9, 791.  
[190] Butor J., Wimmer F., Wimmer S., Castan P., Chem. Biol. Interact., 
1997, 11, 165.  
[191] Paul A., Mansuri-Torshizi H., Srivastava T., Chavan J., Chitnis M., 
J. Inorg. Biochem. 1993, 50, 9  
[192] Zhao G., Sun H., Lin H., Zhu S., Su X., Chen Y., J. Inorg. 
Biochem., 1998, 72, 173.  
[193] Navarro-Ranninger C., López-Solera I., Pérez J., Masaguer J., 
Alono C., Appl. Organomet. Chem., 1993, 7,  57.  
[194] Caries A., Almeide E., Mauro A., Hemerly J., Valentini S., 
Quimica N., 1999, 22, 139.  
[195] Khan B., Bhatt J., Najmuddin K., Shamsuddin S., Annapoorna K., 
J. Inorg. Biochem., 1991, 44,  55.  
[196] Zhao G., Lin H., Zhu S., Sun H., Chen Y., J. Inorg. Biochem., 
1998, 78, 219.  
[197]. Rodrigues E., Silva L., Fausto D., Hayashi M., Dreher S., Santos 
E., Pesquero J., Travassos L., Caires A., Int. J. Cancer, 2003, 107, 498.  
[198] Therrien B., Coord. Chem. Rev., 2009, 253, 493.  
[199] Clarke M., Zhu F., Frasca D., Chem. Rev., 1999, 99, 2511.  
[200] Wang F., Xu J., Habtemariam A., Bella J., Sadler P., J. Am. Chem. 
Soc. 2005, 127, 17734  
[201] Therrien B., Ang W., Chérioux F., Vieille-Petit L., Juillerat-
Jeanneret L., Süss-Fink G., Dyson P., J. Clust. Sci., 2007, 18, 741.  
[202] Ronconi L., Sadler P., Coord. Chem. Rev., 2008, 252, 2239.  
[203] Ronconi L., Sadler P., Coord. Chem. Rev., 2007, 251, 1633.  
[204] Galanski M., Arion V., Jakupec M., Keppler B., Curr. Pharm. Des., 
2003, 9, 2078.  
 
 
[205] Rudnev A., Aleksenko S., Semenova O., Hartinger C., Timerbaev 
A., Keppler B., J. Sep. Sci. 2005, 28, 121.  
[206] Scharwitz M., Ott I., Geldmacher Y., Gust R., Sheldrick W., J. 
Organomet. Chem., 2008, 693, 2299.  
[207] Hillard E., Vessieres A., Le Bideau F., Plazuk D., Spera D., Huche 
M., Jaouen G., Chem. Med. Chem., 2006, 1, 551.  
[208] Dale L., Tocher J., Dyson T., Edwards D., Tocher D., Anti-Cancer 
Drug Des.1992, 7, 3.  
[209] Gopal Y., Jayaraju D., Kandapi A., Biochemistry,1999, 38, 4382.  
[210] Gopal Y., Konura N., Kandapi A., Arch. Biochem. Biophys., 2002, 
401, 53.  
[211] Huxham L., Cheu E., Patrick B., James B., Inorg. Chim. Acta, 2003 
,352, 238.  
[212] Sheldrick W., Heeb S., Inorg. Chim. Acta, 1990, 168, 93.  
[213] Erkkila K., Odom D., Barton J., Chem. Rev., 1999, 99, 2777.  
[214] Metcalfe C., Thomas J., Chem. Soc. Rev., 2003, 32,  215.  
[215] Scolaro C., Bergamo A., Brescacin L., Delfino R., Cocchietto M., 
Laurenczy G., Geldbach T., Sava G., Dyson P., J. Med. Chem., 2005, 48, 
4161.  
[216] Devereux M., O’Shea D., O’Connor M., Grehan H., Connor G., 
McCann M., Rosair G., Lyng F., Kellett A., Walsh M., Egan D., Thati B., 
Polyhedron, 2007, 26, 4073.  
[217] Devereux M., McCann M., Shea D., Kelly R., Egan D., Deegan C., 
McKee V., J. Inorg. Biochem., 2004, 98, 1023.  
[218] Devereux M., McCann M., Shea D., Connor M., Kiely E., McKee 
V., Naughton D., Fisher A., Kellett A., Walsh M., Egan D., Deegan C., 
Bioinorg. Chem. Appl., 2006  
[219] Deegan C., McCann M., Devereux M., Coyle B., Egan D., Chemico 
Biol. Interact. 2006, 164, 115.  
[220] Deegan C., McCann M., Devereux M., Coyle B., Egan D., Cancer 
Lett., 2007, 247, 224.  
[221] Gracia-Mora, Ruiz-Ramirez L., Gomez-Ruiz C., Tinoco- Mendez 
M., Marquez-Quinones A., Romero de Lira L., Marin- Hernandez A., 
Masias-Rosales L., Bravo-Gomez M. E., Met. Based Drugs, 2002, 8, 19.  
[222] De Vizcaya-Ruiz A., Rivero-Mueller A., Ruiz-Ramirez L., Kass G., 
Kelland L., Or R., Dobrota M., Toxicol. In Vitro, 2000, 14, 1.  
 
 
[223] Coyle B., Kinsella P., McCann M., Devereux M., O’Connor R., 
Clynes M., Kavanagh K., Toxicol. In Vitro, 2004, 18, 63.  
[224] Coyle B., Kavanagh K., McCann M., Devereux M., Geraghty M., 
Biometals., 2003, 16, 321.  
[225] Hernandez A., Mora I., Remirez L., Sanchez R., Biochem. 
Pharmacol., 2003, 65, 1979.  
[226] Hirohama T., Kuranuki Y., Ebina E., Sugizaki T., Arii H., Chikira 
M., Selvi P., Palaniandavar M., J. Inorg. Biochem., 2005, 99, 1205.  
[227] Brabec V., Leng M., Proc. Natl. Acad. Sci. U.S.A., 1993, 90, 5345.  
[228] Pantoja E., Álvarez-Valdés A., Pérez J. M., Navarro-Ranninger C., 
Reedijk J., Inorg. Chim. Acta, 2002, 339, 525.  
[229] S. J. Berners-Price, R. J. Bowen, M. J. McKeage, P. Galettis, 
L.Ding, C. Baguley, W. Brouwer, J. Inorg. Biochem. 1997, 67, 154 
[230] R. Dreicer, K. J. Propert, B. J. Roth, L. H. Einhorn, P. J. Loehrer, 
Cancer 1997, 79, 110-114. 
[231] L. R. Bernstein GeoMed US-A 5747482, 1998.  
[232] P. Köpf-Maier, H. Köpf, Chem. Rev. 1987, 87, 1137–1152. 
[233] B. K. Keppler, C. Friesen, H. G. Moritz, H. Vongerichten, E.Vogel, 
Struct. Bonding 1991, 78, 97–127. 
[234] F. Caruso, M. Rossi, Mini-Rev. Med. Chem. 2004, 4, 49–60. 
[235] F. Caruso, M. Rossi, C. Opazo, C. Pettinari, Bioinorg. Chem. Appl. 
2005, 3, 317–329. 
[236] F. Caruso, M. Rossi, J. Tanski, R. Sartori, R. Sariego, S. Moya, S. 
Diez, E. Navarrete, A. Cingolani, F. Marchetti, C. Pettinari, J. Med. 
Chem. 2000, 43, 3665–3670. 
[237] A. M. Christoforou, P. A. Marzilli, L. G. Marzilli, Inorg. Chem. 
2006, 45, 6771–6781. 
[238] G. Kelter, N. J. Sweeney, K. Strohfeldt, H.-H. Fiebig, M. Tacke, 
Anti-Cancer Drugs 2005, 16, 1091–1098. 
[239] P. Köpf-Maier, H. Köpf, Struct. Bonding (Berlin) 1988, 70, 103–
185. 
[240] K. Strohfeldt, M. Tacke, Chem. Soc. Rev. 2008, 37, 1174–1187. 
[241] N. Kruger, U. R. Kleeberg, K. Mross, L. Edler, G. Saβ, D.K. 
Hossfeld, Onkologie 2000, 23, 60–62. 
[242] G. Lummen, H. Sperling, H. Luboldt, T. Otto, H. Rubben, Cancer 
Chemother. Pharmacol. 1998, 42, 415–417. 
 
 
[243] T. Schilling, K. B. Keppler, M. E. Heim, G. Niebch, H. 
Dietzfelbinger, J. Rastetter, A. R. Hanauske, Invest. New Drugs 1995, 13, 
327–332. 
[244] H. Köpf, P. Köpf-Maier, Angew. Chem. Int. Ed. Engl. 1979, 18, 
477–478. 
[245] P. Köpf-Maier, W. Wagner, H. Köpf, Cancer Chemother. 
Pharmacol. 1981, 5, 237–241. 
[246] J. H. Toney, T. J. Marks, J. Am. Chem. Soc. 1985, 107, 947–953. 
[247] B. W. Müller, R. Müller, S. Lucks, W. Hohr, US patent 1994, 
5,296,237. 
[248] J. J. Keller, B. K. Keppler, D. Schmahl, Arzneim.-Forsch./Drug 
Res. 1982, 32, 806–807. 
[249] E. Dubler, R. Buschmann, H. W. Schmalle, J. Inorg. Biochem. 
2003, 95, 97–104. 
[250] M. M. Harding, G. Mokdsi, Curr. Med. Chem. 2000, 7, 1289–1303. 
[251] P. Köpf-Maier, B. Hesse, R. Voigtlander, H. Köpf, J. Cancer Res. 
Clinical Oncol. 1980, 97, 31–39. 
[252] M. C. Valadares, M. L. S. Queiroz, Eur. J. Pharmacol. 2002, 439, 
35–42. 
[253] G. Mokdsi, M. M. Harding, J. Organomet. Chem. 1998, 565, 29–
35. 
[254] J. R. Boyles, M. C. Baird, B. G. Campling, N. Jain, J. Inorg. 
Biochem. 2001, 84, 159–162. 
[255] J. Claffey, M. Hogan, H. Müller-Bunz, C. Pampillon, M. Tacke, 
ChemMedChem 2008, 3, 729–731. 
[256] I. Fichtner, C. Pampillon, N. J. Sweeney, K. Strohfeldt, M. Tacke, 
Anti-Cancer Drugs 2006, 17, 333–336. 
[257] S. Gomez-Ruiz, G. N. Kaluderovic, D. Polo-Ceron, S. Prashar, M. 
Fajardo, Z. Zizak, Z. D. Juranic, T. J. Sabo, Inorg. Chem. Commun. 2007, 
10, 748–752. 
[258] S. Gomez-Ruiz, G. N. Kaluderovic, S. Prashar, D. Polo-Ceron, M. 
Fajardo, Z. Zizak, T. J. Sabo, Z. D. Juranic, J. Inorg. Biochem. 2008, 102, 
1558–1570. 
[259] O. R. Allen, L. Croll, A. L. Gott, R. J. Knox, P. C. McGowan, 
Organometallics 2004, 23, 288–292. 
[260] O. R. Allen, A. L. Gott, J. A. Hartley, J. M. Hartley, R. J. Knox, P. 
C. McGowan, Dalton Trans. 2007, 5082–5090. 
 
 
[261] P. W. Causey, M. C. Baird, S. P. C. Cole, Organometallics 2004, 
23, 4486–4494. 
[262] G. D. Potter, M. C. Baird, S. P. C. Cole, J. Organomet. Chem. 
2007, 692, 3508–3518. 
[263] A. Gansauer, D. Franke, T. Lauterbach, M. Nieger, J. Am. Chem. 
Soc. 2005, 127, 11622–11623. 
[264] A. Gansauer, I.Winkler, D. Worgull, D. Franke, T. Lauterbach, A. 
Okkel, M. Nieger, Organometallics 2008, 27, 5699–5707. 
[265] A. Gansauer, I.Winkler, D. Worgull, T. Lauterbach, D. Franke, A. 
Selig, L. Wagner, A. Prokop, Chem. Eur. J. 2008, 14, 4160–4163. 
[266] F. Caruso, C. Pettinari, F. Marchetti, P. Natanti, C. Phillips, J. 
Tanski, M. Rossi, Inorg. Chem. 2007, 46, 7553–7560. 
[267] R. J. Knox, F. Friedlos, D. A. Lydall, J. J. Roberts, Cancer Res. 
1986, 46, 1972–1979. 
 [268] M. Ravera, C. Cassino, E. Monti, M. Gariboldi, D. Osella, J. Inorg. 
Biochem. 2005, 99, 2264–2269. 
[269] P. Köpf-Maier, D. Krahl, Naturwissenschaften 1981, 68, 273–274. 
[270] P. Köpf-Maier, W. Wagner, E. Liss, J. Cancer Res. Clinical Oncol. 
1981, 102, 21–30. 
[271] P. Köpf-Maier, J. Cancer Res. Clinical Oncol. 1982, 103, 145–164. 
[272] M. L. McLaughlin, J. M. Cronan, T. R. Schaller, R. D. Snelling, J. 
Am. Chem. Soc. 1990, 112, 8949–8952. 
[273] Z. Zhang, P. Yang, M. Guo, H. Wang, J. Inorg. Biochem. 1996, 63, 
183–190. 
[274] M. Tacke, Lett. Drug Des. Discov. 2008, 5, 332–335. 
[275] G. Mokdsi, M. M. Harding, J. Inorg. Biochem. 2001, 83, 205–209. 
[276] P. T. Gomme, K. B. McCann, Drug Discov. Today 2005, 10, 267–
273. 
[277] H. Li, Z. M. Qian, Med. Res. Rev. 2002, 22, 225–250. 
[278] H. Sun, H. Li, P. J. Sadler, Chem. Rev. 1999, 99, 2817–2842. 
[279] M. Guo, H. Sun, H. J. McArdle, L. Gambling, P. J. Sadler, 
Biochemistry 2000, 39, 10023–10033. 
[280] M. Guo, P. J. Sadler, J. Chem. Soc., Dalton Trans. 2000, 7–9. 
[281] H. Sun, H. Li, R. A. Weir, P. J. Sadler, Angew. Chem. Int. Ed. 
1998, 37, 1577–1579. 




[283] A. D. Tinoco, C. D. Incarvito, A. M. Valentine, J. Am. Chem. Soc. 
2007, 129, 3444–3454. 
[284] L. M. Gau, R. Hernández, J. Matta, E. Meléndez, J. Biol. 
Inorg.Chem. 2007, 12, 959–967. 
[285] Y. Perez, V. López, L. Rivera-Rivera, A. Cardona, E. Mel’ndez, J. 
Biol. Inorg. Chem. 2005, 10, 94–104. 
[286] R. Hernández, J. Lamboy, L. M. Gau, J. Matta, F. R. Roman, E. 
Meléndez, J. Biol. Inorg. Chem. 2008, 13, 685–692. 
[287] A. D. Tinoco, E. V. Eames, A. M. Valentine, J. Am. Chem. Soc. 
2008, 130, 2262–2270. 
[288] A. Vessières, M.-A. Plamont, C. Cabestaing, J. Claffey, S. 
Dieckmann, M. Hogan, H. Müller-Bunz, K. Strohfeldt, M. Tacke, J. 
Organomet. Chem. 2009,  
[289]. Miller AB, Hoogstraten B, Staquet M, Winkler A. Re-porting 
results in cancer treatment. Cancer  1981, 47, 207 
[290] Napoli, M.; Saturnino, C.; Sirignano E.; Popolo, A.; Pinto, A.; 
Longo, P. Eu. J. Med. Chem. 2011, 46, 122. 
[291]Longo, P.; Amendola, A.G.; Fortunato, E.; Boccia, A.C.; Zambelli 
A. Macromol. Rapid Commun. 2001, 22, 339. 
[292]De Rosa, C.; Auriemma, F.; Circelli, T.; Longo, P.; Boccia A.C. 
Macromolecules 2003, 36, 3465. 
[293]Napoli, M.; Grisi, F.; Longo P. Macromolecules 2009, 42, 2516. 
[294] Tacke, M.; Cuffe, L.P.; Gallagher, W.M.; Lou, Y.; Mendoza, O.; 
Müller-Bunz ,H.; Rehmann, F-J.K.; Sweeney N. J. Inorg. Biochem. 2004, 
98, 1987. 
[295] Tacke, M.; Allen, L.T.; Cuffe, L.P., Gallagher, W.M., Lou, Y., 
Mendoza, O., Muller-Bunz, H., Rehmann, F.-J.K., Sweeney, N. J. 
Organomet. Chem. 2004, 689, 2242. 
[296] Claffey, J.; Hogan, M.; Muller-Bunz, H.; Pampillon, C.; Tacke, M. 
J. Organomet. Chem. 2008, 693, 526. 
[297] Stone, K.J.; Little, R.D. J. of Organic Chem. 1984, 49, 11. 
[298] Soule, HD; Vazquez J, Long A, Albert S, Brennan M. Journal of 
the National Cancer Institute 1973 1409–1416.  
 
 
 
 
 
 
 
